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Background:  HIV-1 infection is complicated by high rates of opportunistic 
infections against which specific antibodies contribute to immune defense.  Antibody 
function depends on somatic hypermutation (SHM) of variable regions of 
immunoglobulin (Ig) heavy chain genes. SHM is mediated by a B cell-specific enzyme, 
activation-induced cytidine deaminse (AID).   
Methods:  We characterized the frequency of SHM in expressed VH3-family IgD, 
IgM, IgA, and IgG mRNA immunoglobulin transcripts from control and HIV-1-infected 
patients using high-throughput pyrosequencing.  We also compared AID mRNA 
expression by qRT-PCR, AID isoform expression by PCR, and the activation phenotype 
of B and T lymphocyte subsets among peripheral blood mononuclear cells (PBMC) from 
HIV-1-infected and control subjects pre- and post-stimulation.   
Results:  VH3-IgM and VH3-IgA SHM frequencies did not differ between HIV-1-
infected patients and controls.  VH3-IgG SHM frequencies were significantly lower in 
HIV-1-infected patients as they were in another non-Ig AID target, Bcl6.  VH3-IgD SHM 
frequencies were significantly higher in HIV-1-infected patients, however.  Mutation 
iv 
 
patterns were comparable in both groups in all isotypes regardless of SHM frequency.  
AID mRNA expression was significantly higher in HIV-1-infected patients compared 
with controls.  AID increased significantly post-stimulation in both groups, but the 
expression levels were lower among HIV-1-infected patients.  At baseline, activation 
markers for B and T cells in multiple naïve and memory subsets were significantly higher 
in HIV-1-infected patients, but activation levels were not significantly different post-
stimulation.  AID expression correlated significantly with VH3-IgD SHM frequency and 
activation of T cells, but not with VH3-IgG SHM frequency, Bcl6 mutation frequency, B 
cell activation, or plasma HIV-1 RNA.  AID isoform expression was comparable in both 
groups. 
Conclusions:  B cells from HIV-1-infected patients show disparate SHM 
frequencies, especially amongst sequences known to control opportunistic infections 
which commonly cause morbidity during HIV-1 infection.  Similar mutation patterns 
suggest differences in quantity, but not quality, of AID activity.  Despite increased 
expression of AID mRNA and surface activation markers at baseline, B cells from HIV-
1-infected patients demonstrated a diminished capacity to upregulate AID mRNA in 
response to stimuli.  These impairments may compromise humoral immune responses to 
both opportunistic infections and even to HIV-1 itself. 
 
 
 The form and content of this abstract are approved.  I recommend its publication. 
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Human immunodeficiency virus-1 (HIV-1) has become a major global health 
issue since the epidemic was first recognized in 1981 [1].  In the U.S. alone, an estimated 
40,000-60,000 people become newly infected yearly, 1.2 million people are currently 
infected with HIV-1, and nearly 18,000 people die every year due to complications of 
HIV-1 infection [2].  Globally, an estimated 34 million people are infected, with 2.7 
million new infections per year, resulting in 1.8 million deaths annually [3].  Infection 
and death rates are especially high in developing countries due to clinical presentation 






HIV-1 is especially problematic because it infects and can directly and indirectly 
destroy cells of the immune system, CD4
+
 T lymphocytes and macrophages, leaving the 
host susceptible to numerous opportunistic infections that do not normally cause sickness 
or death in the healthy general population [4, 5].   
The course of HIV-1 infection is divided into several stages (Figure 1.1).  The 
primary infection can last up to 6 months post-infection.  During this stage plasma HIV-1 
RNA levels, “viral loads,” can reach as high as a million copies per mL of blood and the 
CD4
+
 T cell count drops below the normal range (800-1200 cells/mm
3
 of blood) [1].  
Most HIV-1 transmission is proposed to occur during this period of high level viremia.  
Within approximately 6 months, the immune system gains partial control over viral 
replication, the viral load decreases and stabilizes at a “set point” that can range from 
<2,000 virions/mL to >100,000 virions/mL and CD4
+
 T cell counts increase.  This 
clinical latency or asymptomatic stage lasts 8-10 years, on average.  The magnitude of the 
viral set point is predictive of the rate of the patients’ disease progression and immune 
decline over this period [6].  During the asymptomatic stage, antigen-selected viral 
mutations can lead to immunological escape from both CD8
+
 cytotoxic T cells and 
antibodies [7] resulting in increasing viral loads and decreasing CD4
+
 T cell counts.  
Patients enter the symptomatic stage, during which viral loads increase to over 100,000 
copies/mL and CD4
+
 T cell counts drop below 500 cells/mm
3
.  Patients develop minor 
infections such as herpes simplex, warts and fungal infections, and oral (thrush) and 
vaginal candidiasis.  As viral loads continue to increase and CD4
+
 T cell counts decrease  
further, patients develop AIDS, acquired immunodeficiency syndrome, characterized as 
having CD4
+
 T cell counts below 200 cells/mm
3
 and the development of opportunistic 
3 
 
infections and cancers, particularly a range of B cell lymphomas, eventually resulting in 
the patient’s death [1, 4].  Understanding the viral life cycle has provided insights into 
identifying vulnerable pathways for antiretroviral medications and potentially, vaccine 
development to limit disease progression and its morbid sequelae. 
 
HIV-1 life cycle 
HIV-1 is a spherical, enveloped virus belonging to the retrovirus family.  Inside 
the envelope is a nucleocapsid core surrounding two copies of a 9 kb single stranded 
positive-sense RNA genome [4, 10].  The genome is composed of three genes common to 
all retroviruses (Gag, Pol, and Env), as well as six accessory genes (Tat, Nef, Rev, Vpr, 
Vif, and Vpu), encoding 17 different proteins [10].  The Env gene product, gp160, is 
cleaved into two glycoproteins expressed in the envelope, gp41 and gp120 that mediate 
viral binding [4]. 
As binding of HIV-1 gp120 to the primary viral receptor, CD4 (Figure 1.2), is of 
relatively low affinity, early attachment of HIV-1 to host cells is likely the result of 
binding to cell surface molecules such as Heparan sulfate proteoglycan, LFA-1, and 
nucleolin [11].  Upon binding of gp120 to CD4 (Figure 1.2, step 1), the conformation of 
gp120 changes, leading to the exposure of new epitopes that can bind to a coreceptor; 
either CCR5, CXCR4, or both.  Binding to the coreceptor induces more conformational 
changes in gp120 which dissociates from gp41, at which point gp41 inserts into the host 






Figure 1.1:  Typical Course of HIV-1 Infection.  During the early period after primary 
infection there is widespread dissemination of virus and a sharp decrease in the number 
of CD4 T cells in peripheral blood.  An immune response to HIV ensues, with a decrease 
in detectable viremia followed by a prolonged period of clinical latency.  The CD4 T cell 
count continues to decrease during the following years, until it reaches a critical level 
below which there is a substantial risk of opportunistic diseases [8, 9].   
 
The details immediately succeeding the virion core entering the cytoplasm are not 
well characterized.  The capsid core may begin to dissolve immediately, releasing the 
Reverse Transcription Complex (RTC) into the cytoplasm, where reverse transcription 
begins [12], or it may remain intact and travel along microtubules and actin filaments to 
the nuclear membrane [13].  In this scenario, reverse transcription occurs inside the core 
and the Pre-Integration Complex (PIC) with the reverse-transcribed viral DNA genome 




Figure 1.2:  HIV-1 Life Cycle.  The infection begins when the envelope (Env) 
glycoprotein spikes engage the receptor CD4 and the membrane-spanning co-receptor 
CC-chemokine receptor 5 (CCR5) (step 1), leading to fusion of the viral and cellular 
membranes and entry of the viral particle into the cell (step 2).  Partial core shell 
uncoating (step 3) facilitates reverse transcription (step 4), which in turn yields the pre-
integration complex (PIC).  Following import into the cell nucleus (step 5), PIC-
associated integrase orchestrates the formation of the integrated provirus (step 6).  
Proviral transcription (step 7) yields viral mRNAs of different sizes (step 8).  mRNAs 
serve as templates for protein production (step 9), and genome-length RNA is 
incorporated into viral particles with protein components (step 10).  Viral-particle 
budding (step 11) and release (step 12) from the cell is mediated by ESCRT (endosomal 
sorting complex required for transport) complexes and is accompanied or soon followed 
by protease-mediated maturation (step 13) to create an infectious particle [12]. 
 
 Reverse transcription, whether it takes place inside the capsid core or in the 
cytoplasm, occurs in the context of the RTC (Figure 1.2, step 4).  This complex is 
proposed to comprise the viral RNA genome and several viral proteins including the 
Reverse Transcriptase (RT) and the matrix protein [13].  Reverse transcription begins 
with the synthesis of minus-strand DNA at the 5’ end of the RNA genome.  This short 
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DNA fragment then undergoes a strand transfer event and becomes the primer at the 3’ 
end of the genome for the rest of the minus-strand DNA.  While the minus-strand DNA is 
being copied, the RNA template is degraded.  Synthesis of the plus-strand DNA then 
begins near the center of the minus-strand DNA template.  After a second strand transfer, 
the remaining plus-strand DNA is synthesized at the 5’ end of the minus-strand DNA 
template [13]. 
 The completed double-stranded (ds) DNA viral genome is now part of the PIC, 
composed of the dsDNA, matrix protein, Viral Protein R (Vpr), and viral Integrase [11, 
12].  This complex is actively transported through nuclear pores through the action of 
both viral and host proteins (Figure 1.2, step 5).  Both Integrase and the matrix protein 
bind host DNA-binding proteins on chromatin, preferentially near genes that are 
transcribed by RNA Pol II [11].  Integrase cleaves both ends of the viral DNA genome as 
well as the host DNA, then joins the viral and host DNA at the resulting free 5’ and 3’ 
ends.  Host enzymes repair the single-stranded gaps, creating the stable provirus (Figure 
1.2, step 6) [10, 12].  
 Transcription of the viral genome is dependent upon the binding of transcription 
factors to the promoter in the 5’ Long Terminal Repeat (LTR) of the viral genome 
(Figure 1.2, step 7).  Early transcripts are multiply spliced, code mainly for viral 
accessory proteins Tat, Nef, and Rev, and can easily exit the nucleus through nuclear 
pores.  Later transcripts are singly or unspliced transcripts and require the action of Rev 
to exit the nucleus (Figure 1.2, step 8) [14].  Rev binds to a region of the transcript and to 
a host nuclear export protein, CRM1, to mediate nuclear exit [12].  These longer 
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transcripts code for structural genes Gag, Pol, and Env, and serve as new viral genomes 
(Figure 1.2, step 9) [10, 12]. 
 Assembly of immature virions occurs in lipid rafts at the plasma membrane 
(Figure 1.2, step 10) [15, 16]. The Env gene product is translated in the endoplasmic 
reticulum, then glycosylated and cleaved at the Golgi complex and directed to the plasma 
membrane [10].  The Gag gene product is myristoylated at its N-terminus and targeted to 
the plasma membrane [15].  The Gag gene product is cleaved into 6 proteins, the matrix 
(p17), nucleocapsid (p7), and capsid proteins (p24), and the smaller core proteins p1, p2, 
and p6 [10].  Both the nucleocapsid and p2 proteins bind to a packaging signal present on 
unspliced RNA viral genomes.  The matrix protein binds Gag-Pol transcripts [10].  Both 
are brought to the plasma membrane when the Gag complex assembles.  Other viral and 
host proteins are also incorporated into the assembled viral core, including Vif, Vpr, and 
Cyclophilin A [16].  The assembled complex induces membrane curvature leading to bud 
formation (Figure 1.2, step 11) [16].  Budding requires the interaction of viral protein p6 
and host protein Tsg101, a component of the endosomal sorting complex required for 
transport (ESCORT) complex [12, 15, 16].  Ion channels formed by Viral Protein U 
(Vpu) also aid in viral budding [12, 15].  Once released, the immature virus must undergo 
additional maturation to become an infectious particle (Figure 1.2, step 12).  Maturation 
involves a conformational change of the structural components of the virus, as well as 
enzymatic cleavage of Gag-Pol precursors.  Maturation requires four cleavage steps.  
First, the Gag-Pol immature protease cleaves Gag-Pol to form the mature protease.  The 
mature protease then cleaves the Gag-Pol precursor into p2, nucleocapsid, and matrix 
proteins (Figure 1.2, step 13) [12, 16].  The enveloped virus is now infectious.  Envelope 
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gp120 and gp41 moieties are the primary targets of neutralizing antibodies that inhibit 
transmission person to person, but appear unsuccessful in limiting viral replication within 
the infected person due to serial antigen-driven mutations and glycosylation in gp120. 
 
Pathogenesis 
HIV-1 infects immune cells which express both CD4 and either of the coreceptors 
CCR5 or CXCR4:  T cells and macrophages [17, 18].  Primary HIV-1 infections most 
often occur at mucosal sites, where the virus is believed to be captured by the dendrites of 
intra- or subepithelial dendritic cells (DCs), Langerhans cells, or macrophages.  Captured 




 T cells in which productive infection is 
established [7, 18].  The virus spreads rapidly to other lymphoid tissues, particularly the 
gut-associated lymphoid tissue (GALT) and especially the effector lamina propria, where 
it can directly and indirectly cause the depletion of ~80% of the largely activated CD4
+
 T 
cells [7], including both memory and IL-17-secreting (Th17) CD4
+
 T cells, within the 
first three weeks of infection [19].  This massive depletion of CD4
+
 T cells, as well as 
indirect dysregulation of B cells results in the loss of nearly half of all gut germinal 
centers as well [7].  As the GALT becomes compromised, the integrity of the gut 
mucosal barrier breaks down, leading to the translocation of microbial products from the 
mucosa into the bloodstream [20].  These microbial products are proposed to contribute 
to the systemic immune activation and dysregulation characteristic of chronic HIV-1 
infection, including non-specific chronic B and T cell activation [7, 19, 20].  From the 
gut, the virus spreads to other lymphoid tissue, especially the lymph nodes, resulting, in 
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later stages of infection, in attenuation of the follicular dendritic cell network and in the 
formation of germinal centers [21].   
Chronic HIV-1 infection results in changes in the proportions of T cells in the 
blood and lamina propria; a drop in CD4
+
 and an increase CD8
+
 T cell numbers with 
increased activated and memory cell subsets.  This skewing is not limited to T cells, 
however, but similarly affects B cell, DC, and natural killer cells as well.  Immune cells 
also frequently become exhausted, losing both functionality and proliferative capacity 
during the course of infection [22-24].  In nearly 50% of patients infected with HIV-1 
subtype B (the predominant circulating subtype in North America and Europe), the virus 
may shift from utilizing CCR5 as a coreceptor, to using CXCR4 during the later stages of 
infection [17].  This switch in viral tropism is classically associated with very advanced 
disease, low CD4
+
 T cell numbers, and the development of AIDS in untreated patients 
[4]. 
Although HIV-1 has only been shown to infect CD4
+
 T lymphocytes and 
macrophages in vivo, the virus does have direct and indirect effects on the phenotype and 
function of the humoral effector arm of the adaptive immune response, B lymphocytes.  
The consequence of this effect is a dramatically increased incidence of infections for 
which antibodies are important in defense (e.g., Streptococcus pneumoniae, Haemophilus 
influenzae, non-typhi Salmonellae, and Cryptococcus neoformans) as well as of auto-







B cell development 
 B cells begin as pluripotent hematopoietic CD34
+
 stem cells in the bone marrow 
(Figure 1.3) [30-33].  With the help of soluble signaling factors produced by bone 
marrow stromal cells, including stem cell factor (SCF), thrombopoietin (TPO), flt3 
ligand, and other unidentified factors [34], these stem cells differentiate into early-B and 
pro-B cells [34, 35].   
Pro-B cells begin antigen-independent rearrangement of the variable portion of 
the B cell receptor (BCR), composed of the variable (V), diversity (D), and joining (J) 
gene segments of the heavy (H)-chain genes (Figure 1.4) [30-32].  V(D)J recombination 
is mediated primarily by two enzymes expressed during the pro-B cell stage, 
recombination activating genes (RAG)-1 and -2 [31, 36, 37].  These enzymes mediate 
recombination first by bringing together two recombination signal sequences (RSSs) that 
have spacer lengths of 12 and 23 base pairs [36, 37].  The RAG proteins both create 
single strand nicks in the RSSs.  The 3’-OH end of the cleaved DNA strand invades the 
opposite DNA strand forming blunt RSS ends and closed hairpin coding ends [37].  
These ends are processed through the endonuclease activity of DNA-PKcs and Artemis 
and repaired by the classical nonhomologous end-joining DNA repair pathway (NHEJ) 
[36, 37].  During this process, splicing inaccuracies by the RAG enzymes may occur, as 
well as the addition of random nucleotides by the activity of the Pol X family of 
polymerases (TdT, Pol, and Pol), both of which create great diversity at the V-D-J 
junctions [36-38].  In the early pro-B cell, D and J gene segments of the H-chain gene 





Figure 1.3:  B Cell Development.  B cells originate in the bone marrow as pluripotent 
hematopoietic stem cells.  Guided by bone marrow stromal cells, the stem cells 
differentiate into pro-B cells where they rearrange the heavy chain genes of the B cell 
receptor (BCR).  Successful rearrangement leads to several rounds of proliferation and 
transition into the pre-B cell stage, where the light chain genes are rearranged.  Immature 
B cells express a functional BCR – rearranged heavy chains linked to the IgM constant 
region, rearranged light chains, CD79 and CD79.  Immature B cells start to express the 
IgD constant region and become mature B cells, which exit the bone marrow and 
circulate in the periphery.  Upon antigen encounter, B cells can either become short-lived 
plasma cells, secreting antibodies that are either IgM or IgA (gut only), or migrate to the 
primary follicle to initiate a germinal center (GC) reaction.  GC B cells undergo somatic 
hypermutation (SHM; centroblasts) and class-switch recombination (CSR; centrocytes) to 
improve BCR/Immunoglobulin affinity and functionality.  High-affinity B cells can then 






cell [31, 32].  When late pro-B cells express the pre-BCR, composed of the in-frame VDJ 
rearrangement linked to a  constant region chain, the VpreB/5 complex (a surrogate 
light chain) and CD79, they become large pre-B cells.  Expression of the pre-BCR signals 
a halt in further rearrangement and several rounds of proliferation [30, 32].  
Rearrangement of the V and J gene segments of the L-chain then commences [32].  A 
complete immunoglobulin, including functional H-chain and L-chains, associates on the 
cell surface with CD79 and CD79 to form a functional BCR [31-33].  Cells which 
express a functional BCR are termed immature B cells [31, 32].   
Immature B cells are negatively selected to remove any self-reacting BCRs from 
the B cell pool, a process dependent on both BCR and BAFF/BAFFR (B cell activation 
factor belonging to the TNF family) signaling [40].  Unselected cells express BCRs of 
both  and  isotypes (IgM and IgD, respectively) and become naive mature cells which 
circulate in the blood stream and lymphatic system [31, 33].   
Upon encountering the antigen to which the BCR is specific, the B cells 
upregulate  CCR7, which attracts them to both CCL19 and CCL21, expressed by stromal 
cells in the T cells zones of secondary lymphoid organs [31, 41].  The antigen is 
internalized and processed by B cells, then is presented by MHC class II molecules on the 
B cell surface.  Nearby CD4
+
 T cells, activated previously by DCs [31, 42], recognize the 
peptide-MHC complex, and express soluble (IL-4) and cognate (CD40 ligand) 
costimulatory molecules [31, 41].  Activated B cells may then develop into antibody- 
secreting plasma cells in extrafollicular sites or mature into germinal-center precursor B 





Figure 1.4:  V(D)J Recombination.  The two DNA coding segments to be joined are 
shown as dark blue and pink rectangles.  The blue coding segment is flanked by a 12-
RSS and the pink coding segment is flanked by a 23-RSS (heptamer, spacer, nonamer 
indicated by 7, 12/23, 9, respectively.  The first step of V(D)J recombination is the 
binding of the RAG1/2 complex to an RSS.  Binding first to a 12-RSS or a 23-RSS are 
equally likely.  Capture of the second RSS occurs in the process of synapsis.  RAG1/2 
cleave the DNA within the synaptic complex, yielding the cleaved signal complex.  
Hairpin structures on coding ends are nicked by DNA-PKcs and Artemis (Art), followed 
by the addition of non-templated nucleotides (N) by terminal deoxynucleotidyl 
transferase (TdT), and coding end ligation by the XRCC40ligase IV (Lig IV) complex.  
The signal joint is formed by blunt end ligation of signal ends by the XRCC4-ligase IV 
complex [adapted from 39]. 
 
Germinal centers (GCs) (Figure 1.5) are composed mostly of proliferating B cells, 
but also a small proportion of antigen-specific T cells and FDCs [31, 43].  They are 
divided into areas called the dark zone, characterized by high frequencies of B cell 
proliferation and high cell density among CXCR4
+




Figure 1.5:  Germinal Center Reaction.  Antigen-activated B cells differentiate into 
centroblasts that undergo clonal expansion in the dark zone of the germinal center.  
Current hypotheses hold that during proliferation, the process of somatic hypermutation 
(SHM) introduces base-pair changes into the V(D)J region of the rearranged genes 
encoding the immunoglobulin variable region (IgV) of the heavy chain and light chain; 
some of these base-pair mutations lead to a change in the amino-acid sequence.  
Centroblasts then differentiate into centrocytes and move to the light zone, where the 
modified antigen receptor, with help from immune helper cells including T cells and 
follicular dendritic cells (FDCs), is selected for improved binding to the immunizing 
antigen.  Newly generated centrocytes that produce an unfavorable antibody undergo 
apoptosis and are removed.  A subset of centrocytes undergoes immunoglobulin class-
switch recombination (CSR).  Cycling of centroblasts and centrocytes between dark and 
light zones seems to be mediated by a chemokine gradient, presumably established by 
stromal cells in the respective zones (not shown).  Antigen-selected centrocytes 
eventually differentiate into memory B cells or plasma cells [42]. 
 
B cell activation, selection, and apoptosis occur among CXCR4
-
 centrocytes [42-44].  In 
the periphery of the light zone are a network of FDCs and CD4
+
 follicular helper T cells 
(TFH) which provide both antigen, and survival and activation signals to the proliferating 
B cells [31, 45, 46].   
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In the dark zone, centroblasts are retained by their expression of CXCR4, which is 
attracted to the high concentration of CXCL12, produced by local stromal cells in the 
dark zone [42-44].  Centroblasts in the dark zone express high levels of activation-
induced cytidine deaminase (AID) and undergo somatic hypermutation (SHM) to alter 
the affinity of the BCR for the antigen [42, 47].  Centroblasts can downregulate CXCR4 
expression and upregulate CXCR5 expression, becoming centrocytes.  CXCR5
+
 GC B 
cells are attracted to CXCL13, produced by FDCs in the light zone [31, 42-45].  
Centrocytes reduce their rate of cell division and undergo positive selection to retain only 
the highest affinity BCRs.  Centrocytes express their newly mutated BCR, which can 
bind with varying affinities to antigen captured by FDCs.  High-affinity binding leads to 
antigen processing and presentation on MHC class II molecules to TFH cells.  B cells 
expressing high densities of MHC class II/antigen complexes elicit survival signals, 
especially CD40L and IL-21, from TFH cells.  B cells expressing low affinity BCRs will 
not be able to compete as well for antigen, will not be able to present high densities of 
antigen to T cells, and thus, will not receive survival signals.  Low-affinity B cells, 
therefore, undergo apoptosis [31, 42, 43, 45-47].  High-affinity B cells that are selected 
can upregulate CXCR4 and return to the dark zone to undergo further rounds of affinity 
maturation as a result of SHM and selection [42, 45, 47].  Current data suggest that after 
SHM occurs, the isotype of the BCR may be altered to change its functionality [48].  
Class switch recombination (CSR), also dependent on the activity of AID, is the switch 
from the constant regions expressed by mature naïve B cells, IgM and IgD, to expression 
of either IgM, IgG, IgA, or IgE alone [47, 49, 50]. 
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 Cells that survive the selection process in germinal centers can differentiate into 
either memory B cells or antibody-secreting plasma cells in the bone marrow and other 
tissues, including the lamina propria of mucosal tissues.  These distinct maturation 
pathways are mediated by T cell factors including CD40/CD40L and IL-4 signaling for 
memory cell development, and OX40-OX40L and IL-2, IL-3, IL-6, and IL-10 signaling 
for plasma cell development [31, 51].  Memory cells are long-lived cells that express 
surface immunoglobulin, but do not secrete antibody.  During subsequent exposures to 
their specific antigen, memory B cells become quickly reactivated, leading to 
proliferation and differentiation into plasma cells [51, 52].  Crotty, et al, have suggested 
that “bystander” activation of memory B cells by adjacent antigen-unrelated but activated 
T cells can also sustain the B cell memory and plasma cell populations [53].  Thus, a 
small pool of memory B cells can be maintained for long periods of time.  Plasma cells 
express surface immunoglobulin and secrete large amounts of antibody [51].  Plasma 
cells persist for several weeks to several years and are responsible for large, rapid 
increases in levels of specific antibody during subsequent antigenic exposure [45, 51, 52].  
Migration of plasmablasts and memory cells from the germinal centers is most likely 
directed by chemokine expression.  After infections are cleared, memory cells will 
circulate between germinal centers to extrafollicular sites such as spleen and bone 
marrow via lymph and blood 47, 51, 54].  Plasma cells are retained in the bone marrow 
and found in peripheral blood only at low frequencies [45, 51, 52, 55]. 
 Not all antibody responses require GC formation.  T cell-independent (TI) 
antigens can activate B cells without any T cell help.  These antigens are divided into two 
groups; TI-1 antigens activate B cells through non-BCR signaling pathways, such as 
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TLRs, and TI-2 antigens bind and cross-link BCRs via their repeating epitopes [56].  TI-1 
antigens include TLR ligands such as single-stranded RNA from viruses (TLR-7/8) and 
CpG DNA from bacteria and viruses (TLR-9) [57].  TI-2 antigens include bacterial 
polysaccharides from S. pneumoniae, H. influenzae, and N. meningitidis, and some viral 
capsid proteins, such as those found in vesicular stomatitis virus (VSV), poliovirus, and 
polyoma virus [56].  Activation signals, in conjunction with TI-antigen binding to B cells, 
can be provided by various cell types, such as epithelial cells and DCs, to activate the B 
cells [58-59].  Transient, short-lived GC may form, but only limited SHM and CSR 
occur, and only involve switch to IgM in extrafollicular sites or IgM and IgA in the gut 
[31, 41, 45, 50].   
 In the context of HIV-1 infection, B cell development from the stem cell to the 
naïve mature stage appears normal.  Indeed, despite decreased total B cell numbers in 
HIV-1-infected patients, multiple studies have shown normal to increased proportions of 
naïve mature B cells compared to healthy control subjects [60-63].  GC responses and 
maturation to memory and plasma cells may be impaired, however.  GC development is 
interrupted early during the course of infection, recovers during the asymptomatic stage, 
and declines again as patients progress to AIDS [7, 21, 63] presumably due to a lack of 
CD4
+
 T cell help [7], but also because of attenuated and disrupted FDC networks [21].  







class-switched plasma cells is also decreased during HIV-1 infection [22, 63-65].  
Whether these perturbations in B cell phenotype are due to the reductions in the number 
or function of GC T cells, particularly TFH cells, to the functional activity of AID, the 
enzyme responsible for CSR, to the numbers and sizes of GC, or to an HIV-1-associated 
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defect in the ability of B cells to respond to antigenic stimuli and/or T cell help is not 
known.  How these conditions affect the genes that encode antibodies (e.g., VH) and the 
molecules that regulate them (e.g., AID) is a primary focus of this thesis. 
 Although the primary function of B cells is antibody production, B cells can also 
direct the immune responses and development of other cell types.  B cells release 
cytokines that can direct T cell and DC differentiation and responses, including IL-4, IL-
6, IL-10, and IFN- [66-68], regulate lymphoid tissue generation and organization, such 
as the differentiation of FDCs through lymphotoxin / expression and M cell 




 Immunoglobulins on the B cell surface (B cell receptor; BCR) and their secreted 
cogeners, antibodies, are composed of two identical heavy (H)-chains and two identical 
light (L)-chains (Figure 1.6).  These four chains are held together by disulfide binding.  
The N-terminal domains of the variable region of each chain (VDJ for H-chains and VJ 
for L-chains) binds antigen.  Each V region is further subdivided into complementarity 
determining regions (CDRs) and framework regions (FRs).  CDR loops come into direct 
contact with the antigen.  FRs provide structural support for the CDRs [70].  The C-
terminal domains form the constant region, which defines the class and function of the 




Figure 1.6:  Antibody Structure.  Pairs of heavy and light chains combine to form a Y-
shaped molecule.  Two antigen-binding sites are formed by the combination of variable 
domains from one light (VL) and one heavy (VH) chain.  Cleavage within the hinge region 
separates the Fab and Fc portions of the protein.  The Fc portion of the molecule also 
contains bound carbohydrate [Adapted from 71]. 
 
All antibodies are glycoproteins; 3-13% of their weight is carbohydrate [38].  The 
extent of glycosylation varies by isotype, is essential for antibody structure, and can 
affect antibody function [38-72].  Glycans can influence binding to both Fc receptors and 
immune mediators, are essential for antibody-dependent cellular cytotoxicity (ADCC), 
play a role in complement-dependent cytotoxicity, can protect the hinge region of IgA 
from proteolytic cleavage, and can even bind antigen [72].   
 The constant regions define the 5 antibody classes or isotypes:  IgG, IgA, IgM, 
IgD, and IgE.  Additionally, there are four subclasses of IgG (IgG1-IgG4) and two 
subclasses of IgA (IgA1 and IgA2) [38].  IgD is predominantly expressed by naïve 
mature B cells and during the GC reaction, expression is downregulated prior to class 
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switching [31].  There are additional exclusively-IgD
+
 B cell subsets that can have both a 
naïve mature (BND anergic) or a memory or antibody-secreting plasma cell phenotype 
(class-switched IgD B cells) [73-75].  While little is known about the function of secreted 
IgD [76], class-switched IgD B cells have heavily mutated VH genes and are typically 
autoreactive [74, 75].  IgM functions in neutralization and opsonization.  IgM antibodies 





 B cells outside of a germinal center without undergoing 
affinity-enhancing SHM.  However, IgM forms pentamers, allowing the resulting 10 
antigen-binding sites to bind antigen at a high overall avidity (functional affinity).  IgM is 
found in blood and lymph [72, 77].  IgG is the most abundant isotype produced in blood 
where it can diffuse into tissues more readily than IgM.  IgG is capable of neutralization, 
opsonization and activation of the complement pathway.  IgA is the principal isotype in 
secretions, especially in the intestinal and respiratory tracts.  It functions mainly as a 
neutralizing antibody.  IgE is present at the lowest serum concentration of all the classes 
and interacts with mast cells to fight off parasitic infections and mediate allergic disease 
[72-77]. 
 Antibodies can have both direct and indirect effects on pathogens.  They can 
directly block pathogens from binding to host tissues, prevent pathogen entry into host 
cells, interfere with pathogen mobility, and block pathogen effector protein activity [78].  
Indirectly, antibodies can activate the classical complement pathway, recruit innate 
immune cells and promote phagocytosis of the pathogen, or bind to Fc receptors found on 
immune effector cells such as macrophages, dendritic cells, neutrophils, natural killer 
cells, eosinophils, basophils, and mast cells.  Different cell types express different Fc 
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receptors for IgG (FcRI (CD64), II (CD32), and III (CD16)), IgA (FcR; CD89), and 
IgM [78, 79].  Fc receptor engagement can activate cells to phagocytose an antibody-
coated microorganism, release stored toxic chemicals such as reactive oxygen and 
nitrogen species, and induce cytokine production, such as IL-4, IL-6, IL-8, and TNF-
. 
 The development of effective, specific antibody structure, and therefore, function, 
is dependent upon a B cell-specific enzyme called activated-induced cytidine deaminase 
(AID).   
 
Activation-induced cytidine deaminase  
 AID is an enzyme expressed predominantly by germinal center B cells and is 
required for both CSR and SHM [80, 81].  This 198 amino acids enzyme is encoded by 
five exons (Figure 1.7) [82, 83].  The N-terminal portion of the enzyme is required for 
SHM and the C-terminal portion is required for CSR [84].  Although a crystal structure 
has not been resolved, it is thought to function as a dimer in vivo, although activity has 
also been shown by the monomer in vitro [85, 86]. 
 AID is expressed in response to B cell activation.  Activation by various stimuli, 
such as T cell engagement (CD40 signaling) [82], Toll-like receptor (TLR) signaling 
(e.g., TLR-9) [87], hormones such as estrogen [88], and many microorganisms (Hepatitis 
C virus, Epstein-Barr virus [87, 89], Helicobacter pylori [90], Bacteroides species [91], 
and HIV-1 [92, 93]), leads to the upregulation of AID mRNA.  These stimuli activate the 





Figure 1.7:  AID Enzyme.  AID is composed of five exons and divided into two 
domains, the N-terminal domain, associated with SHM, and the C-terminal domain, 
associated with CSR.  A nuclear localization signal (NLS) is located in the N-terminal 
domain.  A nuclear export signal (NES) is located in the C-terminal domain.  Deaminase 
activity has been mapped to the center of the enzyme and is completely encoded by exon 
3.  Three phosphorylation sites that are important for CSR and SHM have been 
identified; Serine (S) 38, Threonine (T) 140, and Tyrosine (Y) 184. 
 
 AID initiates both SHM and CSR by deaminating cytidine residues, leaving uracil 
residues behind in the target DNA.  As a result of the potential for subsequent mutagenic 
activity, AID is tightly regulated by four mechanisms:  transcription, cellular 
compartmentalization, phosphorylation, and degradation.  In addition to the transcription 
factors that control activation of AID expression, AID expression can be downregulated 
by the Ca
2+
-sensing protein calmodulin [94] and the hormone progesterone [95].  AID 
expression is also sensitive to post-transcriptional control by the microRNAs miR-181b 
and miR-155, which both downregulate AID protein expression [96-98].  AID protein is 
expressed primarily in the cytoplasm [99, 100].  AID has both a nuclear export signal 
(NES) found in the C-terminal portion of the protein [100, 101] and a nuclear localization 
signal (NLS) in the N-terminal portion [102].  Active nuclear export mediated by CRM-1 
is required to maintain AID in the cytoplasm [100, 102], but active nuclear import is 
required for AID activity [101].   
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 As its name implies, AID deaminates cytidine residues on single stranded DNA 
(ssDNA) substrates [103].  Active transcription of the variable region of heavy and light 
immunoglobulin chains (VH and VL, respectively) is required for SHM and of the switch 
regions near the constant region genes for CSR [80].  Indeed, AID has been shown to 
directly associate with the transcription apparatus, specifically RNA polymerase II, and 
there is a correlation between SHM frequency and transcription levels [104].   
Upon entering the nucleus, AID can be phosphorylated at three sites, S38, T140, 
and Y184 [105].  Both CSR and SHM require phosphorylation at S38 [106], whereas 
T140 phosphorylation affects only SHM [107].  The relevance of Y184 phosphorylation 
is unknown [105].  Phosphorylation of AID is important for its association with 
chromatin [99].  Nuclear AID is targeted for degradation by the ubiquitin-proteasomal 
pathway [108].  It is likely that other regulatory mechanisms exist also, especially 
negative regulatory mechanisms.  Indeed, when AID is constitutively over-expressed 
transgenically, the enzyme has diminished, rather than increased, activity relative to 
endogenous AID [109], although the mechanism limiting AID function is unknown. 
 Phosphorylated AID also interacts directly with Replication Protein A (RPA), a 
single stranded DNA binding protein required for AID activity [110].  After cytidine 
deamination, AID may dissociate from the substrate, leaving RPA bound to the DNA.  
RPA then may act as a scaffold for downstream DNA repair pathways [111]. 
 In addition to the full-length isoform, four other mRNA variants of AID are 
expressed in vivo (Figure 1.8) [83, 112-114].  The longest isoform, AIDins3, contains all 
five exons plus intron 3.  This isoform maintains the cytodine deaminase domain, but 
lacks the portion of the protein responsible for CSR due to a frameshift resulting in a 
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premature stop codon.  The 562 base pair isoform (AID-E4a) contains all five exons, 
but lacks the last 30 base pairs of exon 4 though it retains all functional domains with no 
frameshifts.  The AID-E4 isoform is missing all of exon 4 including the majority of the 
C-terminus due to a frameshift, including the nuclear export signal, resulting in primarily 
nuclear localization and the inability to perform CSR.  Finally, the AID E3-E4 isoform 
lacks both exons 3 and 4 without any frameshifts, but it does delete both the cytidine 
deaminase domain (present in exon 3) as well as the T140 phosphorylation site (exon 4) 
resulting in the loss of both CSR and SHM [83].  Thus, alternative splicing of AID may 
have functional consequences, such as those described below, that may underlie HIV-1-
associated defects in SHM and CSR. 
 
 
Figure 1.8:  AID Isoforms.  Exons (1-5) in AID mRNA can be alternatively spliced into 
5 different isoforms.  The different isoforms have been associated with different levels of 
SHM and CSR activity as well as cellular localization, relative to the full-length isoform.  




 The functional AID multimer is likely a dimer in vivo [85].  Because of deletions 
of many functional domains in the isoforms, many of their functional capacities may vary 
from that of the full-length isoforms.  If multiple isoforms of AID were to be expressed in 
the same cell, heterodimerization of different isoforms may affect the functionality of the 
dimer.  Like the full-length isoform, both AID-E4a and AID E3-E4 are predominantly 
found in the cytoplasm, whereas both AIDins3 and AID-E4 are found more abundantly 
in the nucleus than the full-length isoform because they lack the NES [83, 115].  Whereas 
the full-length isoform is both SHM- and CSR-competent, none of the other isoforms 
mediate CSR.  Similarly, AID E3-E4 is also defective for SHM, likely due to the 
absence of the cytidine deaminase domain.  In contrast, AID-E4a and AID-E4 not 
only were capable of hypermutating a test substrate, but did so at a higher frequency than 
the full-length isoform [116].  However, using a different assay, none of the other 
isoforms had any catalytic activity [115].  Expression patterns of the various AID 
isoforms and their functional capacities in SHM and CSR, both in health and disease 
states, such as with HIV-1 infection, may reveal their physiologic impact on overall AID 
activity. 
 
Somatic hypermutation and class-switch recombination 
 AID mediates two important stages of antibody development:  Class switch 
recombination (CSR) and somatic hypermutation (SHM).  CSR is responsible for the 
switch of antibody constant regions from the IgD to the IgM, IgG, IgA, or IgE isotypes.  
The switch in the constant region is capable of changing the functionality of the antibody, 
as described above in “Antibody structure”.  SHM leads to the introduction of point 
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mutations into the variable region of antibody genes with the goal of producing 
antibodies that are more specific and of higher affinity for a particular antigen.  Both 
processes occur predominantly in the GC, with SHM putatively preceding CSR [48].   
 SHM has been shown in vitro to be impaired by HIV-1.  The viral protein Vif can 
directly bind to AID, when both are co-expressed in E. coli.  Binding interrupts the 
cytidine deaminase activity of AID, thereby preventing the introduction of point 
mutations [117].  It is not known, however, whether this process occurs in vivo or during 
HIV-1 infection. 
 SHM is initially triggered by the deamination of cytidine residues by AID in 
actively-transcribed variable regions (Figure 1.9).  In the nucleus, AID and Protein 
Kinase A (PKA) are likely both recruited to the V regions, where PKA phosphorylates 
the S38 residue [118].  How the T140 residue becomes phosphorylated is unknown, 
though it may involve another protein kinase, PKC [107].  Phosphorylated-AID then 
associates with RPA, a single stranded DNA (ssDNA) binding protein, on chromatin.  
AID begins mutating ssDNA along the V region starting ~150 base pairs downstream of 
the IgV promoter and ending 1-2 kb downstream [82, 119].  Activity of AID on a 
cytidine residue results in a U:G lesion.   
The U:G lesion can be recognized and repaired by several pathways.  If the DNA 
replication machinery encounter the lesion first, an A will be paired with the U, creating a 
C to T transition mutation.  The U:G lesion can also be recognized by DNA repair 
machinery.  Uracil-DNA glycosylase (UNG) will remove the uracil residue, leaving an 




Figure 1.9:  Model of Somatic Hypermutation.  dU is not  relevant to DNA and the 
dU:dG mismatch is ‘replicated over’ or dealt with by the DNA repair machinery.  
Replicating over dU results in a dC→dT transition mutation (Phase 1a), whereas dU 
deglycosylation by Ung gives rise to an abasic site.  In the presence of PCNA (orange 
ring), DNA synthesis opposite the abasic site by TLS pol , which has both nucleotide 
inserter and extender activity, or by the nucleotide inserter pol , Rev1 or, perhaps pol , 
followed by the nucleotide extender pol  or pol , yields dC→dT transitions and 
dC→dA or dC→dG transversions (Phase 1b).  Alternatively, the abasic site can be 
recognized and excised by APE or the Mre11-Rad50 lyase to create a DNA nick.  This 
nick can be repaired by DNA pol  (light pink circles) in an error-free fashion (short-
patch BER) or repaired in an error-prone fashion by a TLS polymerase through a long-
patch BER also involving PCNA and Fen1.  dU:dG mispairs can also be recognized by 
the MMR machinery, resulting in a DNA-gap formation through the intervention of an 
unidentified endonuclease or MRN and Exo I.  Subsequently, TLS pol , pol , Rev1, pol 
and , perhaps, pol  can affect DNA re-synthesis as part of a patch repair, thereby 
inserting mismatches (Phase 2).  In the long-patch BER or MMR, RPA (large brown 
ovals) and PCNA would recruit other repair proteins to the lesion and co-ordinate their 
actions.  MMR proteins are indicated as large green ovals.  Mutated nucleotides are 
shown in red [120]. 
28 
 
pathways.  RPA still bound to the ssDNA can associate with proliferating cell nuclear 
antigen (PCNA), a scaffold protein known to recruit low-fidelity translesion (TLS) DNA 
Polymerases and to promote efficient DNA repair.  Replication over the abasic site by the 
TLS polymerases will result in the random incorporation of a nucleotide at the site, 
creating both transition (purine→purine or pyrimidine→pyrimidine) and transversion 
(purine↔pyrimidine) mutations.  If the abasic site left by UNG is recognized by 
apurinic/apyrimidic endonuclease (APE), the abasic site will be removed, leaving a gap 
in the DNA strand [120, 121].   
This gap can be repaired by either the high fidelity short-patch base excision 
repair (BER) pathway, or the error-prone long-patch BER pathway.  Short-patch repair 
machinery recruits a high fidelity DNA polymerase, polymerase , to the sight of the 
lesion, and corrects the initial lesion leaving no resulting mutation.  Long-patch repair 
machinery recruits PCNA and an endonuclease Fen1, which excises many nucleotides 
around the gap.  The gap is then repaired by low fidelity TLS polymerases which may 
effect several mutations around the original lesion [120, 121].  The abasic site created by 
UNG can also be recognized by the MRN (Mre11-Rad50-Nbs1) complex that can nick 
the abasic site, also creating a gap [119, 120], but leaving ends that high fidelity DNA 
polymerases cannot extend [119].  PCNA is recruited and the gap is repaired by the long-
patch BER pathway [120].  Lastly, the U:G lesion originally created by AID can also be 
recognized by the mismatch repair (MMR) pathway.  MMR pathway machinery is 
recruited to the lesion, including both Exo I and another unknown endonuclease that 
nicks the strand around the lesion.  The lesion is then repaired by TLS polymerases, 
potentially yielding multiple mutations around the original lesion [120, 122].  Thus, a 
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greater number of mutations can be generated in bases other than C by the initial 
deamination of cytidine. 
 Mutations resulting from SHM occur at a one million-fold higher rate than 





changes per base per cell division.  The vast majority of these mutations are point 
mutations [82, 103] and the process has a slight preference for transition over 
transversion mutations [82, 123, 124].  Most AID-induced mutations occur at 
RGYW/WRCY “hotspot” motifs, the sequence targeted by AID [103, 125].  Most AT 
mutations occur at WA/TW motifs [125].  Mutations at each base occur at different rates, 
with mutations occurring most frequently at A bases (35% of mutations), followed by C 
and G bases (both 25%), with the fewest occurring at T bases (15%) [126].  Mutations are 
targeted more to the hypervariable CDR regions of the gene than to the more conserved 
structural FR regions.  This differential mutation frequency is supported in part by the 
increased prevalence of RGYW/WRCY motifs in CDRs, thus recruiting AID more 
frequently to these regions [82].  
 It is not known exactly how AID is targeted to IgV regions of chromatin.  Several 
mechanisms, including immunoglobulin (Ig) enhancer elements, chromatin accessibility, 
cis-acting sequences and cell cycle regulation, could all play a role.  Ig enhancer elements 
have been found in both intronic sequences and at the 3’ end of rearranged Ig variable 
regions [127].  Changes in histone acetylation may also be dependent on AID expression 
and recruit error-prone DNA repair machinery [124].  Cis-acting sequences, such as R- 
and G-loops in transcribed Ig regions may offer AID a stable binding target [124].  SHM 
and CSR are both restricted to the nonreplicative phases of the cell cycle, thus potentially 
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separating error-free DNA repair that occurs during DNA replication from the error-
prone DNA repair that occurs during CSR and SHM.  While all these things may attract 
AID, none are sufficient in themselves to target SHM and CSR. 
 Repair by low fidelity TLS DNA polymerases is essential to the SHM process.  
Without them, mutations might not occur at all, or too many mutations could overwhelm 
the error-free DNA repair machinery leading to the death of the cell.  There are eight TLS 
polymerases in humans that are believed to be involved in SHM and CSR mutation 
repair:  pol , , , , , Rev 1, and pol  and  [120, 128, 129].  Their exact roles in both 
processes are still being discovered, but it is thought that they work cooperatively with 
each other in both filling and bypassing the abasic sites and gaps introduced by the repair 
machinery [120].  Impairment of one or more of these polymerases can affect the 
resulting nucleotide mutation pattern [128, 129].  Pol  and  are thought to have the 
greatest roles in SHM [120, 128, 129], while pol  and  have been implicated in CSR 
[128]. 
 CSR, like SHM, is initiated by AID.  AID is targeted to RGYW/WRCY hotspots  
in the switch (S) regions located upstream of each of the H-chain constant regions except 
for C (IgD), rather than the VH regions with SHM.  S regions are tandem repeats of short 
(20-80 base pair) G-rich sequences.  They differ in sequence and in length (1-12 kb) by 
isotype [49].  Cytokines secreted by T cells in the GC or by DCs and monocytes outside 
the GC direct the isotype switch [49, 58, 59]. 
 Similar to SHM, CSR begins with transcription.  Actively transcribed S regions 
are bound by AID, which deaminates the cytidine residues into uracils in RGYW/WRCY 
“hotspot” motifs in the sequence.  The lesions are recognized by UNG, which cleaves out 
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the uracil, leaving an abasic site.  The abasic site is recognized by APE, which removes 
the phosphate backbone of the DNA, creating single stranded (ss) DNA breaks.  Exo I is 
believed to recognize the ssDNA breaks and continue removing bases until it reaches 
another ssDNA break on the other DNA strand, therefore creating a double stranded (ds) 
break.  The dsDNA breaks create 5’ or 3’ single strand overhangs.  These will be either 
excised by the endonuclease ERCC1-XPF or filled by TLS polymerases recruited to the 
site by MMR machinery and PCNA [49, 77].  Once dsDNA breaks are formed in both the 
donor S region and the acceptor Sx region, the regions are recombined by either non-
homologous end joining (NHEJ) or alternative non-homologous end joining (A-NHEJ) 
[49, 130], and give rise to an extrachromosomal DNA switch circle comprised of the 
deleted DNA sequence [77]. 
 CSR requires at least two complete rounds of cell division to complete.  Once 
complete, the B cell will express an immunoglobulin with the new IgM, IgG, IgA, or IgE 
isotype [49, 77].  The specification of class switching is dependent upon cytokine 
signaling, such as IL-4, TGF-, and IFN-, from activated T cells; these signals promote 
transcription at the different isotype switch region promoters [77].  Similar to SHM, 
studies from Qiao et al. have shown both in vitro and in vivo that CSR can be impaired 
by HIV-1 [131].  HIV-1 protein Nef can suppress NF-B activation by inducing NF-B 
inhibitor IB expression and by inducing suppressor of cytokine signaling (SOCS) 
protein expression, which inhibits CD40/CD40L and other cytokine signaling [131].  
Indeed, data from our lab suggest a subtle but reproducible HIV-1-associated decrement 




B cells and HIV-1 
HIV-1-infected patients experience higher incidences of mucosal and systemic 
secondary and opportunistic infections with microorganisms such as Streptococcus 
pneumoniae, Haemophilus influenzae, Cryptococcus neoformans, and Salmonella species 
than non-infected patients [25-27].  In the case of S. pneumoniae infections, HIV-1-
infected patients have a higher incidence of both pneumonia (infection of the lungs, about 
10 higher than non-infected) and of bacteremia (infection of the bloodstream, 100 times 
higher than non-infected) [134].  The recurrence of infection is also higher in HIV-1-
infected patients than in non-infected patients [65].  These opportunistic infections and 
others are controlled by antibody responses [25-27].   
HIV-1 does not directly infect B cells in vivo, but HIV-1 infection is consistently 
associated with B cell dysfunction.  The consequences of HIV-1-associated B cell 
dysfunction include hypergammaglobulinemia early in infection, increased polyclonal B 
cell activation, lymphoadenopathy, high frequencies of B cell lymphomas, autoantibodies 
in the serum, and autoimmune disease [22, 29, 135-138].  Many of these defects precede 
the significant depletion of CD4
+
 T cells and are not completely corrected in vitro when 
normal T cells are added, or with elimination of viremia with antiretroviral therapy, 
suggesting that the defect in B cell activity, may be, in part, intrinsic to the B cell [138-
140]. 
High levels of B cell activation are caused both directly and indirectly by the 
virus.  HIV-1 can bind directly to B cells through interactions between CD21 on B cells 
and complement C3 fragments bound to virions [93].  Other HIV-1 binding receptors 
found on B cells include DC-SIGN and other C-type lectin receptors, the framework 
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regions of VH3 family-specific surface immunoglobulins [22], and CD40 receptors on the 
B cells that bind host membrane-derived CD40 ligand on the viral envelope [139].  
Indirect activation occurs through other activated immune cell types including virus-
activated CD4
+
 T cells, monocytes, dendritic cells, and natural killer cells either through 
direct CD40-CD40L interaction or through the release of cytokines [64].  HIV-1-infected 
patients have increased serum levels of cytokines and growth factors including IFN-, 
TNF-, IL-6, IL-10, and B cell Activation Factor (BAFF) [22, 141], all of which can 
activate B cells.  High levels of B cell activation are not the only B cell abnormality in 
HIV-1-infected patients.  B cell subpopulations, such as immature transitional cells, 
exhausted cells, activated mature cells, and plasmablasts are found at much higher 
proportions than in uninfected control subjects.  Conversely, the number and proportion 






) are lower, as is memory B cell function [64, 65], 
a phenotype that also is not corrected with successful antiretroviral treatment [22].  
Despite high levels of B cell activation, HIV-1-infected subjects mount 
diminished responses to neoantigens and polysaccharides in vivo and to B cell mitogens 
in vitro [29, 138, 140, 142, 143].  The limited magnitude of such responses may explain, 
in part, the high occurrence of antibody-controlled opportunistic infections and the poor 
responses to vaccines administered to prevent them, as may limitations in the quality of 
responses, such as antibody affinity, a process determined by SHM and controlled by 
AID, as described above.  Numerous studies have shown that immunization using 
pneumococcal vaccines results in poor T cell-dependent vaccination responses in HIV-1-
infected individuals [65, 144-147].  Likewise, poor vaccination responses have also been 
seen when using vaccines targeting both neoantigens (KLH, Hepatitis B) [140] and recall 
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antigens (tetanus toxoid [145] and H. influenzae type b [148, 149]).  Not only may the 
quantities of the antibodies produced be limited, but some data suggest that the quality of 
the antibody response (i.e. avidity and affinity) is also decreased.  Indeed, the avidity of 
oral antibodies to Candida antigens [150, 151] and H. influenza type b specific IgG and 
IgA antibodies in the blood [148] among patients with HIV-1 infection, qualities 
dependent on SHM and AID activity, may be lower than those in control subjects. 
Thus, despite the consistent presence of hypergammaglobulinemia, lower levels 
of antibody responses to infection and vaccination, as well as a potential decrement in 
antibody quality, may contribute to the high rates of opportunistic infections, especially 
those occurring in the blood.  I propose to determine whether B cell function in HIV-1-
infected patients is impaired at the phenotypic and molecular levels, and if so, to 
determine the mechanisms underlying these defects.  I hypothesized that the poor vaccine 
and infection responses identified in HIV-1-infected patients could be attributed, in part, 
to decreased frequencies of SHM in the antigen-binding variable region of circulating 
class-switched IgG B cells, and that these decreases in SHM resulted from a decrement in 








MATERIALS AND METHODS 
 
Patient data 
We enrolled 42 HIV-seronegative control subjects and 72 patients with HIV-1 
infection (19 on antiretroviral therapy (aviremics) and 53 not on therapy with detectable 
plasma HIV-1 RNA (viremics)).  Exclusion criteria included any acute medical illness, 
significant underlying medical illnesses (e.g., renal, hepatic, pulmonary) or 
immunosuppressive therapy and additionally for control subjects, any risks for HIV-1 
infection, including intravenous drug use.  For the 6 months preceding enrollment, all 
HIV-1-infected patients were stable on antiretroviral regimens or had received no 
therapy.  All subjects were enrolled after completing written informed consent with 
protocols approved by Institutional Review Boards at the Veterans Affairs Medical 
Centers in Minneapolis and Denver and at the University of Minnesota and the 






PBMC isolation and stimulation 
Isolation   
PBMC were separated from ≈60 mL of fresh whole blood by Ficoll-Hypaque 
(Sigma, St. Louis, MO) density centrifugation and washed.  For immunophenotyping 
(Flow Cytometry), 2 million cells were resuspended in FACS Staining Buffer and placed 
on ice.  For RNA, 5-10 million cells were resuspended in RNAlater (Qiagen, Inc., 
Valencia, CA) and stored at -80
o
C.   
 
Stimulation   
PBMC (2x10
6
 cells/mL) were cultured with either media alone (RPMI media 
(Invitrogen, Grand Island, NY) with 10% heat-inactivated FCS (HyClone Laboratories, 
Logan, UT) and 10 g/ml gentamicin (Invitrogen)) or stimulated with single agents or a 
combination of IL-4 (10 ng/mL; Peprotech, Inc., Rocky Hill, NJ), anti-CD40 (1 g/mL; 
BD-Biosciences, San Diego, CA), and anti-IgM (1.3 g/mL; Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA) in 25 mL flasks at 37
o
C for 4 days.  On day 4, cells 
were removed from the flasks, and the two halves of each flask were placed in separate 
tubes on ice for Flow Cytometry or RNA extraction. 
 
Total immunoglobulins 
Supernatants from parallel cultures in 96 well plates were harvested on day 7 for 
total IgG, IgM, and IgA by enzyme immunoassay as described from our lab [133].  Total 





RNA was extracted using either an RNEasy RNA Extraction Kit or an AllPrep 
RNA/DNA/Protein Mini kit according to the manufacturer’s protocol (Qiagen, Inc.), 
quantified using a NanoDrop spectrophotometer (NanoDrop Technologies Inc., 





 Genomic DNA was extracted using a DNEasy DNA Extraction Kit or an AllPrep 
RNA/DNA/Protein Mini kit according to the manufacturer’s protocol (Qiagen, Inc.), 






cDNA for sequencing was synthesized according to the manufacturer’s protocol 
in a 60 L reaction consisting of 23 L of RNA template, 0.5 mM each dNTP, 7.5 g/mL 
random hexamers (Invitrogen), 8.3 g/mL oligo(dT) (Invitrogen), and 10 U/L Moloney 
murine leukemia virus (M-MLV) reverse transcriptase (Invitrogen).  The samples were 
incubated at 37
o
C for 1 hour then heated to 70
o
C for 15 minutes.  Two units of RNAse H 
(Invitrogen) were added to the cDNA.  The samples were incubated at 37
o
C for 20 









For reverse transcription of mRNA, 2 g of RNA were aliquoted, dried, and 
reverse transcribed using the First Strand cDNA Synthesis Kit (Invitrogen) and random 
hexamers (Invitrogen) according to the manufacturer’s protocol.  80 l of nuclease-free 
water was added to each reaction, resulting in cDNA concentrated to 20 ng/L.  Real 
time quantitative PCR analysis of AID mRNA expression was performed using either 
Platinum SYBR Green qPCR Supermix-UDG with ROX (Invitrogen) and primer sets 
targeting human -actin and human AID (aicda; SuperArray Bioscience Inc., Frederick, 
MD) or TaqMan Gene Expression Assays for human AICDA and human GAPDH (Life 
Technologies, Grand Island, NY).  Both human AID assay primers sets amplify AID 
cDNA beginning in exon 2 and ending in exon 3.  Samples were tested in triplicate, using 
1 l of template cDNA per 20 l reaction on either an ABI 7300 real time PCR machine 
(SYBR Green reactions; Applied Biosystems, Inc., Foster City, CA) or a BioRad CFX96 
Real Time System (TaqMan reactions; BioRad, Hercules, CA, Figure 2.1).  AID 
expression was determined relative to the “housekeeping”/reference genes -actin or 
GAPDH by subtracting the cycle threshold (Ct) for the reference gene from that for AID 





.  Assays were validated by amplifying a standard curve with 




Figure 2.1:  Representative Real-Time PCR Run.  Cycle number (x-axis) is graphed 
against the Relative Fluorescent Units (RFU; y-axis).  Cycle threshold (Ct) for genes is 
the point on the curve that intersects the horizontal threshold line (blue, above).  20 l 
reactions were run in triplicate for each sample.  AID expression was calculated relative 
to either -actin, or GAPDH (shown above).  The fewer cycles required to attain the 
threshold, the higher the specific cDNA concentration. 
 
AID isoforms amplification and cloning 
AID isoforms PCR   
To determine expression of splice variants (isoforms) of AID, AID-specific 
cDNA transcripts were amplified by PCR.  Primers used for PCR amplification were 
commercially synthesized primers which bind AID cDNA transcripts in exons 2 
(AIDfwd1) and 5 (AIDrev1) (Table 2.1).  Reactions were done in duplicate.  PCR (25 
L) consisted of:  5 L of cDNA or 1.25 ng of cloned positive control, 2.5 L 2 mM 
dNTPs, 1.5 L 25 mM MgSO4, 2.5L of 10x KOD Buffer, 0.75L each primer (10 
M), 0.5 L KOD Hot Start High-Fidelity DNA polymerase (Novagen, Gibbstown, NJ).  
Samples were heated to 95
o
C for 2 minutes in an Applied Biosystems 9700 thermocycler 
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(“hot start”) followed by 45 cycles consisting of 20 seconds of 95
o
C denaturation, 10 
seconds of 60
o
C annealing, and 10 seconds of 70
o
C extension.  PCR products were run 
on a 2.0% 1x TBE agarose gel (Sigma) and stained with ethidium bromide.  The presence 
of each isoform in cDNA samples was determined by comparing the lengths of all 
amplified PCR products with the lengths of the positive control cloned isoform products.   
 
Table 2.1:  AID Isoforms PCR Primer Sequences. 







AID isoforms cloning   
In order to generate positive PCR controls and sequences with which to compare 
test sample product lengths, sequences of all 5 isoforms were PCR amplified, as above, 
gel-extracted using a MinElute Gel Extraction kit (Qiagen), and cloned using a 
StabyCloning kit (Eurogentec) following kit instructions.  Briefly, 10 L of PCR product 
with an STC1 adaptor sequence attached at the 3’ end were cloned into a pSTC1.3 vector 
and transformed into chemically competent E. coli.  Plasmids from individual bacterial 
colonies cultured overnight with 2 mL of LB medium (100 g/mL ampicillin) were 
purified using a QIAprep Spin Miniprep kit as per the manufacturer’s protocol (Qiagen).  
Cloning of each isoform was verified by sequencing in one direction by the Colorado 
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Cancer Center Core Sequencing Facility using an ABI 3739 Sequencer (Applied 
Biosystems). 
 
Amplification, cloning, and sequencing of VH3-IgG genes 
PCR amplification of VH3-IgG genes   
Primers used for amplification were commercially synthesized primers derived 
from the first exon of the IgG constant gene (3’IgG, CH2A (indicates the name of the 
primer, not its position), and SC-CH2A) [152, 153] and the 5’ end of the VH3-family 
specific leader sequence (5’VH3) [154] (Figure 2.2, Table 2.2).  For cloning using a 
TOPO TA kit (Invitrogen), PCR (20 L) consisted of:  0.5 L of cDNA, 0.4 L dNTPs 
(10 mM), 0.8 L 50 mM MgSO4, 2 L of 10x High Fidelity PCR buffer, 0.4 L of 
primer mix (3’IgG and 5’VH3, 10 M each), and 0.1 L Platinum Taq High Fidelity 
DNA polymerase (Invitrogen).  Samples were heated to 94
o
C for 30 seconds in a Perkin-
Elmer 9700 thermocycler before initiating cycling (“hot start”).  Each of the 24 cycles 
consisted of a 30 second 94
o
C denaturation, a 30 second 60
o
C annealing, and a 30 second 
68
o
C extension.  For cloning using a StabyCloning kit (Eurogentec, San Diego, CA), 
PCR (25 L) consisted of:  1 L cDNA, 0.75 L dNTPs (10 mM each), 0.5 L 50 mM 
MgSO4, 2.5 L 10x Pfx Amplification buffer, 0.3 L CH2A primer (10 M), 0.6 L 
5’VH3 primer (10M), 0.75 L SC-CH2A primer (10 M), and 0.2 L Platinum Pfx 
DNA polymerase (Invitrogen).  Samples were heated to 94
o
C for 2 minutes in an Applied 
Biosystems 9700 thermocycler (“hot start”), followed by 45 cycles consisting of a 30 
second 94
o
C denaturation, a 30 second 60
o
C annealing, and a 30 second 68
o
C extension.  
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All PCR product was purified using a QIAquick PCR Purification Kit according to the 
manufacturer’s protocol (Qiagen Inc.). 
 
 
Figure 2.2:  Immunoglobulin Heavy Chain mRNA.  Immunoglobulin heavy chain 
mRNA is composed of VH, D, and JH segments rearranged and linked to a constant region 
(CH).  The VDJ variable domain is divided into 3 complementarity-determining regions 
(CDRs) that directly bind antigen held together by 4 framework regions (FRs).  At the 5’ 
end of the mRNA there is an untranslated leader sequence which is used to distinguish 
VH families.  The 5’VH3 primer binds at the beginning of the leader sequence.  The 
3’IgG and CH2A primers bind in the first exon of the IgG constant region.  
 
Table 2.2:  VH3-IgG PCR Primer Sequences. 









Cloning of VH3-IgG genes   
PCR products (1-4 L) were cloned in a pCR®-4TOPO vector following the 
TOPO TA Cloning® kit instructions (Invitrogen) or a pSTC1.3 vector (10 L of PCR 
product) following the StabyCloning kit instructions (Eurogentec).  Plasmids from 84-
212 individual bacterial colonies cultured overnight with 2 mL of LB medium (100 
g/mL ampicillin) were purified using a QIAprep Spin Miniprep kit as per the 
manufacturer’s protocol (Qiagen).   
 
Sequencing of VH3-IgG clones   
For each patient sample, 56-105 plasmid inserts per patient were sequenced either 
in both directions using SequiTherm Excell (Epicentre Technologies, Madison, WI), or in 
one direction by the Colorado Cancer Center Core Sequencing Facility using an ABI 
3739 Sequencer (Applied Biosystems). 
 
VH3-IgG cloned sequence analysis 
Determination of polymerase fidelity   
Comparison of an 18 bp segment of IgG constant regions from 823 blood IgG-
VH3 sequences with the germline sequences yielded a maximum potential error rate of 
1.15 x 10
-3
 (17 mutations/ 14,814 bp), or about 1 error/ 871 bp (or ≈1 error per 2.5 VH 
genes).  Given the high frequency of mutation in the blood VH3 genes in this analysis 
(mean 20 mutations/VH3 gene in the control subjects), only ≈1.7% of the mutations could 




VH3-IgG cloned sequence alignments and mutation calculations   
Somatic hypermutations in 40-66 sequences per patient were identified by 
comparing the sequences to the Vbase (Http://vbase.mrc-cpe.cam.ac.uk/) database of 
variable region germline sequences using the DNAplot software accessed at this website.  
Multiple identical sequences, as determined by their CDR3 sequence and which 
represented 26.7% of sequences, were excluded from this analysis.  The Batch Analyzer 
program developed and validated in our group by comparison with online programs 
(Vbase, IMGT® http://www.imgt.org [155] and JOINSOLVER® 
http://joinsolver.niams.nih.gov [156]) was used to exclude multiple identical sequences 
from the same patient and to calculate mutation frequencies and patterns in each 
sequence. 
 
Mutation patterns analysis   
Conservative amino acid substitutions in either direction included:  Ala to Gly, 
Ile, or Leu; Ile to Leu, Met, Phe, or Val; Leu to Met, Phe, or Val; Arg to His or Lys; Gly 
to Ile, Leu, or Val; Asp to Glu; Asn to Gln; His to Lys; Met to Phe or Val; Phe to Val; Ser 
to Thr.  All other substitutions, which showed changes in charge or polarity, were 
considered non-conservative.  Insertions or deletions within sequences were not included 
in the analysis.  D regions were identified using the criteria of a minimum of 6 bp of 






CDR3 region analysis   
The first amino acid in CDR3 was assigned as the third amino acid following a 
conserved cysteine residue at position 92 (Kabat numbering system) of the VH gene 
[152].  The last amino acid was assigned just before the first conserved tryptophan of 
FR4 (Kabat position 103).  The CDR3 sequences were analyzed for length, composition 
of acidic (Asp and Glu), basic (Arg, His, and Lys), uncharged polar (Gly, Ser, Thr, Cys, 
Tyr, Asn, and Gln), nonpolar (Ala, Val, Leu, Ile, Pro, Met, Phe, Trp), and aromatic 
residues (His, Phe, Tyr, and Trp), and average hydrophobicity using the Kyte-Doolittle 
scale [158] as normalized by Eisenberg [159]. 
 
VH3 454 PCR/ High-throughput pyrosequencing 
1
st
 round amplification (Figure 2.3)   
We wished to confirm the results of the VH3-IgG clones sequencing study on a 
larger number of sequences and in another class-switched isotype, IgA, as well as more 
naïve isotypes, IgD and IgM.  Therefore, we switched from using a cloning and 
sequencing strategy to performing high-throughput pyrosequencing using Roche’s 454-
FLX Titanium platform (Roche Applied Science, Indianapolis, IN).  The primers used for 
PCR amplification were commercially synthesized primers derived from the VH3-family 
specific leader primer [154] (5’VH3) with random 8 bp nucleotide barcode sequences 
attached at the 5’ end to allow for sample pooling, the CH1 region of the IgG constant 
genes [153] (CH2A) and the first exons of the IgM, IgA [63], and IgD constant genes 
(Table 2.3).  First round synthesis was performed in a 50 L reaction containing 2-5 L 
of cDNA template, 0.2 mM each dNTP, 1.5 mM MgSO4, 5 L 10x KOD Hot Start 
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Buffer, 0.3 M each primer, and 0.02 U/L KOD Hot Start High Fidelity DNA 
Polymerase (Novagen).  Samples were heated to 95
o
C for 2 minutes in an Applied 
Biosystems GeneAmp PCR System 9700 thermocycler before initiating cycling (“hot 
start”).  Samples were run for 5 cycles consisting of a 20 second 95
o
C denaturation, a 10 
second annealing (68
o
C for IgD and IgG primer sets, 63
o
C for IgM and IgA primer sets), 
and a 10 second 70
o
C extension.  PCR product was purified using a QIAquick PCR 
Purification kit (Qiagen) and run on a 1.5% agarose gel stained with ethidium bromide.  
The 5 cycle reaction gel bands were excised and purified from the gel using a MinElute 
Gel Extraction kit according to the manufacturer’s protocol (Qiagen).  Purified PCR 




 round amplification   
The primers used for 2
nd
 round amplification, to add the 454-adaptor sequences to 
the 5’ and 3’ ends of the PCR amplicons, were commercially synthesized primers as 
described above but with 454-sequencing tags (Roche) attached at the 5’ (5’VH3) and 3’ 
(CH2A, IgM, IgA, and IgD) ends (Table 2.3).  Second round synthesis was performed in 
a 50 L reaction containing the 15 L of purified 1
st
 round 5 cycle PCR product 
described above, 0.2 mM each dNTP, 1.5 mM MgSO4, 5 L 10x KOD Hot Start Buffer, 
0.3 M each primer, and 0.02 U/L KOD Hot Start High Fidelity DNA Polymerase 
(Novagen).  Samples were heated to 95
o
C for 2 minutes.  The samples were amplified for 
17-22 cycles consisting of a 20 second 95
o
C denaturation, a 10 second annealing (65
o
C 
for IgD and IgG primer sets, 60
o
C for IgM and IgA primer sets), and a 10 second 70
o
C 
extension.  Samples were purified and run on an agarose gel, then excised and purified 
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from the gel slice as described above for the first round amplification product.  The 
purified PCR product was eluted into 20 l of elution buffer (Qiagen). 
 
 
Figure 2.3:  454-Pyrosequencing Protocol.  454-Pyrosequencing requires two rounds of 
PCR to amplify the specific gene of interest and incorporate the 454 tags required for 
sequencing.  The first round of amplification utilizes gene-specific primers to amplify the 
cDNA of choice.  At the 5’ end of the forward primers are barcode sequences composed 
of 8 random nucleotides.  Addition of the barcodes allows for sample pooling during 
sequencing.  The final product of the first round is the PCR-amplified gene of interest 
attached to the barcode sequence.  First-round PCR product is run out on an agarose gel, 
extracted from the gel, and purified.  The second round of PCR amplifies the levels of 
first round product and adds the 454-sequencing primer sequence to the 5’ end of each 
PCR product and the bead-specific sequence to the 3’ end.  The bead specific sequence 
attaches to the sequencing beads, allowing for sequencing of individual PCR amplicons 
on a multiwell plate.  Second-round PCR product is also run out on an agarose gel, 
extracted, and purified, to ensure that only full-length PCR products are sequenced. 
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Table 2.3:  VH3 454-Pyrosequencing PCR Primer Sequences 
Primer Name Sequence 
1
st
 Round Amplification 
IgG Barcode 
Sequences 
TAAGAACG, TTACCGTG, TCGTCCGT, TTGAGGTT, 
TCCTTAGT, AAGGTGTT, TGTTAGGT, ACTTCGGT, 
CTTACCTT, GTAACCGT, TATATGCG, TATGTGCT, 
TATGCATG, TATGCACA, TAGAGACT 
IgA Barcode 
Sequences 
TTAACGGA, AATTACGG, AACTTAGG, ACGGTACG, 
TTGTACGG, TAAGTTGG, TTCGGTGG, TTCGTAAG, 
TAAGAACG, TTCACCGG, TATAGCTG, TATCGCGT, 
TACTGTCA, TAGATGCT, TCTGTGCA 
IgD Barcode 
Sequences 
ACCGTTAA, AACGGTTA, GGTAACGG, ACAACCGG, 
TTCTAACG, TTATTCCG, TTAACACG, TTACTAGG, 
TTACCGTG, TAGTTACG, CAGCACAT, CGCATACG, 
GATCGAGT, GCACAGCA, GCGAGCTA 
IgM Barcode 
Sequences 
TCGTTACG, CCGGTTAG, AAGTTCCG, TACGACCG, 
TAACGTTG, TAAGTACG, TTGTACGG, TCAACCTT, 
GGTACCGT, ATACCGGT, TCATCACA, TCATGTGT, 
TCACTCTG, TCGTCAGT, TGATGATG 
5’VH3 5’-Barcode sequence-CCATGGAGTTGGGGCTGAGCTGC-3’ 























5’VH3-T454 5’-T454A sequence-Barcode sequence-CCATGGAG-3’ 
CH2A-T454 5’-T454B sequence-CACCGGTTCGGGGAAGTAGTCC-3’ 
IgA-T454 5’-T454B sequence-GAGGCTCAGCGGGAAGACCTT-3’ 
IgD-T454 5’-T454B sequence-CCCAGTTATCAAGCATGCCAGGAC-3’ 
IgM-T454 5’-T454B sequence-CGGGGAATTCTCACAGGAGAC-3’ 
 
VH3 454-pyrosequencing analysis 
VhIGene program  
Due to the nature of the pyrosequencing results (format, number, and a significant 
number of indels per sequence), we were unable to utilize either our previous analysis 
program Batch Analyzer or any other publically available alignment tools.  Therefore, we 
developed the computer software pipeline VhIGene (Figure 2.3) in collaboration with 
Dan Frank, Ph.D., (Division of Infectious Diseases) who did the program coding in order 
to classify the human V, D, and J germline alleles from which a rearranged B cell 
immunoglobulin gene most likely was derived and to calculate a variety of VH mutation 
statistics from high-throughput VH gene pyrosequencing data.  The tasks performed by 
this software include 1) initial polishing of sequence reads (bartab); 2) profile alignment 
(hmmr) to the IMGT reference database of V-D-J allelic variants [155]); 3) identification 
for each VH read of its nearest-neighbor IMGT V-D-J sequence (vdj_match); and 4) 
calculation of a variety of statistics (e.g., base composition and substitutions, indels) for 
CDR1-3 and FR1-3 segments (vdj_stats).  Our software was validated using several test 
sets including:  1) Gold-standard sequences generated by Sanger sequencing (~3000 VH 
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clones from which high-confidence V-D-J classifications were made through Vbase and 
JOINSOLVER) [156], and 2) Mock 454 sequences generated by pyrosequencing 
independent PCR libraries made from 10 Sanger-sequenced VH clones (79,683 polished 
reads), which allow us to model the background frequency of base changes and 
insertions/deletions (indels) from pyrosequencing. 
 
Mutation patterns analysis   
Mutation patterns were calculated according to the same rules as with the VH3-
IgG cloned sequences.  See the VH3-IgG Cloned Sequence Analysis section above. 
 
CDR3 region analysis   
The CDR3 region was determined and characteristics calculated according to the 
same rules as with the VH3-IgG cloned sequences.  See the VH3-IgG Cloned Sequence 
Analysis section above. 
 
Preliminary Bcl6 gene PCR, cloning, sequencing, and analysis 
Preliminary Bcl6 PCR amplification   
To measure SHM in a target other than VH genes, Bcl6 was also sequenced.  We 
wanted to sequence the most highly mutated portion of the sequence, so preliminary 
amplification, cloning, and sequencing were performed on 12 selected segments of the 
gene.  Primers used for amplification were commercially synthesized primers to amplify 




Figure 2.4:  Flow Diagram of VhIGene Program.  Pooled or “Multiplexed” Next-
Generation Sequence Datasets are initially polished by BARTAB, which sorts the 
sequences based on the attached barcodes into individual libraries, removes poor quality 
sequences from the analysis, removes identical copies of sequences from the analysis 
based on alignment of the first 200 base pairs of sequence, and trims poor quality bases 
from the remaining set of sequences.  The polished, de-multiplexed libraries are then 
aligned to each other and to a reference dataset derived from IMGT using HMMER 
alignment software.  VHFILTER removes any insertions or deletions identified from the 
alignment which are not equal to multiples of 3 bp in length (e.g., 3, 6, or 9 base pairs, 
which may represent new or deleted amino acids).  The closest VH, D, and JH gene 
matches in the reference dataset are identified by VHMATCH.  VHSTATS identifies and 
calculates mutation frequencies and patterns in the Complementarity Determining 
Regions (CDRs) and Framework Regions (FRs) of the sequence and outputs the data into 
a .csv file. 
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template DNA, 0.75 L dNTPs (10 mM each), 0.5 L 50 mM MgSO4, 2.5 L 10x Pfx 
Amplification buffer, 0.3 L Bcl6 Rev primer (10 M), 0.6 L Bcl6 Fwd primer (10M), 
0.75 L STC1 Bcl6 Rev primer (10 M), and 0.2 L Platinum Pfx DNA polymerase 
(Invitrogen).  Samples were heated to 94
o
C for 2 minutes in an Applied Biosystems 9700 
thermocycler (“hot start”), followed by 45 cycles consisting of a 30 second 94
o
C 
denaturation, a 30 second 60
o
C annealing, and a 30 second 68
o
C extension.  All PCR 
product was purified using a QIAquick PCR Purification Kit according to the 
manufacturer’s protocol (Qiagen Inc.). 
 
Figure 2.5:  Preliminary Segments Selected for Testing Bcl6 Mutation Frequency.  
Segments 1-11 were chosen based on their RGYW/WRCY AID hotspot motif content.  
Segment 1.5 was chosen based on sequencing experiments found in the literature and 
because its position at the 5’ end of the gene more closely resembles the portion of the VH 
gene that is most highly mutated [160-162]. 
 
Cloning of Bcl6 genes   
PCR products (10 L) were cloned in a pSTC1.3 vector following the 
StabyCloning kit instructions (Eurogentec).  Plasmids from individual bacterial colonies 
cultured overnight with 2 mL of LB medium (100 g/mL ampicillin) were purified using 
a QIAprep Spin Miniprep kit as per the manufacturer’s protocol (Qiagen). 
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Table 2.4:  Preliminary Bcl6 PCR Amplification and Cloning Primer Sequences. 
Primer Name Sequence 
Bcl6-1Fwd 5’-GCTGAAAGTCCCAAGCTGTC-3’ 
Bcl6-1Rev 5’-GAAAGGGGCAATTGGAGAAT-3’ 
STC1 Bcl6-1Rev 5’-CCTTCGCCGACTGAGAAAGGGGCAATTGGAGAAT-3’ 
Bcl6-2Fwd 5’-AATTCTCCAATTGCCCCTTT-3’ 
Bcl6-2Rev 5’-CACTGGTCATCCAGCAAAGA-3’ 
STC1 Bcl6-2Rev 5’-CCTTCGCCGACTGACACTGGTCATCCAGCAAAGA-3’ 
Bcl6-3Fwd 5’-TCTTTGCTGGATGACCAGTG-3’ 
Bcl6-3Rev 5’-GAAGGGGAAGAGAGCGATTT-3’ 










STC1 Bcl6-7Rev 5’-CCTTCGCCGACTGAAGCCTGGAAAACCCTTCTGT-3’ 
Bcl6-8Fwd 5’-ATGCTAGGGTGATTGCATCC-3’ 
Bcl6-8Rev 5’-AGTGGCAGGTTGTTCTCCAC-3’ 
STC1 Bcl6-8Rev 5’-CCTTCGCCGACTGAAGTGGCAGGTTGTTCTCCAC-3’ 
Bcl6-9Fwd 5’-AGGTGGTGGAGAACAACCTG-3’ 
Bcl6-9Rev 5’-GGTCCCCTGCTACATCAAGA-3’ 
STC1 Bcl6-9Rev 5’-CCTTCGCCGACTGAGGTCCCCTGCTACATCAAGA-3’ 
Bcl6-10Fwd 5’-GGGTCTCAGAGCTTGAGTGG-3’ 
Bcl6-10Rev 5’-ATGACCCTGTGCCAAATCTC-3’ 
STC1 Bcl6-10Rev 5’-CCTTCGCCGACTGAATGACCCTGTGCCAAATCTC-3’ 
Bcl6-11Fwd 5’-GGTTTCCTCTGCTGAGCATC-3’ 
Bcl6-11Rev 5’-AGCCCCTCATTAGCACACAG-3’ 
STC1 Bcl6-11Rev 5’-CCTTCGCCGACTGAAGCCCCTCATTAGCACACAG-3’ 
Bcl6-1.5Fwd 5’-GCAGTGGTAAAGTCCGAAGC-3’ 
Bcl6-1.5Rev 5’-AGGGAACACCAAAACACTCG-3’ 
STC1 Bcl6-1.5Rev 5’-CCTTCGCCGACTGA AGGGAACACCAAAACACTCG-3’ 
54 
 
Sequencing of Bcl6 clones   
For each segment and time point, 10-55 (median = 37) plasmid inserts were 
sequenced in one direction by the Colorado Cancer Center Core Sequencing Facility 
using an ABI 3739 Sequencer (Applied Biosystems). 
 
Bcl6 cloned sequence alignments and mutation calculations   
Cloned Bcl6 sequences were trimmed by visual analysis and aligned with a 
human Bcl6 reference sequence derived from GenBank 
(www.ncbi.nlm.nih.gov/genbank) using the BLAST tool bl2seq 
(www.ncbi.nlm.nih.gov/BLAST) which aligns two input sequences.  Individual base 
substitution mutations were manually counted based on the alignment and recorded in an 
excel file.  Insertions and deletions were not counted as mutations.  Mutation frequency = 
the total number of nucleotide mismatch mutations identified / total number of 
nucleotides sequenced. 
 
Bcl6 454 PCR/ High-throughput pyrosequencing 
1
st
 round amplification   
The primers used for PCR amplification were commercially synthesized primers 
designed to amplify 5 fragments (A, B, C, D, and E) derived from segment Bcl6-1.5, 
which had the greatest increase in mutation frequency after PBMC stimulation (Table 
2.5).  First round synthesis was performed in a 50 L reaction containing 400 ng DNA 
template, 0.2 mM each dNTP, 1.5 mM MgSO4, 5 L 10x KOD Hot Start Buffer, 0.3 M 
each primer, and 0.02 U/L KOD Hot Start High Fidelity DNA Polymerase (Novagen).  
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Samples were heated to 95
o
C for 2 minutes in an Applied Biosystems GeneAmp PCR 
System 9700 thermocycler before initiating cycling (“hot start”).  Samples were run for 5 
cycles consisting of a 20 second 95
o
C denaturation, a 10 second 60
o
C annealing, and a 10 
second 70
o
C extension.  PCR product was purified using a QIAquick PCR Purification 
kit (Qiagen) and run on a 1.5% agarose gel stained with ethidium bromide.  The 5 cycle 
reaction gel bands were excised and purified from the gel using a MinElute Gel 
Extraction kit according to the manufacturer’s protocol (Qiagen).  Purified PCR product 




 round amplification   
The primers used for 2
nd
 round amplification were commercially synthesized 
primers as described above but with 454-sequencing tags (Roche), attached at the 5’ 
(Fwd; F) and 3’ (Rev; R) ends (Table 2.5).  Second round synthesis was performed in a 
50 L reaction containing the 15 L of purified 1
st
 round 5 cycle PCR product described 
above, 0.2 mM each dNTP, 1.5 mM MgSO4, 5 L 10x KOD Hot Start Buffer, 0.3 M 
each primer, and 0.02 U/L KOD Hot Start High Fidelity DNA Polymerase (Novagen).  
Samples were heated to 95
o
C for 2 minutes.  The samples were amplified for 17-22 
cycles consisting of a 20 second 95
o
C denaturation, a 10 second 55
o
C annealing, and a 10 
second 70
o
C extension.  Samples were purified and run on an agarose gel, then excised 
and purified from the gel slice as described above for the first round amplification 





Table 2.5:  Bcl6 454-Pyrosequencing PCR Primer Sequences. 
Primer Name Sequence 
1
st
 Round Amplification 
Bcl6A Barcode 
Sequences 
TTCCGGTT, TCCGTTAA, TTAACCGA, TTACCGTA, 




TACGGTTA, TAGTTAGG, TACCAAGG, TAAGTACG, 




AAGACCG, TTGGTTC, TCTTAAC, TTCTAAG, GGTAACC, 




TACGTAA, AACCGGT, TCCTTAC, TTAGGTT, TTACCGT, 




TTACGGAA, AGTTAACC, TTAAGGTC, TCCGGAAC, 
TCGTTAAC, ATTAACGG, CGTTAAGG, TCGGTTGG, 
TTCGGAGG, TTGAACCG 
Bcl6A Fwd 5’-Barcode sequence-GGAACCTCCAAATCCGAGAC-3’ 
Bcl6B Fwd 5’-Barcode sequence-CAAATGCTTTGGCTCCAAGT-3’ 
Bcl6C Fwd 5’-Barcode sequence-CACCCTCCCTTGTGTTGTTT-3’ 
Bcl6D Fwd 5’-Barcode sequence-GCAAACTGCTTTCCTTGCTC-3’ 
Bcl6E Fwd 5’-Barcode sequence-TTCAGAGCCGTGATCTTCCT-3’ 
Bcl6A Rev 5’-GAAAACTTGGAGCCAAAGCA-3’ 
Bcl6B Rev 5’-CTCCTTCCTCTCCTCCACCT-3’ 
Bcl6C Rev 5’-CGGAGTTACCCAGAAGGACA-3’ 
Bcl6D Rev 5’-GCAGGGAACACCAAAACACT-3’ 
Bcl6E Rev 5’-AGCGCCCAAAATACAAACAC-3’ 
2
nd
 Round Amplification 
T454A (Adaptor) 5’-GCCTCCATCTCATCCCTGCGTGTCTCCGACTCAG-3’ 
T454B (Adaptor) 5’-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG-3’ 
BaF-454 5’-T454A sequence-Barcode sequence-GGAACCTC-3’ 
BbF-454 5’-T454A sequence-Barcode sequence-CAAATGC-3’ 
BcF-454 5’-T454A sequence-Barcode sequence-CACCCTCC-3’ 
BdF-454 5’-T454A sequence-Barcode sequence-GCAAACTG-3’ 
BeF-454 5’-T454A sequence-Barcode sequence-TTCAGAGC-3’ 
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Primer Name Sequence 
BaR-454 5’-T454B sequence-GAAAACTTGGAGCCAAAGCA -3’ 
BbR-454 5’-T454B sequence-CTCCTTCCTCTCCTCCACCT -3’ 
BcR-454 5’-T454B sequence-CGGAGTTACCCAGAAGGACA -3’ 
BdR-454 5’-T454B sequence-GCAGGGAACACCAAAACACT -3’ 
BeR-454 5’-T454B sequence-AGCGCCCAAAATACAAACAC -3’ 
 
Bcl6 454-pyrosequencing analysis 
Reference sequences from the GenBank human Bcl6 gene were created for the 5 
fragments sequenced by 454-pyrosequencing.  454-generated sequences were de-
multiplexed, polished, aligned, and analyzed by VhIGene.  The 5 reference sequences 
were used in place of the IMGT reference dataset.   
 
Flow cytometry 
To measure B and T cell marker expression, unstimulated and stimulated PBMC 
(2x10
6
 cells/tube) were washed in filter-sterilized FACS buffer (Dulbecco’s PBS 
(Invitrogen) + 1% BSA (Fisher Scientific, Pittsburgh, PA)) and stained with 9 color 
panels with monoclonal antibodies to B and T cell markers.  Cells were incubated with 
antibodies for 40 minutes at 4
o
C.  After two additional washes in FACS buffer, stained 
cells were fixed in 1% paraformaldehyde for 10 minutes at 4
o
C, then run on an LSRII 
flow cytometer (BD Biosciences) within 24 hours.  Data were analyzed using Flow Jo 
Software (Tree Star, Inc; Ashland, OR).  Cells were gated on singlets, followed by 
lymphocytes, and finally, on CD19
+
 B cells or CD3
+
 T cells.  Positive expression of each 
marker was determined by mean fluorescence intensity measurements (MFIs) from cells 
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singly stained with each marker.  B cell markers included CD38-FITC, CD21-PE, CD10-
PE-CF594, CD40-APC, CD86-BV421 (BD Pharmingen, San Diego, CA), IgM-PerCP-
Cy5.5, IgD-PE-Cy7, CD19-AF700, and CD27-BV650 (Biolegend, San Diego, CA).  T 
cell markers included CD38-FITC, HLA-DR-PE-Cy7, PD-1-APC, CD3-AF700, CD4-
Pacific Blue (Biolegend), CXCR5-PE (RnD Systems, Minneapolis, MN), CD45-RA-




Primary analyses (HIV-1-viremic vs. aviremic vs. control subjects) assumed non-
parametric two-sided tests with a significance level of 0.05.  A Fisher’s projected least 
significant different approach was utilized for secondary analyses, such that pairwise 
(secondary) comparisons are conducted only if the overall primary test was significant.  
Secondary tests utilized a Kruskal-Wallis, non-parametric ANOVA.  Primary analyses 
between HIV-1-infected and control subjects only utilized a non-parametric Mann-
Whitney test.  For each subject, the expression of specific VH3 family genes was 
compiled and the mean percent expression was calculated; the median percent expression 
was calculated from the means of the individual patients for each group.  Generalized 
linear models (binomial family) were used for comparing the proportion of events 









THE SOMATIC HYPERMUTATION FREQUENCY OF VH3 FAMILY 
IMMUNOGLOBULIN GENES IS ALTERED IN HIV-1-INFECTED PATIENTS 
COMPARED WITH HEALTHY CONTROLS 
 
Introduction 
B cell activation and hypergammaglobulinemia are among the first and most 
persistent immunologic consequences of HIV-1 infection [163, 164].  High rates of 
infection and impaired humoral responses to vaccines during HIV-1 infection may be 
related to an impaired ability to generate pathogen-specific antibodies in sufficient 
quantities, but also of sufficient quality and function to control these pathogens [165-
167]. The successful evolution of antibody diversity, specificity and function is 
determined by three distinct processes. First, antigen-independent recombination of 
variable (V), diversity (D) and joining (J) gene segments establishes the primary 




) and appears relatively intact during HIV-1 
infection [29].  Subsequently, in lymph node germinal centers, antigen-dependent 
somatic hypermutation (SHM) modifies the antigen-binding variable regions of the heavy 
(VH) and light (VL) chains, which, following selection, enhances antigen specificity and 
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avidity [168].  Finally, class-switch recombination (CSR) modifies the effector constant 
regions of the heavy chain (CH) to a single isotype (IgG, IgA or IgM) and may be 
somewhat impaired during HIV-1 infection [131, 133, 135, 169]. 
SHM introduces point mutations into the variable regions of immunoglobulin 
genes to increase both specificity and affinity.  While both light (VL) and heavy (VH) 
genes are somatically hypermutated, the major contributor to diversity and specificity is 
from the heavy chain gene [170].  Immunoglobulin heavy chain genes (Figure 3.1) are 
divided into two types of regions, complementarity determining regions (CDRs) which 
bind directly to antigen, and framework regions (FRs) which form the structural regions 
of the molecule [70].  Three CDRs are surrounded by four FRs.  Both CDRs, 1 and 2, as 
well as FR1/2/3 are encoded by the V segment, CDR3 is encoded by the V, D, and J 
rearranged segments, and FR4 is encoded by the J segment [171, 172].  CDRs are more 
highly mutated than the FR regions.  This is due to both the codon composition in both 
regions, where, in the CDRs, mutations are more likely to result in amino acid 
replacements, and due to the greater number of RGYW/WRCY mutation “hotspot” 
motifs found in these regions [82]. 
We focused our studies on sequences of the immunoglobulin VH3 family.  Of the 
seven VH families, VH3 is the largest, comprising 22 of the 44 functional human VH 
genes [170, 173], and is also the most highly expressed VH gene family [174].  VH3 
family genes encode most antibodies to capsular polysaccharides of common HIV-1-
associated pathogens (e.g. Streptococcus pneumoniae, Haemophilus influenzae, 
Cryptococcus neoformans, and Salmonella spp.) [25-27, 173].  VH3 genes have also been 




Figure 3.1:  Immunoglobulin Heavy Chain mRNA.  Immunoglobulin heavy chain 
(IgH) mRNA is composed of V, D, and J segments rearranged and linked to a constant 
region.  The VDJ variable domain is divided into 3 complementarity-determining regions 
(CDRs) that directly bind antigen held together by 4 framework regions (FRs).  At the 5’ 
end of IgH mRNA there is an untranslated leader sequence which is used to distinguish 
VH families.  The CDR3 region, composed of V, D, and J gene segments is the most 
variable of all regions. 
 
envelope glycoprotein, gp120, can bind to several VH3 family genes in an area outside of 
the antigen-binding region and can lead to B cell activation in vitro [175, 176].  In the 
absence of adequate T cell signals, such binding and activation could deplete these cells 
[175, 176].  Thus, impairment of SHM of VH3 family genes could have a huge impact on 
HIV-1 disease progression. 
We show that, compared with uninfected control subjects, HIV-1 infection is 
associated with significantly decreased frequencies of SHM in CDR1/2 (nucleotides and 
amino acids) of IgG class-switched VH3 cDNA.  While the quantity of the SHM response 
may be decreased during HIV-1 infection, the quality of the process, as determined by 
examining the mutation pattern, appears intact.  Consistent with this result, a significantly 
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lower mutation frequency was also found in HIV-1-infected patients in another non-Ig 
target of the SHM machinery, Bcl6.  Because antibody avidity and function are 
determined by SHM, these decrements in VH3 mutation may contribute to the increased 
rates of primary and recurrent infections against which antibodies contribute to 
protection, and to the limited efficacy of polysaccharide vaccines to protect against these 
pathogens in this adult population [177].   
Surprisingly, when we examined the SHM frequency in presumably naïve IgD 
VH3 transcripts, we found that it was significantly higher in the HIV-1-infected patients 
compared with controls.  However, as seen in the VH3-IgG transcripts, mutation patterns 
imply only a change in quantity of mutation, not quality.  The mechanisms of HIV-1-
associated disparities in SHM frequency may include altered regulation in the frequency 
or magnitude of the SHM process mediated by activation-induced deaminase (AID) 
protein, related DNA repair enzymes, antibody selection in germinal centers, altered B 
cell subset proportions, and/or non-specific peripheral T-independent activation of 
circulating naïve B cells.   
 
Results 
VH3 somatic hypermutation frequency is reduced in VH3-IgG cloned samples from 
viremic HIV-1-infected patients but the mutation pattern is normal 
VH3-23 gene expression is reduced in viremic HIV-1-infected patients.  We began 
our study by examining VH3-family immunoglobulin gene expression in IgG mRNA 
transcripts from 10 control subjects compared with two HIV-1-infected cohorts, one 
group on stable therapy with no detectable plasma HIV-1 viral loads (aviremic, 6  
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patients) and another untreated group with high viral loads (viremic, 15 patients) (Table 
3.1).   
V-D-J gene recombination is the first step in generating the antibody repertoire.  
We characterized VH3 gene utilization by cloning and sequencing 494 VH3- IgG cDNA 
clones from circulating class-switched IgG B cells from 10 HIV-1-seronegative control 
subjects, 793 clones from 15 viremic HIV-1-infected patients (80% >10,000 copies/mL) 
and 278 clones from 6 aviremic HIV-1-infected patients (median 50 clones/subject; range 
40-66; accession numbers JN576421-JN577983).  Of the 22 individual VH3 genes, at 
least 20 out of 22 were represented in all groups. VH3-23, although the most frequently 
expressed gene [173, 174], was also significantly decreased among viremic HIV-1-
infected patients compared with control subjects, as were VH3-7, VH3-9, and VH3-53  
 
Table 3.1:  Clinical Characteristics of VH3-IgG Cloning Study Subjects. 
 Control Aviremic Viremic p value 
Number 10 6 15  









Gender (M:F) 6:4 6:0 14:1 0.04 
% Non-Caucasian
a
 0 33% 33%  
CD4
+ 







HIV-1 RNA median 
copies/mL (Range) 





 N/A    
No Therapy N/A 0 10 (67%)  
1 medication N/A 0 2 (13%)  
≥3 medications N/A 6 (100%) 3 (20%)  
a
Non-Caucasian = African American, Asian/Pacific Islander, Native American, Hispanic, or 
Other.  
b
Antiretroviral therapy:  1 medication = NRTI, ≥3 medications = 1 PI + 2 NRTI or 
NNRTI + 2 NRTI.  Effect of gender was evaluated by Fisher’s exact test. 
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(Figure 3.2a).  This decrease was consistent for most viremic patients, among whom the 
frequency of VH3-23 expression was below the median for control subjects in 13 of 15 
patients (Figure 3.2b). 
D and JH gene expression is very similar in all groups.  Only limited differences 
were observed in the utilization of the other variable region genes, D and JH.  D regions, 
located centrally in the hypervariable CDR3 region and the most commonly mutated of 
the 3 variable region segments, could be assigned in 84.6% of sequences.  We identified 
few significant differences in D gene utilization of less prevalent D genes across all 
groups (Figure 3.3a).  Similarly, utilization of JH segments was comparable in each 
group, with JH4b comprising approximately half of all JH segments (Figure 3.3b).  Thus, 
as suggested in earlier work on naïve B cells [29], the repertoire of expressed variable 
region genes appears fundamentally intact in these patients with HIV-1 infection. 
CDR3 region characteristics are similar in all groups.  The CDR3 region of the 
antigen-binding variable segment typically plays the greatest role in antigen binding 
[178] and has the greatest degree of diversity.  We characterized the CDR3 region of each 
sequence by analyzing its length, hydrophobicity, and the composition of acidic, basic, 
uncharged polar, nonpolar, and aromatic residues (Table 3.2) as these attributes all make 
important contributions to the region’s antigen specificity [172].  CDR3 length, which 
overlaps the junctions of VH, D, and JH genes [172], was similar in sequences from the 
three groups.  The degree of hydrophobicity, a reflection of the tendency of hydrophobic 
residues to be buried within the protein, was also comparable between groups, as was the 
amino acid composition in the CDR3 region. Together with results on the expression of 
VH3, D, and JH genes, these data suggest that the initial V(D)J recombination process, 
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VH3 Family Gene Expression








































































Figure 3.2:  Expression of VH3-IgG Family Genes and VH3-23.  A)  VH3 family gene 
expression.  Data are shown as group medians among control subjects (n=10; black bars), 
aviremic HIV-1-infected patients (n=6; gray bars), and viremic HIV-1-infected patients 
(n=15; white bars).  Values were calculated from individual mean percent expression for 
each gene.  “Other” includes VH3-13, -20, -43, -49, -64, -65, -66, -72, and unidentified 
genes which ranged from 0.4% to 12.6% expression.  B) VH3-23 expression.  Each point 
represents the mean percentage of VH3-23/total VH3 genes for each control subject 
(n=10; black circles), aviremic HIV-1-infected patient (n=6; gray squares), and viremic 
HIV-1-infected patient (n=15; white triangles).  Primary p=0.008.  The solid bar indicates 









































































Figure 3.3:  Expression of D and JH Genes.  A)  D gene expression was calculated as 
with VH3 gene expression.  “Other” includes D1-1, D1-7, D1-14, D1-20, D2-2, D2-8, 
D2-21, D3, D3-9, D3-16, D4, D4-b, D4-11, D4-23, D5-12, D6-6, and D6-25 which        
ranged from 0.4% to 4.3% expression.  Gene identification could not be assigned in 12.5-
18.0% of sequences.  B)  JH gene percent expression was calculated as described above.  





involving RAG1, RAG2, and terminal deoxytransferase (TdT), is intact in HIV-1-
infected individuals and does not materially contribute to the reported decreased avidity 
and functional activity of antibodies produced by HIV-1-infected patients [29, 179, 180]. 
Mutation frequency is reduced in CDRs and FRs of VH3-IgG genes from viremic 
HIV-1-infected patients.  SHM is typically an antigen-driven process that enhances 
antibody affinity and function.  Hypervariable complementarity determining regions 
(CDR), the principle antigen-binding regions that serve as the primary targets for SHM, 
were assessed.  The nucleotide mutation frequency in the CDR1/2 regions of cloned VH3- 
IgG sequences from B cells of the viremic HIV-1-infected group was significantly lower 
 
Table 3.2:  Biochemical Characteristics of Amino Acids in the CDR3 Regions. 
























































CDR3 length and hydrophobicity index were calculated as described in the methods.  
Residue characteristics were calculated with the number of each type of residue divided 
by the total number of residues in the CDR3 region of each sequence.  Values are listed 




than that of control subjects (p=0.033; Figure 3.4a), whereas values for aviremic patients 
on effective antiretroviral therapy were not different.  Although the overall frequency of 
nucleotide mutation was lower in the viremic patients, the ratio of replacement to silent 
(R/S) amino acid changes resulting from these nucleotide mutations, one indicator of 
positive antigen-driven selection, was high and similar in all three groups. 
Nevertheless, consistent with the nucleotide results, the frequency of amino acid 
mutation in CDR1/2 was also lower among the viremic patients compared with control 
subjects (Figure 3.4b).  However, the character of amino acid changes were similar in 
that over two-thirds were non-conservative, changes which are more likely to impact 
antigen binding than conservative mutations.  Non-conservative mutations are more 
likely to be positively selected during affinity maturation of VH immunoglobulin genes.  
The percent of non-conservative mutations was not statistically different between the 
three groups suggesting that mutations were antigen-driven and targeted rather than more 
randomly distributed in these patients.  Thus, although the frequency of nucleotide and 
resultant amino acid replacement mutations were lower in viremic HIV-1-infected 
patients, the types and changes in nucleotides (replacement vs. silent) and amino acids 
(non-conservative vs. conservative) were not.   
For the structural framework (FR1/2/3) regions (Figure 3.5a), the nucleotide 
mutation frequency in general, as expected [82, 181], was lower than in the CDR1/2 
regions (2-8% vs. 5-15% (Fig. 3.4a), respectively).  The variance in individual FR 
nucleotide and amino acid mutation frequencies was greater in FR from viremic patients 
than in the other two groups, but only significantly different for amino acids (Figures 3.5a 
and 3.5b).  The R/S ratios were also similar between groups but lower overall compared 
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with the CDRs, reflecting the targeted effect of antigen-driven selection on the latter.  
Similarly, the proportion of non-conservative amino acid mutations did not vary among 
groups either.  Results from aviremic patients effectively treated with antiretroviral 
therapy were most similar to those of control subjects.   
While the mutation frequencies were lower in sequences from viremic patients 
compared with control subjects, the median proportions of unmutated sequences did not 
differ between groups (controls:  median = 1.14%, range = 0 - 12.8%; aviremic:  median 
=1.07 %, range = 0 – 4.3%; viremic:  median = 7.69%, range = 0 - 18.8%; overall 
p=0.15), suggesting that the lower frequencies were not due to skewing by unmutated 
IgG class-switched sequences, as have been described in young infants [182].  Rather, the 
lower number of mutated nucleotides per sequence in the viremic group was distributed 
throughout the antibody population (Figure 3.6).  Neither the frequencies of mutations 
nor amino acids in CDR1/2 or FR1/2/3 correlated significantly with either plasma HIV-1 
RNA (r=0.46, p=0.30) or CD4
+
 T cell number (r=0.15, p=0.63; data not shown). 
VH3-IgG gene-specific SHM is consistent with overall SHM frequency in viremic 
HIV-1-infected patients.  The decrement in mutation frequency in CDR1/2 of viremic 
patients was present across nearly all VH3 family genes, including the 5 most commonly 
expressed genes, representing 53% of all sequences analyzed (833/1,565) (Figure 3.7).  
Differences in mutation frequencies between viremic patients and control subjects were 
only statistically significant for VH3-33 (p=0.01).  Mutation frequencies in the 5 genes 
proposed to bind to the HIV-1 envelope protein gp120 in a nontraditional manner to VH 
regions outside the antigen-binding pocket [183] were also evaluated.  Such targeted 
binding has been proposed as a superantigen-like stimulus for selective deletion of B 
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CDR Nucleotide Mutation Frequency

































CDR Amino Acid Mutation Frequency





































Figure 3.4:  Mutation Frequency is Reduced in CDR1/2 Regions of VH3-IgG Genes 
from Viremic HIV-1-Infected Patients.  The mean percent of mutated nucleotides (A) 
or the mean percent of mutated amino acids (B) in CDR1 and CDR2 regions was 
calculated for each control subject (n=10; black circles), aviremic HIV-1-infected patient 
(n=6; gray squares), or viremic HIV-1-infected patient (n=15; white triangles) based on 
the alignment of the cloned sequences with VH3 sequences from the Vbase 
immunoglobulin database.  The solid bar indicates the group median.  A) The median 
(and range) of R/S ratios listed below the data points indicates the number of amino acids 
replaced as a result of nucleotide mutations relative to unchanged (silent) amino acids.  
B) The median (and range) percent non-conservative mutations (listed below the data 
points with the range of patient means in parentheses) was calculated relative to the total 
number of replaced amino acid mutations.   
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Figure 3.5:  Replacement Amino Acid Mutation Frequencies are Reduced in 
FR1/2/3 Regions of VH3-IgG Genes from Viremic HIV-1-Infected Patients.  The 
mean percents of mutated nucleotides (A) or mutated amino acids (B) in FR1, FR2, and 
FR3 was calculated for each control subject (n=10, black circles), HIV-1-infected 
aviremic patient (n=6, gray squares), and HIV-1-infected viremic patient (n=15, white 
triangles) based on the alignment of cloned sequences with VH3 sequences from the 
Vbase immunoglobulin database.  The solid bar indicates the group median.  A) The 
median (and range) of R/S ratios listed below the data points indicates the number of 
amino acids replaced as a result of nucleotide mutations relative to unchanged (silent) 
amino acids.  B) The median (and range) percent non-conservative mutations listed 
below the data points were calculated relative to the total number of replaced amino acid 
mutations.  The solid bar indicates the group median. 
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Proportions of Mutated Sequences





























































Figure 3.6:  The Proportions of Mutated Sequences in VH3-IgG Genes.  The median 
proportion of sequences with varying percentages of nucleotide mutations per sequence is 
graphed for control subjects (n=10, black circles), HIV-1-infected aviremic patients (n=6, 
gray squares), and HIV-1-infected viremic patients (n=15, white triangles).  Proportions 
are expressed as a percent of the total number of sequences from each individual.  
Primary p values are listed on the graph.  Secondary analyses:  0-1.9%, control vs. 
viremic p<0.05; 4-5.9%, aviremic vs. viremic p<0.05; 6-7.9%, control vs. viremic 
p<0.05. 
 
cells bearing these gene products (VH3-30.5, -23, -15, -30, and -73).  However, we found 
no consistent differences in the pattern of amino acid replacement frequencies by group 
for each of these genes (Figure 3.7).   
The topographical pattern of amino acid mutations was similar in all groups.  The 
frequency of amino acid replacements by numbered position within the VH molecule was 
virtually identical in all groups (Figure 3.8).  Moreover, the proportion of non-




Figure 3.7:  Frequencies of Amino Acid Replacement Mutations in Specific VH3-IgG 
Genes.  The group median for CDR1/2 in each of the 5 most frequently expressed VH3 
genes (VH3-74, -33, -07, -30.5, and -23) and for the VH3 genes proposed to bind to HIV-1 
gp120 outside of the antigen-binding region (VH3-30.5, -23, -15, -30, and -73) are 
calculated with the mean mutation frequencies for each individual patient in a group.  
The table below shows the total number of sequences cloned (N) for each gene by group. 
 
noted, the highest mutation frequencies were found in the CDR1/2 regions.  A larger 
portion of these mutations in the CDR1/2 regions were non-conservative compared with 
those in the FR1/2/3 (2.23-2.71 in CDR1/2 vs. 1.32-1.47 in FR1/2/3; Figure 3.8), again 
suggesting antigen-driven selection requiring functional differences in structure 
compared with germline. In contrast, a larger portion of the replacement amino acid 
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mutations in the FR1/2/3 regions were conservative mutations, as we expected based on 
FR function and nucleotide content [82].   
Binding of HIV-1 gp120 to VH3 genes in a superantigen-like fashion has been 
reported to involve amino acid residues in regions FR1 (residues 10, 13, 19, 23, 28), 
CDR1 (residue 32), CDR2 (residues 54, 59, 64, 65), and FR3 (residues 75, 79, 81, 82a, 
83, and 85) [183].  Despite suggestions that gp120 binding would be sensitive to SHM at 
these residues [183], amino acid replacement frequencies at nearly all of these positions 
did not vary by group, as might be expected if large proportions of the VH3-expressing B 
cells that bound gp120 at these positions were being selectively deleted.  Only at amino 
acid position 54 was there a significant difference in the proportion of non-conservative 
mutations between viremic patients and control subjects, with viremic patients less likely 
to have a non-conservative mutation at this site.  This was the only significant difference 
seen between groups when all VH3 gene sequencing results were compared (p=0.033), 
when only putative gp120-binding VH3 gene sequencing results were compared 
(p=0.063), or when only VH3-23 gene sequence results were compared (p=0.016). 
Nucleotide mutation patterns were similar in all groups.  Mutations in G and C are 
a direct result of the activity of activation-induced cytidine deaminase (AID).  AID 
targets SHM mutations to “hotspot” motifs (RGYW and complementary WRCY 
nucleotide motifs) that comprise a minority of total nucleotides but include the majority 
of mutations in CDR1/2 (Table 3.3) [82, 125].  The decreased mutation frequency 
observed in the CDR regions from patients with plasma viremia was not due to 
differences in the number of these hotspot motifs in the variable regions (11-24 per 
sequence in all groups) (Table 3.3).  In addition, nucleotide mutations in both CDRs and 
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FRs were clustered equally.  In cells from all groups, 59-61% of all CDR mutations 
occurred in these hotspots, as did over a third of mutations in FR1/2/3. 
The initial deamination of cytidine nucleotides by AID [184] is subsequently 
repaired by low-fidelity translesion DNA synthesis (TLS) polymerases (DNA pol , , , 
, and Rev1) yielding mutations in A and T nucleotides [121].  Impairment of one or 
more of these polymerases can affect the resulting nucleotide mutation pattern [128, 129].  
Based on knock-out mutations and RNA silencing studies in mice, yeast, and humans, 
loss of Pol , , , and  do not result in any changes in mutation frequency or pattern.  
However, loss of Pol , , , and Rev 1 result in a decrease in some or all types of 
mutations [128]. Fewer A:T but more G:C mutations are found in the absence of Pol 
.  Decreases of all nucleotides are seen in the absence of Pol  (moderate 
decreases) and Pol  (60-80% decrease) [128].  Loss of Rev 1 may lead to a decrease in 
C:G transversion mutations [128].  Whereas all nucleotides tended to show a lower 
proportion of mutation, mutation of both A and G nucleotides, relative to the total 
number of A and G nucleotides in the unmutated reference sequence, were significantly 
lower in viremic patients compared with control subjects (Table 3.4) in the CDR1/2 
regions.  Changes in nucleotide mutation patterns in FR1/2/3 regions were less 
pronounced, however, the mutation of G nucleotides was again significantly lower 
among viremic patients compared with control subjects.  Despite the lower proportions of 
mutated A and G nucleotides, the relative frequency of each nucleotide mutated, relative 
to the total number of mutations, was not different between groups (G> A> C> T in 












































































































































































































FR1 CDR1 FR2 CDR2 FR3
CDR N/C ratio:  2.23
FR N/C ratio:  1.32






























































































































































































































FR1 CDR1 FR2 CDR2 FR3
CDR N/C ratio:  2.71
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CDR N/C ratio:  2.45























Figure 3.8:  Frequencies of Amino Acid Mutations at Each Amino Acid Position in 
VH3-IgG Genes.  The percent of non-conservative (black bars) or conservative (gray 
bars) mutations relative to the total number of amino acids sampled at each position are 
represented, the sums of which equal to the total percent replaced amino acid mutation 
frequency at each position.  The mean percent replacement amino acid mutation 
frequency was calculated for each individual at each amino acid position, and the median 
of the group mutation frequencies at each amino acid position was calculated from the 
individual means.  Control subjects (A; n=10), HIV-1-infected aviremic patients (B; 
n=6), and HIV-1-infected viremic patients (C; n=15). 
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Table 3.3:  RGYW/WRCY Motifs and Targeted Mutation Frequencies in CDR and 
FR Regions in VH3-IgG Genes. 
 Control Aviremic Viremic p value 
Number of RGYW/WRCY 








 Median Percent (Subject Range) 









% of CDR mutations 


















% of FR mutations present 

















% of all mutations present 








Group medians are listed with the range of individual means in each group in 
parentheses. 
 
Characterization of neighboring bases can also be useful in examining both stages 
of SHM; AID-induction and subsequent TLS DNA polymerase-mediated repair.  
Consistent with previous data that AID-mediated mutation of cytidine nucleotides is 
determined in part by neighboring bases, particularly A or G in the +1 (3’) position [185], 
we showed that 76-82% of mutations of C occurred in the presence of an A or G in the 
adjacent -1 position (-1R, Figure 3.9A), regardless of whether the mutation resulted in a 
transition (C:T) or a transversion (C:A or C:G) (Table 3.6).  C or T were the preferred -1 
(5’) adjacent nucleotides in 54-74% of C mutations (-1Y).  These values were identical in 
each group.  Mutations of G showed a very similar preference of -1 and +1 adjacent 
nucleotides [186].  Mutations of A and T were more variable in the preference of adjacent 
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Table 3.4:  Nucleotide Mutation Patterns in VH3-IgG Genes. 




Median Percent (Range) 
% C nucleotides mutated 13.0 




























Framework Regions (FR) 
    




























“% C nucleotides mutated” indicates the proportion of nucleotides in either the CDR1/2 
or FR1/2/3 regions that were mutated relative to the total number of C nucleotides present 
in the unmutated reference sequence, expressed as a percent.  The group medians are 
listed (individual patient mean ranges in parentheses). 
 
nucleotides depending on the type of resulting mutations.  For A:G transition mutations, 
an A or G in  the -1 adjacent nucleotide was preferred (66-68%), whereas in A:T 
transversion mutations a preference for C or T was seen.  A:C transversion mutations 
showed no significant preference at either the -1 or +1 positions.  The only difference 
seen between control subjects and viremic patients was in the preference at the +1 
position in A:G transition mutations.  In controls, a +1 C or T was slightly preferred over 
A or G and in viremic patients a +1 A or G was slightly preferred over a C or T (Figure 
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Table 3.5:  Nucleotide Mutation Proportions in VH3-IgG Genes. 




Median Percent (Range) 
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“% of mutations that were C nucleotides” indicates the proportion of mutations in either 
the CDR1/2 or FR1/2/3 regions that were C nucleotides in the unmutated reference 
sequence relative to the total number of mutations in the region expressed as a percent.  
The group medians are listed (individual patient mean ranges in parentheses). 
 
3.9B).  No differences were seen in the aviremic group compared with controls.  C or T 
was the preferred nucleotide in both the -1 and +1 position for A:T transversions (Table 
3.6).  An A or G in the -1 position of T mutations resulting in a transition or a 
transversion was found in 67-82% of mutations.  However, only in the case of T:A 
transversions was there any preference at the +1 position (A or G, 61-70%).  These 
results, consistent with those in the literature [125], now shown for the first time among 
patients with HIV-1 viremia, and taken together with the previous mutation pattern  
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Figure 3.9:  Dinucleotide Analysis of C:T and A:G Transition Mutations in VH3-IgG 
Genes.  The percent either of R (A or G) or Y (C or T) nucleotides occurring in either the 
-1 (5’) position or the +1 (3’) position to a mutation were calculated for A) C → T 
transition mutations and B) for A → G transition mutations.  Medians are represented for 
the control group (black bars), the HIV-1 aviremic group (gray bars) and the HIV-1 




Table 3.6:  Nucleotide Mutations and Adjacent Nucleotide Patterns in VH3-IgG 
Genes. 
Mutation R:Y Ratio 
5’               3’ 
 Mutation R:Y Ratio 
5’                 3’ 
C → G (Tr)    G → C (Tr)   
Control 4.9 : 1 1 : 2.2  Control 2.7 : 1 1 : 2.5 
Aviremic 3.9 : 1 1 : 2.6  Aviremic 3.0 : 1 1 : 2.4 
Viremic 4.2 : 1 1 : 2.9  Viremic 2.9 : 1 1 : 2.4 
p value 0.47 0.45  p value 0.93 0.98 
C → A (Tr)    G → A (Ts)   
Control 3.2 : 1 1 : 1.2  Control 2.1 : 1 1 : 3.1 
Aviremic 3.1 : 1 1 : 1.3  Aviremic 2.1 : 1 1 : 2.8 
Viremic 4.0 : 1 1 : 1.3  Viremic 2.1 : 1 1 : 2.9 
p value 0.37 0.60  p value 0.74 0.30 
C → T (Ts)    G → T (Tr)   
Control 4.2 : 1 1 : 1.9  Control 1 : 1.1 1 : 3.1 
Aviremic 4.3 : 1 1 : 1.8  Aviremic 1 : 1.0 1 : 3.3 
Viremic 3.6 : 1 1 : 1.8  Viremic 1.2 : 1 1 : 3.6 
p value 0.28 0.80  p value 0.42 0.09 
       
A → C (Tr)    T → C (Ts)   
Control 1 : 1.1 1.3 : 1  Control 1.6 : 1 2.7 : 1 
Aviremic 1 : 1.2 1.1 : 1  Aviremic 1.5 : 1 2.4 : 1 
Viremic 1 : 1.1 1.4 : 1  Viremic 1.5 : 1 2.7 : 1 
p value 0.85 0.85  p value 0.10 0.76 
A → G (Ts)    T → G (Tr)   
Control 1 : 1.1 2.2 : 1  Control 1 : 1.2 2.3 : 1 
Aviremic 1 : 1.0 2.0 : 1  Aviremic 1 : 1.4 2.6 : 1 
Viremic 1.2 : 1 2.1 : 1  Viremic 1 : 1.1 2.1 : 1 
p value 0.02 0.30  p value 0.52 0.93 
A → T (Tr)    T → A (Tr)   
Control 1 : 2.8 1 : 2.2  Control 1.6 : 1 4.8 : 1 
Aviremic 1 : 3.6 1 : 2.1  Aviremic 1.7 : 1 4.5 : 1 
Viremic 1 : 3.6 1 : 2.1  Viremic 2.4 : 1 3.5 : 1 
p value 0.13 0.44  p value 0.17 0.23 
R = A or G; Y = C or T.  Mutations:  Ts = transition (purine ↔ purine or pyrimidine ↔ 




results reveal that the process, if not the frequency of SHM, as well as SHM-associated 
lesion repair are intact during HIV-1 infection.   
Finally, the preference of AID-induced mutations to be transitions (purine:purine 
or pyrimidine:pyrimidine) rather than transversions (purine:pyrimidine) [82, 123, 124] is 
preserved in all groups (53-56% vs. 45-48%, respectively, data not shown).  Overall, we 
show that the frequency of SHM is significantly decreased during HIV-1 infection, 
particularly in the critical antigen-binding CDR regions.  In contrast, the hierarchies in 
SHM and AID activity described in other non-HIV-1 groups [82, 120, 121, 125, 128, 
184], such as nucleotide mutation patterns, mutation proportions, and mutation 
preferences, are maintained among patients with HIV-1 viremia. 
 
VH3 somatic hypermutation frequency is reduced in VH3-IgG 454-pyrosequenced genes 
from viremic HIV-1-infected patients but increased in VH3-IgD genes 
454-pyrosequencing reduces time and increases the number of sequence reads 
generated per patient sample.  Due to the limited number of sequences obtained for each 
patient by cloning, we decided to pursue high-throughput 454-pyrosequencing 
technology to more completely characterize the VH3-IgG
+
 B cell compartment.  We also 
decided to expand the analysis to include the more naïve Ig isotypes, IgD and IgM, as 
well as confirm the IgG results in another class-switched isotype, IgA.  454-
pyrosequencing is a technique that allows for large numbers of sequences to be generated 
straight from PCR product, therefore bypassing time- and labor-intensive cloning steps.  
Our initial experiments were performed using 454-FLX technology which produces 







 cDNA transcripts isolated from the mRNA of PBMCs from a 
healthy control subject (Figure 3.10).  The majority of VH3-IgA sequences were in the 
expected length range, however, many of the VH3-IgM sequences were very short and did 
not cover much of the variable region sequence.  Even at their longest, sequences 
generated on the 454-FLX platform extend only partially through the VH region and do 
not cover the V-D-J junction and CDR3 regions. 
Shortly after this experiment was performed, Roche introduced 454-FLX 
Titanium technology, producing up to 1 million sequences per plate with lengths of up to 
500 base pairs.  For Ig molecules, this longer length would cover nearly the entire 
variable region of the expressed immunoglobulin molecule.  Thus, switching from the 
cloning and Sanger sequencing method to the high-throughput pyrosequencing method 
would allow us to generate 100- to 200-fold additional sequences in less time with less 
cost per sequence, without potentially sacrificing sequence data.  This would allow us to 
have a much larger number of sequences identified for each VH3 gene and remove any 
potential type-II errors associated with low experimental numbers.     
The VhIGene alignment and analysis program is designed to accommodate 454-
pyrosequencing generated data.  Pyrosequencing offered many new challenges to data 
analysis.  Several groups have reported high incidences of insertions and deletions 
(indels) present in the sequencing results [187-191] and our data was consistent with 
these reports.  Because of the nature of the sequence results, the publically available 
websites commonly used for Ig alignment, Vbase, IMGT [155], and JOINSOLVER 
[156], which we had utilized before to analyze cloning data, could not accurately align 







Figure 3.10:  454-FLX Pyrosequencing of VH3 cDNA Sequences Isolated from 
Control Subject PBMCs.  454-FLX Pyrosequencing was performed on VH3 family 
sequences of either A) the IgA isotype or B) the IgM isotype.  The total number of 




public tools also allow for only single sequence or small batch sequence alignments, 
potentially making our new datasets very time-consuming to analyze even if indels could 
be removed or accommodated.  Therefore, we collaborated with Dr. Daniel Frank to 
develop a new alignment and analysis program, VhIGene, to polish, align, and calculate 
gene expression, mutation frequency, and mutation patterns in our new Ig data sets.   
Use of barcode-labeled PCR primers allowed us to pool multiple samples and 
isotypes on a single 454-pyrosequencing plate.  VhIGene’s first step is to take the pooled 
“multiplexed” dataset and sort the sequences into individual libraries based on 
identification of the barcode sequence.  Any sequences where a barcode cannot be 
identified are excluded from the dataset.  Once libraries are created, VhIGene then 
“polishes” the sequences by removing sequences with a low overall quality score, 
removing sequences shorter than 200 base pairs in length, removing identical copies of 
sequences (“de-replication”) based on the alignments of the first 200 bps, and identifying 
and trimming poor quality bases from the remaining set of sequences.  The polished, de-
multiplexed libraries are then aligned with each other using an alignment program called 
HMMER3 (hmmer.org) [192].  VhIGene uses these alignments to identify and remove 
any indels found that are not equal to multiples of 3 base pairs in length.  Our assumption 
is that one or two nucleotide indels represent sequencing errors whereas 3 indels 
represent bona fide codon insertion during V(D)J recombination.  Sequences are then 
aligned to the IMGT reference dataset [155] using HMMER3.  Mutation frequencies and 
patterns are identified from the alignments to the reference sequences and cataloged by 
VhIGene.  The resulting output is the most comprehensive and detailed analysis of Ig 
alignments currently available.  VhIGene also includes additional analyses that were not 
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calculated by Batch Analyzer, such as tracking total nucleotide counts and proportions in 
both references sequences and test sequences, and tracking the number of indels and poor 
quality bases excluded from analysis. 
While our older analysis program, Batch Analyzer, utilized alignments derived 
from the Vbase Ig database, unfortunately, the Vbase reference dataset is no longer 
updated by its programmers.  VhIGene utilizes a reference dataset from IMGT, a site that 
is frequently updated to include the most current sequencing datasets and used frequently 
by other alignment tools (JOINSOLVER) and in the literature [190, 191, 193].  VhIGene 
was also designed to utilize probabilistic models (HMMER) rather than local sequence 
alignment tools (BLAST) to ensure the most accurate alignments.  BLAST-based 
alignment tools align short stretches of nucleotides, unlike HMMER which utilizes an 
algorithm closer to Smith/Waterman alignments and aligns individual nucleotides (the 
most accurate but time-consuming).  Therefore, HMMER runs somewhat slower than 
BLAST-based alignment tools.  However, due to the high number of indels present in 
454-pyrosequenced samples, in most cases our sequences could not be accurately aligned 
using BLAST-based alignment tools. 
VhIGene was validated using Sanger-sequenced clone results and a mock-454 
sequencing experiment.  454-Pyrosequencing and VhIGene were both validated in several 
ways.  First, results from 2983 sequences generated from cloned VH3-IgG, VH3-IgA, and 
VH3-IgM transcripts that were Sanger sequenced and analyzed by Vbase, JOINSOLVER 
[156], and Batch Analyzer were run through VhIGene.  VhIGene’s results were compared 
with both Batch Analyzer’s results as well as outputs from JOINSOLVER [156] (NIH’s 
Ig alignment program that also utilizes IMGT’s [155] reference dataset).  VhIGene 
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identified the correct VH3 gene in 99.9% of cloned sequences, the correct JH gene in 
93.8% of cloned sequences, and the correct D gene in 85% of cloned sequences.  The 
CDR3 sequence was correctly identified in 97.8% of cloned sequences.  In the remaining 
2.2%, the CDR3 region could not be identified.  VhIGene also correctly identified all 
mutations identified in each sequence by Vbase, JOINSOLVER [156], and Batch 
Analyzer as well as correctly characterized each mutation. 
 Next, to determine the error frequency of both the PCR and sequencing steps of 
454 pyrosequencing, 10 of the clones analyzed above were PCR-amplified separately and 
sequenced using barcoded and 454-tagged PCR primers and 454-Pyrosequencing 
reagents and technology.  The results from the 10 pooled clones were de-multiplexed by 
VhIGene and aligned to the 10 clones reference sequences as determined by Sanger 
sequencing without any further polishing steps.  Any base pair changes discovered in 
these sequencing results were considered errors.  The error frequency detected in this 
dataset was 1.31%.  This frequency is slightly higher than others reported in the 
literature.  One study performed using 454-FLX technology which produces shorter 
sequences reported an error frequency of ~0.5% [187].  Another study using 454-FLX 
Titanium technology and, therefore, sequencing longer amplicons, reported an error 
frequency of 1.07% [189].  However, the longer amplicons reported by Gilles, et al., were 
not PCR amplified prior to sequencing as our samples were, and our sequences were 
longer than those reported in the 454-FLX study [187].  Indeed, according to Gilles, et 
al., error frequency increases with sequence length.  After additional sequence polishing 
by VhIGene, including removing any sequences which have <80% homology with the 
sequences in the reference dataset, a step which is performed during polishing for 
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analysis of all additional sequencing results, the error frequency dropped to 0.49% 
(Figure3.11).  The levels of nucleotide mutation detected in our ~3000 Sanger-sequenced 
clones due to SHM are 2-8% in FR regions (median = 4-5%) and 5-15% in CDR regions 
(median = 9-12%) in both HIV-1-infected patients and control subjects, well above both 
the raw 1.31% error frequency due to the 454-Pyrosequencing technique and especially 
the 0.49% error frequency after polishing. 
Analyzing this dataset also validates VhIGene’s ability to accurately analyze 454-
generated sequencing data, which contains much higher frequencies of indels than Sanger 
sequencing results.  We were also able to use this dataset to determine the ideal quality 
score cutoff.  Each base identified by 454-pyrosequencing analysis tools is assigned a 
quality score ranging from 0-40 based on PHRED values [194].  PHRED scores use log-
transformed error probabilities to calculate a quality value, such that a score of 40 
indicates that there is a 1/10,000 change of a base call being incorrect and a score of 20 
indicates a 1/100 chance.  By running the 10 clones 454-sequencing data through 
VhIGene and adjusting the quality score filter, we were able to calculate the error 
frequency relative to quality scores (Figure 3.11).  Based on our results we have chosen a 
quality score cutoff of 20, such that any bases in a sequence with a score between 0 and 
19 are ignored by VhIGene and not included in mutation calculations.  This quality score 
was selected as a reasonable compromise between including all data but increasing the 
error frequency and decreasing the error frequency but losing sequencing information.  
As seen in Figure 3.11, much less data is lost by using a quality cutoff score of 20 versus 
30 or 40, without significantly increasing the error frequency.  All subsequent datasets 
were run through VhIGene with the quality score filter set at 20. 
89 
 
















































Data Cut from Analysis
 
Figure 3.11:  Error Frequency vs. Quality Score Cut-Off.  Quality scores were 
calculated based on log-transformed PHRED sequence quality scores.  The error 
frequency (number of miscalled bases) was calculated at various quality score cut-offs 
(ranging from 0-40), such that bases with quality scores below the cut-off were ignored in 
the analysis.  The amount of poor quality data cut from analysis was calculated from the 
total number of bases ignored per analysis expressed as a percentage of the total number 
of nucleotides in the dataset. 
 
454-FLX Titanium pyrosequencing was used to sequence VH3 transcripts from 
viremic HIV-1-infected patients and control subjects.  We analyzed 198,570 unique VH3-
IgD sequences (median = 10,401 sequences per patient, range = 82 - 56,425), 185,566 
unique VH3-IgM sequences (median = 8,806 sequences per patient, range = 4,314 - 
21,763), 251,810 unique VH3-IgA sequences (median = 8,850 sequences per patient, 
range = 3,528 - 66,147), and 218,844 unique VH3-IgG sequences (median = 10,017 
sequences per patient, range = 4,512 - 45,868) from 8 HIV-1-seronegative control 
subjects and 9 HIV-1-infected patients with detectable viremia and low CD4
+
 T cell 




Table 3.7:  Clinical Characteristics of 454-Pyrosequencing Study Subjects 
 Control HIV-1+ p value 
Number 8 9  



























Antiretroviral Therapy    
-No Therapy (%) N/A 9 (100%)  
-≥1 Medication N/A 0   
a
Calculated by Fisher’s Exact test.  
b
Ethnicity:  C = Caucasian, B = Black, H = Hispanic, 
O = Other. 
 
VH3-23 expression was reduced in 454-pyrosequenced VH3-IgG transcripts from 
viremic HIV-1-infected patients.  We first looked at individual VH3 gene expression in all 
isotypes of both groups.  Of the 21 functional individual VH3 genes (as defined by IMGT 
[155] in 2010 when our reference dataset was created), all 21 genes were expressed 
amongst all four isotypes in both groups.   VH3-23 and VH3-30 were consistently the 
most dominant genes expressed across all isotypes, while the naïve IgD
+
 B cells had the 
most evenly distributed gene expression of the four isotypes (Figure 3.12A).  Whereas 
VH3-11 and VH3-74 were significantly lower in the HIV-1-infected group, no other 
differences were found in VH3-IgD sequences compared with controls.  Similarly, gene 
expression amongst VH3-IgM (Figure 3.12B) and VH3-IgA (Figure 3.12C) sequences was 
comparable between groups.  There was a significantly higher proportion of VH3-7 gene 
expression amongst VH3-IgM sequences compared with controls, while VH3-11 was 
significantly lower amongst VH3-IgA sequences.  Consistent with our previous cloning 
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results, VH3-23 expression was significantly lower in VH3-IgG sequences from the HIV-
1-infected group compared with controls, though a slightly higher level of VH3-13 
expression was also discovered in this group (Figure 3.12D). 
D and JH gene expression are comparable in both groups among isotypes except 
for IgD.  Few differences were also seen in D gene expression and nearly all the 
differences were present in the VH3-IgD sequences (Figure 3.13A).  The more commonly 
expressed IGHD2-02 and IGHD2-15 genes were significantly lower in the HIV-1-
infected group as were the rarely expressed IGHD5-24 (p=0.01) and IGHD6-13 (p=0.01) 
(data not shown).  Conversely, expression of IGHD1-14 (p=0.04) and IGHD3-03 
(p=0.007) were significantly higher in the HIV-1-infected group compared with controls.  
Similar to VH3 gene expression, few differences were seen in VH3-IgM (Figure 3.13B) 
and VH3-IgA sequences (Figure 3.13C).  In VH3-IgM sequences, both IGHD4-04 
(p=0.01) and IGHD6-13 (p=0.05) were lower in the HIV-1-infected group, as was 
IGHD5-05 (p=0.01) in VH3-IgA sequences.  No significant differences in D gene 
expression were found amongst the VH3-IgG sequences (Figure 3.13D). 
Finally, JH gene expression was even less variable than D gene expression.  Only 
one difference in the naïve IgD
+
 B cell subset was found; IGHJ4*02 gene expression was 
lower in the HIV-1-infected group compared with controls (Figure 3.14A).  No 
differences were detected amongst the other three isotypes (Figure 3.14).  Taken together, 
and consistent with the previous VH3-IgG cloned dataset results, the repertoire of 


































             





























                                   





























             






























Figure 3.12:  VH3 Gene Expression in 454-Pyrosequenced Samples.  VH3-family mRNA sequences were amplified from A) 
naïve IgD
+
 B cells, B) IgM
+
 B cells, C) IgA
+
 class-switched B cells, or D) IgG
+
 class-switched B cells from control subjects 
(black bars) and HIV-1-infected patients (HIV-1+, white bars).  Group median values for the 13 most highly expressed VH3 


































           




















































           







































Figure 3.13:  D Gene Expression in 454-Pyrosequenced Samples.  VH3-family mRNA sequences were amplified from A) 
naïve IgD
+
 B cells, B) IgM
+
 B cells, C) IgA
+
 class-switched B cells, or D) IgG
+
 class-switched B cells from control subjects 
(black bars) and HIV-1-infected patients (HIV-1+, white bars).  Group median values for the 10 most highly expressed D 
genes are shown.  Due to both sequence length and junctional sequence diversity, gene identification could be assigned in 







                         




























          



























           
     
                         



























          









































Figure 3.14:  JH Gene Expression in 454-Pyrosequenced Samples.  VH3-family mRNA sequences were amplified from A) 
naïve IgD
+
 B cells, B) IgM
+
 B cells, C) IgA
+
 class-switched B cells, or D) IgG
+
 class-switched B cells from control subjects 
(black bars) and HIV-1-infected patients (HIV-1+, white bars).  Group median values for each gene are shown.  Due to 
sequence lengths, gene identification could be assigned in 54.61% of sequences.  “Other” indicates IGHJ1*01, 2*01, 3*01, 






CDR3 region characteristics were similar in both groups among all isotypes.  
Characteristics of the main antigen-binding segment of the variable region, CDR3, were 
determined for each isotype (Appendix Table A1).  Due to the limit in sequence length, 
the CDR3 region could only be identified in a small portion of the sequences from all 
isotypes (median = 6.66% of sequences, range = 0.68-32.79%), though the numbers of 
CDR3 regions identified did not vary by group.  Neither the amino acid length nor the 
degree of hydrophobicity varied by group for any isotype.  The only difference in amino 
acid composition was seen in the VH3-IgD sequences, where HIV-1-infected patients had 
a slight, but significantly lower proportion of aromatic residues.  This could be due to the 
differences seen in D gene usage in the VH3-IgD sequences in this group as described 
earlier.  The CDR3 region overlaps the VH-D-JH junction, and thus, the majority of its 
composition is contributed by the D gene.  Combined with the VH3, D, and JH gene 
expression results, these data suggest that the initial V(D)J recombination process is 
intact during HIV-1 infection. 
 SHM frequencies are lower in CDR1/2 and FR1/2/3 regions of VH3-IgG 
sequences but higher in VH3-IgD sequences in viremic HIV-1-infected patients.  Next, 
we characterized the SHM frequencies of both nucleotides and amino acids in the CDR1 
and CDR2 regions (Figures 3.15A and 3.15B, respectively).  Surprisingly, both 
nucleotide and amino acid SHM frequencies in the VH3-IgD sequences were significantly 
greater in the HIV-1-infected group compared with controls.  This was unexpected as the 
majority of circulating IgD
+
 B cells are naïve cells are not believed to be either antigen-
experienced or have participated in a germinal center reaction, and thus, should have 
unmutated sequences.  There was no difference in either the nucleotide or amino acid 
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SHM frequencies in the VH3-IgM and VH3-IgA sequences.  Consistent with the previous 
VH3-IgG cloned dataset results, but contrary to the VH3-IgA results above, in VH3-IgG 
454-pyrosequences both the nucleotide and amino acid SHM frequencies were lower in 
the HIV-1-infected group compared with controls, however, the differences did not quite 
reach statistical significance due to a high degree of variability in the HIV-1-infected 
samples.     
The high SHM frequency found in VH3-IgD sequences in HIV-1-infected patients 
is not likely due to technical error or contamination.  The four patients with significantly 
higher SHM frequency in VH3-IgD sequences were PCR-amplified at different times with 
different reagent aliquots, including different barcode sequences.  They were also pooled 
and run with other samples with low VH3-IgD SHM frequencies.  Similarly, high VH3-
IgD SHM frequency did not correlate with SHM frequency among other isotypes within 
the same patient.  Mutation patterns were also the same in these four patients compared 
with the four patients with normal VH3-IgD SHM frequencies.  Even the inversion of the 
ratio of transition-to-transversion mutations, as discussed below, remains consistent 
despite high or normal levels of VH3-IgD SHM frequency.  Though unexpected, the 
results in the VH3-IgD compartment appear authentic.  
Despite the varied SHM frequencies between controls and HIV-1-infected 
patients in VH3-IgD and VH3-IgG pyrosequenced genes, no differences were found in the 
R/S ratios or the proportion of non-conservative amino acid changes.  R/S ratios in the 
CDR1/2 regions were high and consistent with the VH3-IgG cloning results (median 
ratios from controls vs. HIV-1-infected patients; IgD:  3.4 vs. 3.6, p=0.67; IgM:  3.8 vs. 
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Figure 3.15:  Mutation Frequencies in CDR1/2 Regions of VH3 454-Pyrosequenced 
Samples.  The mean percent of mutated nucleotides (A) or the mean percent of replaced 
mutated amino acids (B) in CDR1 and CDR2 regions was calculated for each isotype 
(IgD, IgM, IgA, and IgG) for each control subject (black circles) or HIV-1-infected 
patient (HIV-1+, white triangles).  The solid bar indicates the group median.  
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ratios in the pyrosequenced genes, the proportion of non-conservative amino acid 
mutations relative to the total number of mutations was also high and similar between 
groups (median percent non-conservative mutations in controls vs. HIV-1-infected 
patients; IgD:  78.4% vs. 73.9, p=0.19; IgM:  74.4 vs. 74.2 p=1.00; IgA:  74.8 vs. 75.0, 
p=0.76; IgG:  74.4 vs. 74.1, p=0.92). 
As expected, both the nucleotide and amino acid SHM frequencies in the 
structural FR1, FR2, and FR3 regions (Figures 3.16A and 3.16B, respectively) were 
lower, in general, than the SHM frequencies found in the CDR1/2 regions in all isotypes 
and in both groups.  Similar to SHM frequencies in the CDR1/2 regions, both nucleotide 
and amino acid SHM frequencies were higher in VH3-IgD sequences in HIV-1-infected 
patients, although in this case, the differences did not reach statistical significance.  Also, 
consistent with results in CDR1/2 regions, no significant differences were seen in either 
nucleotide or amino acid SHM frequencies in VH3-IgM and VH3-IgA sequences.  Though 
the lower nucleotide SHM frequency in VH3-IgG sequences also did not reach statistical 
significance, the amino acid SHM frequency was significantly lower in the HIV-1-
infected group compared with controls, as seen in the VH3-IgG cloned dataset results.  
FR1/2/3 R/S ratios were not different between groups in any isotype and were lower, in 
general, than those in the CDR1/2 regions (median ratios for controls vs. HIV-1-infected 
patients; IgD:  1.6 vs. 1.9, p=0.44; IgM:  1.6 vs. 1.5, p=0.16; IgA:  1.6 vs. 1.6, p=0.71; 
IgG:  1.7 vs. 1.7, p=0.66).  Similarly, the proportion of non-conservative amino acid 
mutations was also lower, in general, compared with those in the CDR1/2 regions and did 
not vary by group in VH3-IgD, -IgM, or –IgA sequences (median percent of non- 
conservative mutations in controls vs. HIV-1-infected patients; IgD:  57.7% vs. 58.7, 
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p=0.67; IgM:  56.8 vs. 56.1, p=0.48; IgA:  57.2 vs. 57.2, p=0.79).  However, in contrast 
to the VH3-IgG cloned dataset results described earlier, the proportion of non-
conservative amino acid changes was significantly lower in VH3-IgG sequences from 
HIV-1-infected patients compared with controls (58.0% for controls vs. 56.5% for HIV-
1-infected patients, p=0.03), suggesting potentially altered antigen-driven selection 
pressure during the affinity maturation process during HIV-1-infection.  
To further characterize the populations of mutated sequences in each group and 
isotype, the proportions of sequences with varying densities of mutations were graphed 
(Figure 3.17).  In VH3-IgD and VH3-IgM sequences, a majority of sequences had no or 
few nucleotide mutations (Figures 3.17A and 3.17B, respectively).  The proportions of 
unmutated sequences in both groups also did not differ in either isotype (IgD:  39.3% 
unmutated sequences for controls vs. 25.1% for HIV-1-infected patients, p = 0.10; IgM:  
26.3% vs. 22.9%, p=0.74), suggesting that for at least IgD, a larger proportion of 
unmutated “naïve” VH3-IgD transcripts in control subjects was not biasing the difference 
in SHM frequency.  In VH3-IgM sequences, though the proportion of sequences with 14-
15.9% mutation density was significantly higher in the HIV-1-infected group compared 
with the controls, the small percentage of sequences (0.16% for HIV-1-infected patients) 
in this category was not enough to affect the overall SHM frequency across all sequences.  
In the class-switched isotypes, IgA and IgG (Figures 3.17C and 3.17D, respectively), a 
higher proportion of sequences were more densely mutated than in the IgD and IgM 
isotypes.  In VH3-IgA sequences, while both the control and HIV-1-infected sequences 
peak at the same density (4-5.9%, Figure 3.17C), a significantly higher proportion of 
sequences were also more densely mutated (6-7.9%) than in the HIV-1-infected group, 
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Figure 3.16:  Mutation Frequencies in FR1/2/3 Regions of VH3 454-Pyrosequenced 
Samples.  The mean percent of mutated nucleotides (A) or the mean percent of replaced 
mutated amino acids (B) in FR1, FR2, and FR3 regions was calculated for each isotype 
(IgD, IgM, IgA, and IgG) for each control subject (black circles) and HIV-1-infected 




although, as with VH3-IgM sequences, this difference was not enough to drive a change 
in the overall SHM frequency when both control and HIV-1-infected groups were 
compared.  In the case of VH3-IgG sequences, however, mutation density in the HIV-1-
infected group peaks at a much lower density (2-3.9%, Figure 3.17D) compared with 
controls (6-7.9%) and is consistent with previous VH3-IgG cloned dataset results.  The 
differences in the proportion of sequences measured at each density in these groups may 
explain the lower mutation frequencies observed in the VH3-IgG sequences from HIV-1-
infected patients.  The proportion of unmutated sequences, though similar in the cloned 
sequences, was higher in the pyrosequenced HIV-1-infected group compared with 
controls (median 0.76% unmutated sequences for controls vs. 2.61% for HIV-1-infected 
patients, p=0.004) and may have contributed to the reduced SHM frequency. 
VH3 gene-specific SHM is consistent with overall SHM frequencies measured in 
each isotype in viremic HIV-1-infected patients.  The differences in overall SHM 
frequencies can also be seen in individual VH3 genes.  In general, CDR1/2 amino acid 
mutation frequencies were higher in VH3-IgD sequences from HIV-1-infected patients 
compared with controls and significantly higher in VH3-9 (Figure 3.18A) and VH3-30-3 
(p = 0.03, data not shown).  Consistent with finding no differences in the overall CDR1/2 
amino acid SHM frequency, in VH3-IgM sequences no differences were seen in any 
specific gene between groups (Figure 3.18B).  In VH3-IgA sequences from HIV-1-
infected patients, a significant decrease was seen in the SHM frequency in VH3-30, one 
of the most highly expressed VH3 genes and potentially bound by HIV-1 gp120 in vivo 
(Figure 3.18C).  However, no other significant differences were found in the other 
putative gp120-binding genes or other highly expressed VH3 genes when compared with 
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controls.  In contrast, nearly every VH3 gene from VH3-IgG sequences displayed a lower 
SHM frequency in the HIV-1-infected patients compared with controls, with statistically 
significant differences found in 10 of the 21 VH3 genes, including the most highly 
expressed VH3 genes (VH3-33, -48, -7, -30, and -23; Figure 3.18D) and in all putative 
gp120-binding genes (VH3-30, -23, -73, and -15), contrary to results previously seen in 
the VH3-IgG cloned dataset. 
 Finally, CDR1/2 amino acid SHM frequencies were compared with SHM 
frequencies of all other isotypes, with HIV-1 plasma viral load, and with CD4
+
 T cell 
number.  Only VH3-IgD and VH3-IgM SHM frequencies were significantly correlated 
(Figure 3.19A).  None of the other CDR1/2 SHM frequencies correlated with either VH3-
IgD or each other, including VH3-IgD versus VH3-IgG (r=0.10, p=0.71, data not shown).  
No CDR1/2 SHM frequencies in any isotype correlated significantly with CD4
+
 T cell 
number (IgD:  r=0.0, p=1.0; IgM:  r=0.24, p=0.58; IgA:  r=-0.31, p=0.46; IgG:  r=0.14, 
p=0.75).  However, the CDR1/2 amino acid SHM frequency in VH3-IgD sequences did 
positively correlate with HIV-1 plasma viral load (Figure 3.19B).  The CDR1/2 amino 
acid SHM frequencies from the other three isotypes, including IgG, did not significantly 
correlate with viral load (IgM:  r=0.35, p=0.36; IgA:  r=0.23, p=0.55; IgG:  r=0.22, 
p=0.58).  Therefore, the increased mutation accumulation in VH3-IgD sequences may be 
dependent on HIV-1 viral loads, however, the decreased SHM frequencies seen in VH3-
IgG sequences, consistent with the previous VH3-IgG cloned dataset results, does not 
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Figure 3.17:  Proportions of Mutated Sequences in VH3 454-Pyrosequenced 
Samples.  The median proportion of sequences with varying percentages of nucleotide 
mutations per sequence is graphed for control subjects (black circles) and HIV-1-infected 
patients (HIV-1+, white triangles) from A) naïve IgD
+
 B cells, B) IgM
+
 B cells, C) IgA
+
 
class-switched B cells, or D) IgG
+
 class-switched B cells.  Proportions are expressed as a 






















Figure 3.18:  Frequencies of Replacement Amino Acid Mutations in Specific VH3 Genes from 454-Pyrosequenced 
Samples.  The group median for CDR1/2 in each of the 5 most frequently expressed VH3 genes (33, 48, 11, 9, 7, 30, 23) and 
the VH3 genes proposed to bind to HIV-1 gp120 outside of the antigen-binding region (30, 23, 15, and 73) are calculated with 
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Figure 3.19:  VH3-IgD SHM Frequency Correlates with VH3-IgM SHM Frequency 
and HIV-1 Plasma Viral Load.  Spearman correlations were calculated for VH3-IgD 
CDR1/2 amino acid SHM frequency and A) VH3-IgM CDR1/2 amino acid SHM 
frequency and B) HIV-1 plasma viral load (RNA copies/mL blood). 
 
Nucleotide mutation patterns were similar between groups among all isotypes.  
Despite variable levels in SHM frequencies, mutation patterns were generally comparable 
between groups amongst the different isotypes.  Any differences resulting from the 
targeting of the mutational machinery were discerned by comparing 1) the targeting of 
mutations to specific “hotspot” motifs (RGYW/WRCY), 2) the proportion of mutations 
occurring at each nucleotide, 3) the nature of the mutational event, and 4) the pattern of 
nucleotides surrounding the mutation. 
 SHM is initiated by the enzyme AID, which targets RGYW/WRCY motifs in 
both variable and switch region sequences.  RGYW/WRCY motifs were present in 
similar proportions in both groups (Appendix Table A2) in all isotypes except in IgM, 
where the number of motifs per sequence was significantly lower.  This may be due to 
109 
 
the significantly higher proportion of VH3-7 sequences in the HIV-1-infected population 
as the VH3-7 reference sequence has fewer RGYW/WRCY motifs than some of the other 
more highly expressed VH3 genes (e.g., VH3-23).  However, despite a smaller number of 
motifs in the VH3-IgM sequences of HIV-1-infected patients, there were no differences in 
the proportion of mutations found in the motifs in either the CDR1/2 or FR1/2/3 regions.  
Whereas no differences were observed in the proportion of mutations occurring in these 
motifs in the CDR1/2 regions of VH3-IgD sequences, a significantly higher proportion of 
mutations were found in the FR1/2/3 regions of HIV-1-infected patients compared with 
controls, suggesting targeting to these motifs was actually increased in these sequences.  
No other targeting differences were found in the VH3-IgA or VH3-IgG sequences, 
consistent with previous VH3-IgG cloned dataset results. 
 Whereas decreased targeting to “hotspot” motifs by AID was not observed in 
either group in any isotype, downstream mutation repair mechanisms can disrupt the 
proportions and patterns of nucleotide mutations.  The overall increased SHM frequency 
seen in VH3-IgD sequences from HIV-1-infected patients was present across all 
nucleotides, and especially in the CDR1/2 region in the proportions of C, A, and T 
nucleotides mutated, relative to the total number of C, A, and T nucleotides present in the 
unmutated reference sequence (Table 3.8).  Increased proportions of all nucleotides 
mutated were also seen in the FR1/2/3 regions, but did not reach statistical significance.  
The relative frequency of each nucleotide mutated, relative to the total number of 
mutations in the CDR1/2 regions was similar in both groups (G> A> C> T).  Although 
the frequency pattern of mutations in the FR1/2/3 regions was similar in both groups (G> 
C> A> T), the frequency of T mutations was significantly lower in the HIV-1-infected 
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group compared with controls.  No differences in the proportions of each nucleotide 
mutated were found in VH3-IgM sequences between groups (Appendix Table A3).  A 
significantly higher frequency of mutations in the FR1/2/3 regions occurred at C 
nucleotides in the HIV-1-infected patients compared with controls, although the 
frequency patterns were the same in both CDR1/2 and FR1/2/3 regions in both groups.  
In VH3-IgA sequences from HIV-1-infected patients, A nucleotides were mutated in the 
CDR1/2 regions at a significantly decreased frequency compared with controls, however, 
no other differences were found in nucleotide proportions or frequency patterns between 
groups in either the CDR1/2 or FR1/2/3 regions (Appendix Table A3).  Contrary to 
previous VH3-IgG cloned dataset results which showed a decrease in only A and G 
nucleotide proportions, all nucleotides were mutated at a lower frequency in 
pyrosequenced VH3-IgG sequences in both the CDR1/2 and FR1/2/3 regions, however, 
the proportions of C and G nucleotides in the CDR1/2 regions and T nucleotides in the 
FR1/2/3 regions were significantly lower (Table 3.8).  While frequency patterns were 
similar in both groups in both the CDR1/2 and FR1/2/3 regions, there were significantly 
fewer T nucleotide mutations present in the CDR1/2 regions compared with controls.  
The decrease seen across all nucleotides in VH3-IgG sequences from HIV-1-infected 
patients does not suggest nor eliminate a potential deficit in the downstream mutation 
repair mechanisms. 
 Mutations that result from AID activity are more likely to be transitions than 
transversions [82, 123, 124].  While no differences in the proportions of transition 




Table 3.8:  Nucleotide Mutation Patterns and Proportions in VH3 454-
Pyrosequenced Samples. 
IgD Control Day 0 HIV-1
+
 Day 0 p value 
CDR Median Percent (Subject Range) 
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CDR Median Percent (Subject Range) 




















FR    




















CDR    




























FR    




























“% C nucleotides mutated” indicates the proportion of nucleotides in either the CDR1/2 or 
FR1/2/3 regions that were mutated relative to the total number of C nucleotides present in the 
unmutated reference sequence, expressed as a percent.  “% of mutations that were C nucleotides” 
indicates the proportion of mutations in either the CDR1/2 or FR1/2/3 regions that were C 
nucleotides in the unmutated reference sequence relative to the total number of mutations in the 
region, expressed as a percent.  The medians of each group are listed with individual patient mean 
ranges in parentheses.  
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(Table 3.9), interestingly, the opposite pattern was observed in the VH3-IgD sequences.  
Transversion mutations were slightly more common in these sequences in controls and 
this pattern was maintained in HIV-1-infected patients, possibly suggesting that AID may 
not be the only source of these mutations, downstream mutagenic repair mechanisms may 
vary, or selection pressures may vary in the highly mutated IgD
+
 B cell subset. 
Finally, AID-mediated mutation is determined, in part, by bases immediately 
surrounding the targeted nucleotide.  Similar to previous reports [125, 185, 186] and to 
the previous VH3-IgG cloned dataset results, all C mutations showed a strong preference 
for an A or G nucleotide in the -1 (5’) position (Appendix Table A4).  All G mutations 
showed preferences for both either an A or G nucleotide in the -1 position and either a C 
or T nucleotide in the +1 (3’) position.  An A or G nucleotide in the +1 position was 
preferred for T → C transition and T → A transversion mutations, however, T → G 
transversion mutations did not reveal any preferences in either neighboring base.  A → G 
transversion mutations showed a preference for an A or G nucleotide in the +1 position.  
Conversely, A → T transversion mutations had a preference for a C or T nucleotide in the 
+1 position.  Similar to T → G transversion mutations, no strong preferences were 
observed for A → C transversion mutations.  These patterns were consistent in all 
isotypes between both groups, although a few significant differences were found in the 
degree to which certain nucleotides were preferred.  Contrary to the previous cloning 
data, no significant differences in the pattern of preferred neighboring bases was 
observed in the VH3-IgG sequences.  Taken together, these data suggest that despite the 
increased SHM frequencies found in VH3-IgD sequences and the decreased SHM 
frequencies found in VH3-IgG sequences from HIV-1-infected patients, targeting of AID 
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Table 3.9:  Transition and Transversion Mutation Proportions in VH3 454-
Pyrosequenced Samples. 
 Control HIV-1+ p value 
Transition Mutations    




















Transversion Mutations    




















Transition Mutation = purine ↔ purine or pyrimidine ↔ pyrimidine; Transversion 
Mutation = purine ↔ pyrimidine.  The median percents of each group are listed with 
individual patient mean ranges in parentheses. 
 
and subsequent downstream repair pathways do not appear to be impaired during HIV-1 
infection. 
 In the 454-pyrosequenced dataset, we have shown that although SHM frequency 
is lower in VH3-IgG class-switched sequences, consistent with our previous VH3-IgG 
cloned dataset results, SHM frequency in presumably naïve VH3-IgD sequences is 
significantly increased in HIV-1-infected patients.  However, such patterns could not be 
confirmed in sequences from either the other class-switched isotype, IgA, or in IgM 
sequences, which may, even in class-switched memory cells, retain a “naïve-like” 
repertoire of no or little SHM in healthy adults.  Despite variable SHM frequencies in 
both VH3-IgG and VH3-IgD transcripts, mutation patterns were similar in both groups, 
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suggesting a deficit in VH3-IgG SHM frequency and an increase in VH3-IgD SHM 
frequency of the quantity of mutation, but not the quality. 
 
Mutation frequency is reduced in Bcl6 genes in HIV-1-infected patients 
 AID targets non-Ig genes, including Bcl6.  VH genes are not the only targets of 
AID during SHM.  Many other genes, including Bcl6, CD83, CD79a, CD79b, Pim1, and 
Myc have been shown to be targeted by AID also [160, 162].  Of these known additional 
SHM targets, Bcl6 accumulates the highest mutation frequency [45, 160, 162, 195, 196]).  
Mutations found in Bcl6 are also known to have been caused by AID activity, as the 
mutation frequency in Bcl6 in AID
-/-
 murine B cells is reduced by 80-fold compared to 
wild type B cells [162].  The Bcl6 protein is a transcriptional repressor that affects B cell 
activation, differentiation, cell cycle regulation, and a cell’s response to DNA damage 
[45, 195-197].  The gene encoding the protein is highly expressed in B cells during the 
germinal center reaction and concurrent with SHM [42, 195-197].  The Bcl6 gene is 24.3 
kilobases (kb) long and encodes 10 exons.  Within its genomic sequence are 1457 
RGYW/WRCY AID “hotspot” motifs.  In order to determine if aberrant mutation 
frequencies exist in other AID-targeted genes, such as Bcl6, multiple segments of the 
Bcl6 gene were amplified and sequenced. 
 Preliminary Bcl6 sequencing reveals different levels of mutation at different gene 
segments.  First, we determined which of several selected segments had the highest 
mutation frequency in the gene.  Primer pairs for 11 segments were designed, covering 
11.8 kb of both intronic and exonic sequences (Figure 3.20).  These 11 segments were 
selected because they had the highest densities of RGYW/WRCY “hotspots”.  Indeed, 
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though they cover less than half of the genomic sequence, they include over half 
(753/1457) of the encoded RGYW/WRCY “hotspot” motifs in the gene.  An additional 
segment was also selected based on previous sequencing experiments found in the 
literature and because its position at the 5’ end of the gene more closely resembles the 
portion of the VH gene that is most highly mutated (e.g. the first 1.5 kb of VH genes)  
[160-162].  Shen, et al., in normal murine B cells, and Dijkman, et al., in primary 
cutaneous follicle center lymphoma (PCFCL) and primary cutaneous large B cell 
lymphoma (PCLBCL) patients, found that the first 1.5 kb of the Bcl6 gene was the most 
highly mutated portion of the sequence [160, 161] (Figure 3.20).   
Genomic DNA was extracted from fresh PBMCs isolated from a healthy control 
subject.  Of the 12 selected Bcl6 segments, primer pairs for segments 4 and 6 did not 
successfully amplify product from the DNA.  The remaining 10 segments were PCR 
amplified, cloned into plasmids, and sequenced by Sanger sequencing.  Sequencing of 
 
Figure 3.20:  Bcl6 Gene and Segment Positions.  The 24.3 kb Bcl6 gene encodes 10 
exons and 1457 RGYW/WRCY AID “hotspot” target motifs.  Segments 1-11 were 
chosen based on their high density of RGYW/WRCY motifs.  Segment 1.5 was chosen 
based on sequencing experiments in the literature and because its position at the 5’ end of 




segment 2 gave consistently poor results and cloning and sequencing were discontinued.  
Cloned sequences were aligned using the BLAST tool bl2seq 
(www.ncbi.nlm.nih.gov/BLAST) with a human Bcl6 reference sequence from the 
GenBank database (www.ncbi.nlm.nih.gov/genbank).  Mutations were detected in all 9 
sequenced segments (Table 3.10).  The segments with the highest mutation frequencies 
were 5, 9, and 10.  The segment with the lowest mutation frequencies was 7.  The 
segment covering the first 1.5 kb of the Bcl6 gene, Bcl6-1.5, also had a low mutation 
frequency compared with the other segments.  
 
Table 3.10:  Preliminary Bcl6 Mutation Frequencies 
Bcl6 Segment Mutation Frequency  Number of Base Pairs 
Bcl6-1 6.5 x 10
-4
 24470 
Bcl6-3 8.1 x 10
-4
 35707 
Bcl6-5 1.2 x 10
-3
 35753 
Bcl6-7 1.2 x 10
-4
 33210 
Bcl6-8 8.0 x 10
-4
 28787 
Bcl6-9 9.6 x 10
-4
 36381 
Bcl6-10 1.9 x 10
-3
 22508 
Bcl6-11 6.8 x 10
-4
 27752 




 Bcl6 accumulates mutations during stimulation at the 5’ region of the gene.  We 
wanted to investigate not only the baseline levels of SHM in Bcl6, but also the 
accumulation of mutation in the Bcl6 gene in stimulated PBMCs over time.  This method 
may indirectly measure AID activity within stimulated B cells.  In order to determine 
which of the segments would be best for further testing, we selected the 3 most highly 
mutated segments from the previous experiment, 5, 9, and 10, as well as the 1.5 kb 
segment for testing in stimulated PBMCs.  Genomic DNA was isolated from PBMCs 
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from a healthy control subject at baseline (fresh cells), or after stimulation for 4 or 10 
days in culture with B cell stimulants anti-CD40, anti-IgM, and IL-4.  PCR-amplified 
segments were cloned and sequenced and analyzed as before. 
 Baseline mutation frequencies were similar for each segment, except for segment 
10, which was 1.5-fold lower in this batch of sequences (Table 3.11).  Though the Bcl6-
1.5 segment had the lowest baseline mutation frequency of all 4 segments tested, this 
segment had the greatest increase in mutation frequency over time (2-fold increase).  
However, this increase only occurred between Days 0 and 4.  No additional mutation 
accumulation was observed at Day 10.  Therefore, the Bcl6-1.5 segment was selected for 
high-throughput 454-pyrosequencing in both control subjects and HIV-1-infected patients 
at baseline and post-stimulation in order to measure AID functionality in these two 
populations. 
 Bcl6 baseline mutation frequencies were lower in viremic HIV-1-infected 
patients.  High-throughput 454-pyrosequencing was done on genomic DNA isolated from 
patients in the same dataset as the 454-pyrosequenced VH3 gene analysis (Table 3.12).  
The 1.5 kb segment selected from the preliminary studies was too long for the 454-
pyrosequencing platform, which routinely gives results in the 300-500 bp range.  
Therefore, the 1.5 kb segment was divided further into 5 smaller fragments – A, B, C, D, 
and E – ranging in size from 252-411 bp.  These 5 fragments cover the entire 1.5 kb 
segment sequenced in the preliminary results.  Genomic DNA was isolated from fresh 
and stimulated PBMCs from both control subjects and HIV-1-infected patients.  All 5 
barcoded fragments were PCR-amplified, aligned to the reference sequence for each 
fragment using VhIGene, and analyzed for mutation frequency at both Days 0 and 4. 
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Table 3.11:  Preliminary Bcl6 Mutation Frequencies Post-Stimulation. 
Bcl6 Segment Mutation Frequency  Number of base pairs 
Bcl6-5   
Day 0 2.3 x 10
-3
 22425 
Day 4 2.5 x 10
-3
 22008 
Day 10 1.8 x 10
-3
 27800 
Bcl6-9   
Day 0 7.7 x 10
-4
 24823 
Day 4 6.1 x 10
-4
 19713 
Day 10 6.6 x 10
-4
 13568 
Bcl6-10   
Day 0 7.0 x 10
-5
 14271 
Day 4 0 7228 
Day 10 0 9343 
Bcl6-1.5   
Day 0 6.0 x 10
-4
 11684 
Day 4 1.2 x 10
-3
 11325 





Table 3.12:  Clinical Characteristics of Bcl6 Study Subjects. 
 Control HIV-1
+
 Viremic p value 
Number 8 8  







Sex (M:F) 8:0 8:0  
Ethnicity
b





 T cells/l – median  
(range) 
N/A 299  
(93-736) 
 






Fisher’s Exact test.  
b
Ethnicity:  C = Caucasian, B = Black, H = Hispanic, O = Other. 
 
We analyzed 244,507 sequences from control subjects (median = 23,612 
sequences per patient, range = 909 – 32,216) and 145,058 sequences from HIV-1-
infected patients (median = 23,415 sequences per patient, range = 3059 – 58, 315).  Bcl6 
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sequencing results were calculated in two ways.  To determine the overall mutation 
frequency, the total number of nucleotides sequenced in all 5 fragments was calculated 
per patient.  The mutation frequency was calculated by dividing the total number of 
mutations counted by VhIGene by the total number of nucleotides sequenced.  This “all 
sequences” mutation frequency was significantly lower in the HIV-1-infected patients 
compared with controls (Figure 3.21A) both at baseline (Day 0) and post-stimulation 
(Day 4).  The mutation frequency did not change significantly from baseline to post-
stimulation in either group, however. 
 As genomic DNA was extracted from PBMCs, including B cells, T cells, and 
monocytes, and not from sorted B cells, we also determined the mutation frequency in 
sequences that had ≥1 mutation in order to adjust for any differences in circulating non-B 
cell subsets between control and HIV-1-infected patients.  Such cells do not express AID 
and do not undergo SHM, and presumably have nonmutated Bcl6 sequences.  This 
mutation frequency was calculated by dividing the total number of mutations counted by 
VhIGene by the total number of nucleotides present in only the mutated sequences per 
patient (Figure 3.21B).  This “mutated sequences only” mutation frequency was also 
significantly lower in HIV-1-infected patients and reduced the amount of variance in both 
groups, both at baseline and post-stimulation.  The number of unmutated sequences in 
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Figure 3.21:  Mutation Frequencies in 454-Pyrosequenced Bcl6 Sequences are 
Reduced in HIV-1-Infected Patients.  Mutation frequency was calculated by dividing 
the number of mutations by the total number of nucleotides sequenced and expressed as a 
percent.  Mutation frequency was determined from the number of mutations and 
nucleotides totaled for all 5 fragments from either A) all sequences per control subject 
(black/dark gray circles) and HIV-1-infected patient (white/light gray triangles), or B) all 
sequences with ≥1 mutation identified.  Changes between Day 0 (Baseline) and Day 4 
(Post-Stimulation) were not significant in either controls or HIV-1-infected patients when 
calculating mutation frequency from all sequences or mutated sequences only. 
 
 Bcl6 mutation frequency correlates with VH3-IgG SHM frequency, but not with 
VH3-IgD SHM frequency.  The Bcl6 mutation frequencies found in control and HIV-1-
infected patients mirror those found in the VH3-IgG pyrosequenced transcripts, and 
indeed, these two variables are significantly and positively correlated in this patient 
cohort (Figure 3.22A).  Baseline Bcl6 mutation frequency, however, did not correlate 
with the CDR1/2 amino acid SHM frequency of either VH3-IgD (Figure 3.22B), VH3-
IgM (p=0.99, data not shown), or VH3-IgA (p=0.22, data not shown).  Similar to VH3-
IgG CDR amino acid SHM frequency, baseline Bcl6 mutation frequency did not correlate  
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Figure 3.22:  Baseline Bcl6 Mutation Frequency Correlates with VH3-IgG SHM 
Frequency and CD4
+
 T Cell Count.  Spearman correlations were calculated for 
Baseline Bcl6 mutation frequency from mutated sequences only and A) Baseline VH3-
IgG CDR1/2 amino acid SHM frequency or B) Baseline VH3-IgD CDR1/2 amino acid 
SHM frequency and for C) Baseline Bcl6 mutation frequency from all sequences and 
CD4
+
 T cell count. 
 
with HIV-1 plasma viral load (p=0.78, data not shown), however, baseline Bcl6 mutation 
frequency did positively correlate with CD4
+
 T cell counts (Figure 3.22C).  Therefore, 
though Bcl6 mutation frequency does not appear to be directly related to viral levels, it 
does appear to be affected by low CD4
+





 In summary, consistent with the reduced VH3-IgG CDR1/2 amino acid SHM 
frequency characterized in viremic HIV-1-infected patients in both the cloning and 454-
pyrosequenced datasets, mutation frequency is reduced in another non-Ig target of SHM, 
Bcl6.  Unfortunately, the lack of change in mutation frequency in Bcl6 sequences from 
baseline to post-stimulation does not provide any additional information on the potential 
mechanism(s) creating low Bcl6 and VH3-IgG mutation frequencies and, conversely, high 
VH3-IgD mutation frequencies. 
 
Discussion 
Disparate SHM frequencies occur during HIV-1-infection   
We demonstrate on a molecular level that the frequency of SHM is decreased 
among class-switched VH3-IgG B cells in patients with advanced viremic HIV-1-
infection.  We confirmed this phenotype in multiple datasets and by measuring mutation 
frequency in an additional non-Ig SHM target, Bcl6.  Unexpectedly, we also discovered a 
significantly increased SHM frequency in VH3-IgD transcripts in 4/8 patients with 
advanced HIV-1 infection.  This result correlated significantly and positively with patient 




 B cell 
subsets in HIV-1-infected patients, mutation frequencies were normal in another class-
switched isotype IgA, as well as a more “naïve-like” isotype, IgM, when compared with 
controls.   
SHM underlies the ability of B cells to make antibodies of high specificity, 
avidity and function.  We targeted the VH3 genes due to their frequency (half of all 
expressed VH genes) and because VH3 antibodies are prominent in defense against 
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invasive HIV-1-associated mucosally-acquired systemic pathogens [25-27] (e.g., S. 
pneumoniae, H. influenzae, and Cryptococcus neoformans) and in responses to associated 
preventive vaccines [25-28].  Thus, a decreased ability to support SHM in IgG-class-
switched effector B cells, and, by inference, an impaired capacity to generate high 
affinity antigen-specific antibodies that target systemic pathogens [29, 179, 180] may 
underlie, in part, the high rates of invasive and often fatal HIV-1-associated bacterial 
infections [25, 198-200].   
 
V(D)J recombination is normal during HIV-1 infection   
Three processes underlie the development of antibody diversity, specificity and 
function.  The first, establishment of the primary B cell repertoire by V(D)J 
recombination, appears to be intact in B cells of all four isotypes tested in HIV-1-infected 
patients.   In the VH3-IgG cloned dataset, we found slightly decreased expression of only 
4 of 22 VH3 genes in HIV-1-infected patients compared with controls, consistent with 




 repertoire in HIV-1-infected patients is intact [29].  
The results in the VH3-IgG cloned dataset were confirmed in the 454-pyrosequenced 
samples.  Few differences were seen between control subjects and HIV-1-infected 
patients in any of the isotypes in VH, D, or JH gene expression, although, just as in the 
VH3-IgG cloned dataset, expression of VH3-23 was significantly lower in the HIV-1-
infected patients. 
Of note, selected VH3 genes (VH3-15, -30, 30.5, -73, and the prominent VH3-23) 
have been reported to bind gp120 in a non-classical superantigen-like manner outside of 
the antigen-binding pocket [183].  In the absence of adequate T cell signals, such binding 
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and activation could deplete these cells [175].  In the VH3-IgG cloned dataset we 
identified only a decrement in VH3-23 expression, although low numbers of sequences of 
the other genes may have precluded finding such a difference.  Thus, we performed high-
throughput pyrosequencing in multiple isotypes to increase the number of sequences 
acquired per patient.  In the 454-pyrosequenced sequencing dataset only decreased 
expression of VH3-23 could be confirmed in the VH3-IgG sequences.  Additionally, the 
much greater number of sequences analyzed in this set rule out decreased expression of 
the other putative gp120-binding genes in HIV-1-infected patients.  We also did not 
confirm suggestions that such putative gp120-binding residues would be more frequently 
mutated during SHM in expressed VH3
+
 B cells, nor in VH3
+
 B cells thought to be targets 
of gp120-binding [183].  Therefore, our data do not support preferential deletion of 
specific VH3 family members by gp120 binding nor preferential mutation at putative 
gp120 binding sites in the VH3 B cell repertoire. 
 
Regulation of AID may be altered during HIV-1 infection   
The second and third processes, SHM and CSR, are both mediated by AID.  For 
SHM, the decreased frequencies of nucleotide and amino acid mutations in cloned VH3-
IgG sequences from viremic HIV-1-infected patients may imply decreased levels of AID 
activity.  This trend in SHM frequencies was confirmed in the 454-pyrosequenced VH3-
IgG dataset.  Surprisingly, in contrast, no differences in SHM frequencies were found in 
the other class-switched VH3-IgA 454-pyrosequenced samples from the same patients 
and VH3-IgD sequences displayed an increased SHM frequency, again, predominantly in 
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the CDR1/2 regions.  Therefore, potential differences in AID function may be specific to 
certain B cells or to certain lymphoid tissues but not a global humoral defect. 
That the increased mutation frequency was not also seen in the VH3-IgM subset of 






































 class-switched IgD cells [75].  An increased population of the class-
switched IgD cells, which have characteristically high SHM frequencies [73, 75] may 
imply altered CSR regulation during HIV-1 infection, as class-switch to IgD occurs 
through an alternative mechanism than class-switch to any other isotype [49], though this 
process still requires AID [76]. 
The lower frequencies of SHM in the VH3-IgG sequences of both datasets and 
higher frequency of SHM in the VH3-IgD sequences both had very similar patterns of 
mutation during HIV-1 viremia, suggesting a disparity in mutation quantity, but not 
quality.  Three studies have shown increased expression of AID, the enzyme that initiates 
SHM, among comparable patients with HIV-1 infection [92, 201, 202].  These findings 
would predict higher, as discovered in the VH3-IgD subset, but not lower, mutation 
frequencies.  However, it is the VH3-IgG data that are consistent with results addressing 




 memory B cells (which 
include IgG
+
 cells) that the mutation frequencies are lower in HIV-1-infected patients 
than those in controls [202].  That AID mRNA expression was higher among CD27
+
 B 
cells is compatible with a murine study showing that high, constitutive AID expression 
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was accompanied by decreased SHM, presumably due to negative regulation of AID 
activity [109].  In addition to positively influencing AID expression, HIV-1 can also have 
a negative effect on AID function.  The HIV-1 protein Vif can block the SHM-associated 
activity of AID in E. coli in vitro by direct protein-protein interactions [117], although 
any effects of Vif-AID interactions on CSR or Vif activity in vivo are unknown.  
Similarly, the HIV-1 protein Nef has been shown to be taken up by B cells in vivo and 
interrupt CSR in vitro by blocking B cell activation pathways [131].  However, effects of 
Nef on SHM have not been determined. 
 
DNA repair pathways involved in SHM may be impaired during HIV-1 infection   
AID initiates SHM by deaminating cytidines, creating a U:G lesion.  The lesion 
can either be replicated over, creating a dC to dT transition mutation, or repaired by DNA 
repair pathways utilizing low fidelity translesion (TLS) DNA polymerases, creating 
additional mutations at A and T [128, 129].  Among the cloned VH3-IgG CDR1/2 
nucleotide studies herein, the significant decrease in overall mutation frequency, 
particularly in the percent of A and G mutations, does not match any phenotypes in cells 
or mice observed with selectively-deleted DNA repair pathways [128, 129].  And no 
other significant patterns were found in the 454-pyrosequenced samples for any isotype 
that would specifically suggest a decrement in DNA repair pathway activity.  Thus, our 
data do not support disruption of lesion repair and no effects of HIV-1 virions or proteins 




Antibody selection and germinal center function may be decreased during HIV-1 
infection   
SHM occurs with antigen stimulation and selection, processes that occur in 
germinal centers.  Indeed, that germinal centers are smaller in patients such as ours with 
advanced HIV-1 infection, among whom the follicular dendritic cell (FDC) networks are 
attenuated and disrupted [21] may explain the decreased VH3-IgG SHM frequency.  Loss 
of rigorous selection of high-affinity serially-mutated B cells within a germinal center 
reaction may allow for the survival and escape of low affinity and less mutated B cells 
into the periphery.  Along with attenuated FDC networks, germinal center function may 
also be impaired by a decreased population of follicular helper T cells (TFH cells), which 
are an important source of HIV-1 replication [203].  TFH cells are thought to participate in 
positive B cell selection during the GC reaction by providing survival signals to 
somatically hypermutating B cells [204, 205].  TFH cells are also the primary producer of 
IL-21, which is required for GC maintenance [46, 205].  Indeed, IL-21 serum levels have 
been shown to be reduced during HIV-1-infection [206].  Therefore, deletion of TFH cells 
may interrupt selection and encourage the dissolution of the GC and escape of low 
affinity B cells prior to selection.   
 
Non-specific B cell activation during HIV-1 infection   
Alternatively, polyclonal bystander activation of non-specific and low affinity B 
cells by cytokines and growth factors (e.g. IFN-, TNF-, IL-4, IL-10, BAFF) and 
surface CD40L, which may be over-expressed in untreated HIV-1 infection [22, 141], 
may also affect the selection process.  Such non-specifically activated B cells may 
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compete with antigen-specific activated B cells for survival factors [141], avoid deletion 
in attenuated FDC networks and diminished TFH populations during the selection process 
and survive to migrate from GCs to the periphery.  However, the ratios of 
replacement/silent nucleotide mutations and of non-conservative/conservative amino acid 
mutations, both measures of positive antigen-driven selection were similar in both groups 
in both sequencing data sets. Though a single R/S ratio alone cannot predict the degree of 
positive selection in an Ig sequence [181, 207, 208] comparison of R/S ratio values 
between controls and HIV-1-infected patients supports the suggestion that the process, if 
not the rigor of selection may be relatively intact during HIV-1-infection.   
 
Limitations of the studies   
Potential limitations of the study include the unequal distribution of age, gender, 
and ethnicity among groups in the VH3-IgG cloning dataset.  HIV-1-infected patients 
with and without viremia, although older than controls, are distributed across the age 
range.  As reported in the literature, both VH diversity and mutation frequencies were 
similar in 1200 transcripts from tonsillar B cells from older adults (50-73 years) and 
children [209], and mutation frequencies were higher among older (65-92 years) than 
younger (19-30) adults [210].  If mutation frequencies are higher among older adults, as 
suggested by the literature, under the null hypothesis, our age distribution should have 
shown an opposite result to those reported herein or the decreased SHM frequency would 
be more difficult to detect.  Also, although gender may be a potential confounder of 
differences between groups in this dataset, mutation frequencies in CDR1/2 between 
male (25.8%; 95% C.I.=18.1-29.7%) and female (22.1%; 95% C.I.=15.2-31.0%) controls 
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were not different (p=0.61).  In addition, despite the age range being higher in the 
aviremic population compared with the viremic population and gender and ethnicity 
being similar, SHM frequency more closely resembled the control group rather than the 
viremic group, further supporting our conclusion that age, gender, and ethnic differences 
are not confounding our results in this data set.  As our results were confirmed among the 
VH3-IgG 454-pyrosequenced dataset where age, gender, and ethnicity were not different 
between groups, we conclude that none of these variables significantly confounded the 
results of the VH3-IgG cloned dataset.   
Finally, due to the number of cells acquired from each patient, we sequenced 







 class-switched, or IgG
+
 class-switched B cells) rather 
than sorted B cell populations.  Despite the presence of non-B cells, in the case of Bcl6 
sequencing, which could have potentially masked an effect on Bcl6 mutation frequency, 
we were able to discover the decrement in mutation frequency in the HIV-1-infected 
patients.  In addition, although multiple identical Ig sequences were isolated from 
patients, only one of these sequences was included from each patient in both datasets to 
prevent overrepresentation of a single clone or plasmablast.  Future experiments may 
facilitate the identification of specific B cell subtypes that may harbor the lower VH3-IgG 











AID mRNA EXPRESSION IS INCREASED IN FRESH PBMC FROM HIV-1-
INFECTED PATIENTS COMPARED WITH HEALTHY CONTROLS 
 
Introduction 
 Somatic hypermutation (SHM) is a process initiated by the B cell enzyme, 
activation-induced cytidine deaminase (AID) [80, 81].  AID is predominantly expressed 
during germinal center (GC) reactions, but can be also be induced by cytokines derived 
from activated peripheral cells (T cell-independent) and by some pathogens, including 
HIV-1 [80, 82, 87, 89, 90, 211].  Once translated, AID is targeted to the nucleus by the 
presence of a 5’ nuclear localization signal (NLS) in its sequence [100, 101].  The exact 
mechanism of targeting AID to VH regions remains undiscovered; however, stalling of 
RNA Pol II during transcription is thought to recruit Spt5 which in turn recruits AID 
[212, 213].  AID is phosphorylated by PKA, and perhaps PKC, which enables it to 
interact with RPA, a single stranded DNA (ssDNA) binding protein, believed to stabilize 
ssDNA generated during transcription [99, 100, 111, 214].  AID deaminates cytidine 
residues to uracils, creating single nucleotide point mutations that are mutagenically  
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repaired by down-stream DNA repair pathways, including Base Excision Repair and 
Mismatch Repair pathways which can extend the original U:G lesion to neighboring 
bases [120, 121]. 
 During a GC reaction, AID expression is induced by CD40-CD40L signaling 
between activated B cells and TFH cells [59, 82].  Signaling through CD40 leads to NF-
B activation and through interactions with other transcription factors including E47, 
Pax5, E2A, and STAT6, binds to the AID promoter and activates transcription [87].  
Transcription can also be activated in a TFH-independent CD40-independent manner 
involving B cell cytokines BAFF and APRIL in peripheral tissues outside of GCs [50, 58, 
59].  Like CD40 signaling, BAFF, bound to BAFF-R, or APRIL, bound to TACI 
(Transmembrane Activator and CAML (calcium-modulator and cyclophiling ligand) 
Interactor) receptors on B cells, activates NF-B and promotes transcription of AID [55, 
215].  Such activation is common in the lamina propria, where AID expression leads to 
IgM and IgA class switching.  BAFF is expressed by monocytes and DCs, whereas 
APRIL is expressed by locally activated epithelial cells, macrophages, monocytes, DCs 
and activated T cells [58, 59].  Additionally, a few pathogens can directly induce AID 
expression, through the Type IV secretion system in the case of H. pylori [90, 211], 
through binding of CD81 on the surface of B cells in the case of Hepatitis C [87, 89], 
through LMP-1 signaling in the case of Epstein-Barr Virus (EBV) [87, 89], or through 
binding of envelope proteins gp160 and gp120 in the case of HIV-1 [141, 216].  Indeed, 




 B cells 
during HIV-1 infection [202].  However, despite increased AID mRNA expression, the  
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outcomes of AID activity, CSR and SHM, are thought to be impaired during HIV-1 
infection [131, 148, 150, 151] (see previous chapter).  Impairment may be due to negative 
regulation by resident B cell factors, as has been shown in murine cells transgenically 
expressing AID [109], or may be due to direct viral interactions, such as has been shown 
with HIV-1 viral proteins Vif and Nef [117, 131]. 
 Direct binding of HIV-1 envelope glycoproteins to B cells is not the only means 
by which the virus can upregulate AID expression during HIV-1 infection.  HIV-1 can 
also activate B cells indirectly by being bound by complement fragments which bind 
CD21 on the cell surface [93], or by incorporating CD40L into its envelope during 
budding from infected T cells and binding CD40 on nearby B cells [139].  HIV-1 can 
also activate other cells which, in turn, produce cytokines and chemokines such as IFN-, 
TNF-, IL-6, IL-10, CD40L and BAFF and activate nearby B cells [19, 22].  Such non-
specific polyclonal B cell activation is thought to be a cause of 
hypergammaglobulinemia, an accumulation of high serum antibody titers, commonly 
described during HIV-1 infection [64].   
 Abnormalities in the B cell compartment are one of the first detrimental events on 
immune system function during HIV-1 infection [7, 139].  Though not directly infected 
by HIV-1 in vivo, both naïve and memory B cell populations are quickly depleted during 
acute HIV-1 infection [19, 60, 61, 64, 203], likely due to activation-induced death [217].  
These effects are not entirely corrected by successful antiretroviral therapy [22, 29, 65].  
Specific B cell subsets are more affected by chronic HIV-1 infection than others.  Naïve  
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B cells, for instance, in addition to depletion, express increased levels of activation 
markers [19, 22, 24, 64, 65, 218].  IgM memory B cells are disproportionately more 
depleted than their non-IgM expressing memory counterparts [65].  Plasma cell  
proportions are also frequently found to be decreased [22, 64, 65].  Several groups have 
also described increased levels of immature/transitional B cells [22, 24, 219].  Finally, B 
cell exhaustion has been described in memory B cell populations during chronic HIV-1 
infection [22, 24, 220].  
 The different B cell subsets are defined by surface marker expression (Table 4.1), 
developmental stage, and function.  Transitional/immature B cells are the first subset to 
enter the periphery after development in the bone marrow [31, 32, 55].  After positive 




 cells, which circulate through the blood 
and lymph waiting for antigen encounter [31, 40].  Another naïve B cell subset, the 
exclusively IgD-expressing B cells, BND anergic cells, are naïve autoreactive B cells 
thought to be precursors to high-affinity autoreactive B cells implicated in several 




 naïve B cells bind antigen and are activated 
by cognate T cell signals and cytokines (i.e. CD40L and IL-4), they can form GCs where 
they proliferate, undergo affinity maturation and CSR, and differentiate further into 
memory cells and plasmablasts [42, 43].  Plasmablasts will further mature into antibody-









cells can be short or long-lived and recirculate through the blood.  Upon re-exposure to 
antigen they rapidly differentiate into antibody-secreting plasma cells [51, 74, 75, 222].  
Not all B cell subsets mature through a GC reaction, however.  Marginal zone B cells  
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arise from activated naïve B cells [42, 43, 56] and circulate through the blood.  They have 
a much lower threshold of activation than GC-derived B cells, react to antigens derived 
from blood-borne bacteria, and once activated, can differentiate into antibody-secreting 
plasma cells [56].  
In response to antigen, B cell activation is normally driven by help from activated 
CD4
+
 T cell subsets [42, 47].  CD4
+
 T cell subsets are the primary targets of HIV-1 
infection and, just as B cell subsets are impaired by chronic HIV-1 infection, T cell 
subsets are even more devastated by direct infection, chronic antigen stimulation, as well 
as stimulation from abnormal proinflammatory cytokine levels [19].  Indeed, acute HIV-1 
 
Table 4.1:  Cell Marker Expression in CD19
+
























































































IgD + + + - -/low - + - 
IgM + + -/low +/- + + - - 
CD10 + - - +     
CD21 -/+ +   +    
CD27 - - - - + + + + 
CD40    +     
AID - -  +     
Bcl6 - -  +     
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infection leads to a massive depletion of CD4
+
 T cells, and especially CXCR5 expressing 
effector memory cells in the lamina propria of the gut [7, 19, 23, 223].  In response to 
vast amounts of antigen produced by the virus during replication, CD8
+
 T cell numbers 




 T cells become more highly activated [19, 23].   
Increased levels of T cell exhaustion, as evidenced by increased Programmed Cell Death 
(PD)-1 receptor expression, have also been discovered [224-226], further weakening the 
ability of the T cell compartment to combat the infection. 
Similar to B cells, T cell subsets are defined by surface marker expression (Table 
4.2), developmental stage, and function.  Naïve T cells encounter antigen, become 
activated, proliferate, and differentiate into effector T cells [227, 228].  These effector 
cells, including terminally differentiated effector cells (TD), are not long-lived, however, 
and >90% apoptose shortly after an infection recedes [227, 228].  The remaining T cells 
can differentiate into either central memory (CM) cells or effector memory (EM) cells.  
TEM cells are found in the spleen, blood, and non-lymphoid tissues and provide the first 
line of defense against re-exposure to a pathogen.  TEM cells have cytotoxic capability 
and produce IFN-, TNF-, IL-4, and IL-5 upon reactivation [227-230].  TCM cells 
circulate through the blood and secondary lymphoid tissues but can enter inflamed 
peripheral sites also.  TCM cells can proliferate extensively, produce IL-2, and constitute 
the second wave of action against a recurring pathogen [227-229].  An additional T cell 
subset important in GC B cell activation and implicated as an HIV-1 viral reservoir, is the 
follicular helper (TFH) subset [203].  These cells are found within the GC where they 
provide costimulatory molecules (CD40L) and survival signals (IL-4, IL-21) to GC B 
cells undergoing affinity maturation [43, 46]. 
137 
 
We confirm that although evidence demonstrates that CSR and SHM may be 
inhibited during HIV-1 infection [131] (see previous chapter), AID mRNA in circulating 
B cells of viremic [202], and now aviremic, HIV-1-infected patients is significantly  
higher compared with control subjects and highlight the association with both general T 
cell activation and TFH cell activation.  We extend these results to show that, despite 
increased AID mRNA expression at baseline, and the ability to upregulate markers of B 
cell activation in multiple B cell subsets to levels comparable to those in control subjects, 
the ability to induce new AID mRNA upon stimulation with surrogates for antigen (anti-
IgM) and both cognate (anti-CD40) and soluble T-cell (IL-4) stimuli may be significantly 
impaired.  These data suggest that the inability to appropriately respond to B cell stimuli 
may, in part, impair humoral responses in HIV-1-infected patients. 
 





































































CD3 + + + + + 
CD4 +/- + +/- +/- +/- 
CD8 +/- - +/- +/- +/- 
CD45RA +  - - + 
CD27 +  + - - 
CXCR5  +    




Baseline AID mRNA expression is higher, but AID mRNA induction post-stimulation is 
lower in HIV-1-infected patients in which VH3-IgG cloning and sequencing was 
performed 
Immunoglobulins.  As suggested in previous studies, HIV-1 can inhibit CSR, a 
process mediated by AID [131, 133, 169].  To test for the ability of AID to initiate class 
switch in our HIV-1-infected groups levels of total IgG, IgM, and IgA were measured in 
serum from 16 HIV-1-infected viremic patients, 17 aviremic patients, and 20 control 
subjects in serum that were included in the VH3-IgG cloned dataset in which VH3-IgG 
SHM frequency was measured in the last chapter (Table 4.3).  Levels of total IgG were 
significantly higher in the viremic patients compared with those in both the controls and 
aviremic patients, as were levels of IgM but not IgA.  Despite the differences in the 
quantity of immunoglobulins in serum, the median proportions of IgG (73.6%, 77.3%, 
76.9% p=0.30) and IgA (15.8%, 15.6%, 10.3%, p=0.26) compared with total serum Ig in 
controls, aviremic and viremic patients, respectively, were comparable.  IgM was lower 
only in the aviremic group compared to controls (4.8 vs. 10.6%, p=0.02).  Similarly, as 
measured in culture, IgG and IgA produced spontaneously by PBMCs over 7 days were 
significantly higher among viremic patients. Spontaneous IgG production in culture did 
not correlate with serum values in any group.  Thus, the distribution of antibodies in 
serum and secreted in culture ex vivo by isotype suggests that the ability to class-switch 
from IgM to IgG or IgA, a function of AID, appears to be generally intact in our HIV-1-
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Antiretroviral Therapy N/A 100% 0%  
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median
e (Range) 
    




















































Primary p value listed on table.  Secondary analyses – control vs. aviremic p<0.001, 
control vs. viremic p<0.01, aviremic vs. viremic p>0.05 (not significant).  
b
Secondary 
analyses – control vs. aviremic p=0.0008, control vs. viremic p=0.0003, aviremic vs. 
viremic p=1.0. 
c
Ethnicity:  C = Caucasian, B = Black, A = Asian, H = Hispanic, O = 
Other.  
d
Secondary analyses – control vs. aviremic p=0.12, control vs. viremic p=0.008, 
aviremic vs. viremic p=0.32.  
e
Control n=20, aviremic n=17, viremic n=16.  
f
Secondary 
analyses – control vs. aviremic p<0.05, control vs. viremic p<0.001, aviremic vs. viremic 
p<0.05.  
g
Secondary analyses – control vs. aviremic p>0.05 (not significant), control vs. 
viremic p<0.01, aviremic vs. viremic p<0.001.  
h
Immunoglobulins were measured in 
supernatants from 10
5
 unstimulated PBMC cultured in RPMI and 10% heat-inactivated 




 viremic: n=7. 
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AID mRNA expression is upregulated in HIV-1-infected patients at baseline but 
impaired post-stimulation.  In order to determine AID expression profiles in HIV-1-
infected patients, we measured expression of AID mRNA relative to -actin (Ct) in 
freshly-isolated PBMC and post-stimulation from 16 viremic, 17 aviremic patients, and 
21 control subjects from the VH3-IgG cloned dataset.  Baseline AID mRNA was 
significantly higher in both HIV-1-infected patient groups (Day 0; Figure 4.1a).  The 
presence of HIV-1 viremia did not affect levels of AID mRNA, as levels between 
aviremic and viremic patients were comparable. 
After four days of stimulation with surrogates of B cell receptor engagement 
(anti-IgM) and cognate (anti-CD40) and soluble (IL-4) T cell stimulation, AID mRNA 
expression (Ct) increased significantly in all groups (Day 4; Figure 4.1a).  Despite the 
lowest baseline values, AID mRNA was highest in controls post-stimulation.  Thus, the 
increase in expression from baseline to Day 4 post-stimulation (Ct) was also greater in 
the control group than in either HIV-1-infected group (Figure 4.1b), and especially in the 
viremic group where the magnitude of AID induction was significantly lower than in 
control subjects.  Neither expression of AID mRNA at baseline nor post-stimulation 
correlated significantly with VH3-IgG SHM frequency, CD4
+
 T cell counts, plasma HIV-
1 RNA, or total levels and proportions of IgG, IgA, or IgM (Table 4.3) (data not shown).  
These baseline levels of AID mRNA were also unrelated to those of proposed soluble 
biomarkers in plasma of systemic exposure to mucosal bacterial antigens (levels of LPS, 
IgM specific for LPS (EndoCab IgM)) and systemic inflammation (soluble CD14) [22, 





Figure 4.1:  AID mRNA Expression in PBMCs.  A)  AID mRNA expression was 
measured by qRT-PCR in freshly isolated PBMCs from control subjects (black circles, 
n=21), aviremic patients (gray squares, n=17), and viremic patients (white triangles, 
n=16) at and after 4 days of culture with B cell stimulants (anti-CD40, IL-4, anti-IgM).  
AID expression levels were normalized to -actin expression.  The primary p value for 
baseline expression between all groups is 0.001.  The primary p value for Day 4 
expression is 0.04.  B) The change in AID mRNA expression, relative to -actin 
expression, was calculated by subtracting baseline expression levels from day 4 post-
stimulation levels.  The primary p value for change in expression level is 0.03. 
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Individual stimulants have varying effects on AID mRNA expression.  Next, we 
determined whether our VH3-IgG cloned dataset subjects with and without HIV-1 
infection showed a differential AID mRNA response to individual B cell stimuli alone or 
in combination (Figure 4.2), each of which engages different receptors and activates 
distinct pathways.  PBMCs incubated in media alone for four days showed a significant 
rise in AID mRNA in all groups compared with baseline values (Figure 4.2).  Similarly, 




) increased when incubated in media 
alone for 4 days among controls (p=0.006 and p=0.03, respectively), but not among HIV-
1-infected patients (data not shown).  Using values on day 4 without stimulation (Day 4 
no stims) as the comparator, all stimuli, alone or in combination, elicited a significant rise 
in AID mRNA in all groups, with the exception of anti-CD40 alone in both HIV-1-
infected groups (Figure 4.2, panel 1). 
 Although expression increased within each group, we identified differences in the 
magnitude of responses between groups (Figure 4.2, panels 2 and 3).  Averaged over all 
groups, the relative effect on AID expression of the single stimuli IL-4, anti-IgM, and 
anti-CD40 were mean log Ct (standard deviation) 0.94 (0.71, 1.18), 0.69 (0.41, 0.97), 
and -0.31 (-0.60, -0.12), p=0.04, respectively, compared with Day 4 no stimulation.  
Thus, the overall pattern of change in the relative expression of AID in stimulated PBMC 
was IL-4 ≥ anti-IgM > anti-CD40; this pattern was consistent in all groups.   
However, although similar in both HIV-1-infected groups, the change in AID 
mRNA responses from Day 4 no stimulation to Day 4 with either IL-4 and anti-IgM 
stimulation were lower in viremic patients compared with controls, albeit with low 




Figure 4.2:  AID mRNA Expression Induced by B Cell Stimulants.  AID mRNA expression was determined by qRT-PCR 
in PBMC from control subjects (C, black circles, n=9-21), aviremic (A, gray squares, n=4-18), and viremic (V, white triangles, 
n=3-16) patients with HIV-1 infection.  Numbers tested per condition varied by cell availability.  AID mRNA expression was 
measured at baseline, after 4 days of culture in media alone, and after 4 days of culture with B cell stimulants alone or in 
combination.  AID expression levels were normalized to -actin expression.  The final model, determined by likelihood ratio 
tests, demonstrated group effects (IL-4, anti-CD40, and anti-IgM, p<0.0001), but not on the interactions terms (estimates with 
>1 stimulus (p=0.50)).  *0.05 > p > 0.01, **0.01 > p > 0.001, ***p < 0.001, ns = not significant.  The ‘X’ in the baseline 







4.2, panel 2).  Combinations of two or more stimuli elicited higher AID mRNA 
expression in all three groups compared with single stimuli.  Finally, the combination of 
all three stimuli did not result in a significant increase in either HIV-1-infected group 
when compared with IL-4 + anti-CD40 or anti-IgM + anti-CD40 combinations.  
Therefore, additions of either anti-IgM or IL-4, respectively, with the other two stimuli in 
the HIV-1-infected groups did not significantly increase AID mRNA expression.  Taken 
together, these data suggest that control subjects could generate increased amounts of 
AID mRNA with each additional stimulus, whereas B cells from HIV-1-infected patients 
may lack this additional reserve to respond. 
HIV-1 infection does not affect AID splicing.  Alternative splicing of AID 
transcripts may yield five different isoforms of AID in healthy adults and patients with 
cancer [83, 112-114] (Figure 1.8).  Whether the isoforms have functional implications 
remains controversial [115, 116].  To determine AID isoform expression levels during 
HIV-1 infection, we amplified AID cDNA by PCR using primers specific for exons 
shared by all isoforms (exons 2 and 5) (Table 2.1).  We cloned and amplified each of the 
5 isoforms, verified the sequence by Sanger sequencing and used the sizes of the 
isoforms as positive controls to assign the presence or absence of each isoform in patient 
samples.  We used total mRNA isolated from baseline and stimulated PBMCs to generate 
cDNA from 9 control subjects, and 12 viremic patients taken from both the VH3-IgG 
cloned sequence and the 454-pyrosequenced datasets (Figure 4.3, Table 4.4).  All viremic 
patients and 8/9 control subjects showed expression of 3 or more isoforms at baseline 
(Table 4.5).  Expression increased visibly after stimulation with anti-IgM, anti-CD40 and 
IL-4, primarily of the full-length isoforms; only 2/12 viremic patients and 2/9 control 
145 
 
subjects expressed 3 or more isoforms.  Thus, HIV-1-infected patients and controls 
subjects share AID isoform expression profiles in circulating cells, and the full length 
isoform predominates in each group after stimulation. 
 
Baseline B cell and T cell activation is higher in HIV-1-infected patients in whom VH3-
IgG cloning and sequencing was performed, but activation levels are comparable to 
controls post-stimulation 
B cell activation does not correlate with AID mRNA expression in HIV-1 
infection.  Because AID mRNA expression is upregulated with B cell activation, we 
determined whether AID expression levels correlated with markers of B cell activation in 
subjects from the VH3-IgG cloned dataset (Table 4.3).  In fresh PBMC, three surface 
markers of activation (cells expressing CD86 and those lacking CD21 and CD23 
expression) were increased in CD19
+
 B cells from viremic patients compared with those 
from controls (Figure 4.4a); results for aviremic patients were intermediate.  These B cell 
markers in viremic patients correlated directly with CD4
+













 p<0.04).  The proportions 
expressing the memory marker, CD27, and CD69, an early activation marker, were 
similar. 
After stimulation with anti-IgM, anti-CD40, and IL-4 for four days, the 









 (p<0.05), whereas the proportion of CD23
- 
B cells did 
not change significantly in any group (p>0.07) (Figure 4.4b).  The magnitude of change 
in the surface activation molecules was similar.  Only the change in CD27
+
 memory cell 
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Number 9 12  







Gender (M:F) 9:0 12:0  
Ethnicity
a
















Ethnicity:  C = Caucasian, B = Black, H = Hispanic, O = Other.  
b




Figure 4.3:  AID Isoforms Expression.  Representative agarose gel of a control subject 
and an HIV-1-infected viremic patient at baseline and at day 4 post-stimulation.  Positive 
controls (AIDins3, FL, E4a, E4, and E3-E4) were cloned and PCR-amplified to 
compare amplicon sizes. 
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 Baseline Day 4* Baseline Day 4 
AIDFL 8/9 (89%) 8/9 (89%) 
Intensity increases 
12/12 (100%) 12/12 (100%) 
Intensity increases 
AID-ins3 8/9 (89%) 6/9 (67%) 
No change in intensity 
9/12 (75%) 9/12 (75%) 
No change in intensity 
AID-E4a 6/9 (67%) 2/9 (22%) 
No change in intensity 
11/12 (92%) 1/12 (8%) 
No change in intensity 
AID-E4 7/9 (78%) 2/9 (22%) 
No change in intensity 
12/12 (100%) 3/12 (25%) 
No change in intensity 
AID-E3-E4 4/9 (44%) 1/9 (11%) 
No change in intensity 
10/12 (83%) 0/12 
*Day 4 indicates AID isoforms expression after four days of stimulation with anti-IgM, 
anti-CD40, and IL-4. 
 
expression post-stimulation was significantly lower in both HIV-1-infected groups 
compared with controls, suggesting a potential HIV-1-associated limitation in generating 
new memory cells.  The percent of CD19
+
 B cells did not increase in culture over time, 
independent of group or stimulus (baseline primary p=0.48, post-stimulation primary p= 
p=0.11).  Thus, B cells in PBMC from HIV-1-infected patients can upregulate surface 
markers of activation with sufficient stimulus, but may not be able to differentiate 
appropriately into CD27
+
 memory cells.  
Despite increases in both AID mRNA and B cell activation marker expression 
following stimulation, we identified no direct correlations between any of the B cell 
activation markers or CD27 with AID expression at baseline, or changes in marker 
expression post-stimulation with upregulation of AID post-stimulation in vitro (data not 
shown).  However, B cell activation did correlate with CD4
+











Figure 4.4:  Activation Phenotype of B Cells and T Cells at Baseline and Post-Stimulation.  B cell and T cell activation 
markers were measured in control subjects (dark gray bars, n=22), aviremic patients (light gray bars, n=16), and viremic 
patients (white bars, n=17).  A)  We measured markers of memory (CD27
+











 B cells by flow cytometry at baseline.  B)  The change in B cell marker expression levels from baseline to 











T cells at baseline.  D)  Change in T cell activation marker expression from 












 T cell subsets showed more activation at baseline in the viremic, 
but not aviremic, patients compared with controls based on co-expression of CD38 and 
HLA-DR (Figure 4.4c) in subjects from the VH3-IgG cloned dataset.  Because AID 
expression in germinal center B cells is largely dependent on T cell help [202], we 
correlated T cell activation with AID expression.  Indeed, baseline AID expression 




 T cells (Figures 4.5a and 
4.5b).  Of note, the B cell-targeted stimuli did not promote increased T cell activation in 
any group (Figure 4.4d).  Thus, the increased activation of B cells and of AID expression 
in vitro was due to the crosslinking of the BCR and the added surrogate cognate and 
soluble T cell stimulation and not likely related to the effects of these stimuli on the T 
cells themselves.  Therefore, the limitations in AID responses to stimulation in vitro 
among the HIV-1-infected patients was not due to a failure of their own T cells to elicit 
these responses but, rather, due to B cell defects. 
 
Baseline AID mRNA expression is higher in HIV-1-infected patients in which 454-
pyrosequencing of VH3 genes was performed 
Baseline AID mRNA expression is higher during HIV-1 infection.  We also 
measured AID mRNA expression at baseline and post-stimulation in subjects from the 
454-pyrosequenced dataset (Table 4.6).  As in the previous VH3-IgG cloned dataset, 
baseline AID mRNA levels, relative to GAPDH expression, were significantly higher in 
the HIV-1-infected group compared with controls in the 454-pyrosequenced dataset 




Figure 4.5:  Relationship Between T Cell Activation with Baseline AID mRNA 
Expression in PBMC.  Baseline AID mRNA expression (log10 Ct) values increased 
with baseline CD4
+
 T cell (A) or CD8
+





among all patient groups by linear regression (control n=9, aviremic n=6, viremic n=7).  






 T cell) we estimate a 1.19 







 T cell we estimate a 0.74 (0.11, 1.36) increase in baseline AID 
mRNA expression. 
 
1-infected patients reached levels comparable to those in control subjects after 
stimulation for four days with anti-IgM, anti-CD40, and IL-4.  Similarly, the magnitude 
of induction was also comparable between the groups in this data set (Figure 4.6b), 
though this differs from the results in the VH3-IgG cloned dataset.  These different results 
could be due, in part, to the different control groups used in the comparisons.  In the VH3-
IgG cloned dataset, control patients are significantly younger (Table 4.3), whereas the 
control group in the 454-pyrosequenced dataset more closely matches the HIV-1-infected 
patient group (Table 4.6).  However, we did not see any significant relationship between 














=0.001, p=0.83, data not shown) to suggest that age may have been a 
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confounding factor.  Normal levels of AID mRNA expression post-stimulation in the 
HIV-1-infected group could also be due to sampling error, as even some of the patients in 
the VH3-IgG cloned dataset had AID mRNA levels equivalent with control subjects, 
though they were a minority (Figures 4.1A and B).   
 Baseline AID mRNA expression positively correlates with VH3-IgD SHM 
frequency.  As we saw in the VH3-IgG cloned dataset, baseline AID mRNA expression in 
the 454-pyrosequenced dataset did not correlate with CD4
+
 T cell count (r=0.156, 
p=0.52), HIV-1 plasma RNA (r=0.040, p=0.87), or VH3-IgG SHM frequency (Figure 
4.7D).  However, baseline AID mRNA expression did positively correlate with VH3-IgD 
SHM frequency (Figure 4.7A), suggesting, at least in this B cell subset, that SHM 
frequency is related to AID levels and that increased AID expression can lead to 
increased SHM frequencies in vivo.  Baseline AID mRNA levels did not correlate 
significantly with VH3-IgM SHM frequency (Figure 4.7B) or VH3-IgA SHM frequency 
(Figure 4.7C). 
 
Table 4.6:  Clinical Characteristics of Study Subjects 
 Control HIV-1+ p value 
Number 15 26  


























Antiretroviral Therapy N/A 1/26 (3.8%)  
a
Fisher’s Exact test.  
b
Ethnicity:  C = Caucasian, B = Black, H = Hispanic, O = Other. 
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Baseline and Stimulated AID Expression




























































Figure 4.6:   AID mRNA Expression in 454-Pyrosequenced PBMCs.  A)  AID mRNA 
expression was measured by qRT-PCR in freshly isolated PBMCs from control subjects 
(black circles, n=14) and HIV-1-infected (HIV-1+) patients (white triangles, n=19) at and 
after 4 days of culture with B cell stimulants (anti-CD40, IL-4, anti-IgM).  AID 
expression levels were normalized to GAPDHexpression.  The difference between Day 4 
Relative AID Expression levels and baseline (Day 0) Relative AID Expression levels 
were significant in both Controls and HIV-1-infected groups (p<0.0001 for both).  B) The 
change in AID mRNA expression, relative to GAPDH expression, was calculated by 
subtracting baseline expression levels from day 4 post-stimulation levels. 
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Figure 4.7:  Baseline AID mRNA Expression Positively Correlates with IgD CDR1/2 
Amino Acid SHM Frequency.  Spearman correlations were calculated for baseline AID 
mRNA expression and A) IgD CDR amino acid SHM frequency, B) IgM CDR amino 
acid SHM frequency, C) IgA CDR amino acid SHM frequency, and D) IgG CDR amino 
acid SHM frequency. 
 
B and T cell subsets are more activated in HIV-1-infected patients in whom 454-
pyrosequencing performed 
 B cell subsets are more activated during HIV-1 infection.  In the 454-
pyrosequenced dataset, we did a more comprehensive examination of both B and T cell 
subset proportions and activation levels, rather than just activation levels as in the VH3-





























































) at baseline and after four days of stimulation with 
anti-IgM, anti-CD40, and IL-4.  Activation was determined by expression of CD21, 
CD40 and CD86. 
 Contrary to previous reports [22, 24, 219], we did not find any significant 
difference in the proportion of transitional cells in our HIV-1-infected group at baseline 
(Figure 4.8A).  CD21 expression, which is downregulated with activation, was 
significantly higher in the control group (p=0.01), though CD86 and CD40 levels, which 
increase with activation, were not different.  The proportion of naïve and GC B cells was 
also not different between groups, though activation of naïve cells was significantly 




, p<0.0001), which is 
consistent with previous studies [19, 22, 24, 64, 65, 218] and thought to be caused by 
non-specific bystander B cell activation by cytokines and surface markers on activated T 
cells and activated antigen presenting cells [64, 137].  In contrast, the proportion of BND 
anergic IgD
+
 B cells was significantly lower in the HIV-1-infected group, though 




, p=0.003). Few significant differences 
were found post-stimulation (Figure 4.8C).  The proportions of both naïve and BND 
anergic cells were significantly lower in the HIV-1-infected group, however, there were 
no differences in activation marker expression in either of these subsets.  Marker 
expression was also comparable in transitional cells.  Only CD21 expression was 





In the memory cell subsets, both MZ and IgD C-S B cell proportions were 
comparable between groups at baseline (Figure 4.8B) and had similarly lower CD21 
expression in the HIV-1-infected group (MZ, p<0.0001; IgD C-S, p=0.001).  Likewise, 
the proportion of non-IgM, non-IgD class-switched memory cells (Switch Memory) was 





, p=0.05).  In contrast, the IgM C-S memory cell proportion 





, p=0.002).  None of the memory subset proportions were different between 
groups post-stimulation (Figure 4.8D).  Only CD40 expression on Switch Memory B 
cells was significantly different between groups (p=0.02) and was higher in the control 
group. 
 Only one difference was found in the magnitude of change from baseline to post-
stimulation between the two groups in all subsets (Figure 4.8E and F).  The proportion of 
IgM C-S cells decreased in the HIV-1-infected group, resulting in normal proportions 
post-stimulation compared with control subjects (Figure 4.8D).  Within each group, the 
proportions of IgD C-S and Switch Memory significantly increased from baseline to post-





, p<0.0004).  In contrast, proportions of transitional, naïve, and 
marginal zone cells decreased (p<0.04).  Despite the decrease in proportion, however, 





, p<0.0002).  The proportions of BND anergic cells did not change 
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Figure 4.8:  B Cell Subsets in 454-Pyrosequenced PBMCs.  CD19
+
 B cells were divided into subsets based on marker 






















































).  Immature and 
mature subset proportions were measured in control subjects (gray bars, n=13) and HIV-1-infected patients (HIV-1+, white 
bars, n=19) at baseline (A) and post-stimulation (C).  Memory subset proportions were measured at baseline (B) and post-
stimulation (D).  Changes in the proportions of immature and mature subsets (E) or memory subsets (F) with stimulation were 
calculated by subtracting baseline proportions from post-stimulated proportions.  Median, interquartile range, and minimum 







significantly in the HIV-1-infected group (p=0.009), increases in activation only occurred 




, p=0.001), although CD21 levels were 
significantly reduced in the HIV-1-infected group also (p=0.003). 
 In summary, B cell subset proportions were mostly comparable at baseline 
between groups, though activation levels in naïve, GC, IgM C-S, and Switch Memory B 
cells were significantly higher in the HIV-1-infected group.  After stimulation, however, 
proportions of subsets were comparable with the exception of naïve and BND anergic 
cells, as were activation levels, suggesting that B cells of all subsets were capable of 
achieving activation levels similar to control subjects upon stimulation.  Interestingly, the 
only exception to increased activation was in GC B cells from HIV-1-infected patients.  
While the proportion of these cells was significantly increased during stimulation, 
activation was not.  Of note, however, activation levels measured post-stimulation were 
not different from control subjects, possibly suggesting that GC activation had already 
peaked at baseline in HIV-1-infected patients. 
AID mRNA expression positively correlates with BND, GC, and IgM C-S B cell 
subsets.  To determine whether high baseline AID mRNA expression in HIV-1-infected 
patients was related to high levels of B cell activation, we correlated baseline and post-
stimulation AID mRNA levels with proportions of total B cell subsets and activated B 
cell subsets (Figure 4.9).  Baseline AID expression was negatively correlated with total 
BND Anergic cell proportions (Figure 4.9A), a cell population characterized as having 
unmutated germline VH sequences, as well as naïve BND Anergic cells (CD21
+
, p=0.004), 
data not shown.  Baseline AID was positively correlated with GC B cells (Figure 4.9B), 






) GC B cells 
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(p>0.37).  Additionally, baseline AID expression also positively correlated with IgM C-S 
B cells, both total proportions (Figure 4.9C), and CD21
+
 proportions (p=0.03), therefore 
suggesting that elevated levels of AID mRNA in HIV-1-infected patients may be driving 
the increased proportions of IgM C-S B cells found in our HIV-1-infected patients.  Post-
stimulation AID mRNA levels correlated only with post-stimulation total IgM C-S B cell 
proportions (Figure 4.9D) and, as with baseline results, CD21
+
 IgM C-S B cell 
proportions (p=0.04). 
 T cell subsets are more activated during HIV-1 infection.  We next measured 




 T cell subsets in patients from the 454-

























cells, as well as CD4
+






) T cells.  Activation 
was determined by expression of HLA-DR and CD38.   
Total proportions of CD4
+
 T cells were significantly decreased in the HIV-1-
infected group with a concurrent increase in CD8
+
 T cells (Figure 4.10A), as commonly 




 T cells were also more 
activated in HIV-1-infected patients compared with control subjects (Figures 4.10B and 
C).  PD-1 levels, a marker commonly used to identify T cell exhaustion in non-TFH T 
cells, were significantly higher in CD4
+
 T cells from the HIV-1-infected group, as has 
also been previously seen during chronic HIV-1 infection (Figure 4.10B) [224-226].  
Surprisingly, PD-1 levels were not significantly elevated in CD8
+
 T cells in HIV-1-
infected patients (Figure 4.10C).  In general, all other CD4
+
 T cell subsets were similar, 
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Figure 4.9:  Baseline and Stimulated AID mRNA Expression Correlate with BND, 
GC, and IgM C-S B Cell Subsets.  Spearman correlations were calculated for baseline 
AID mRNA expression and baseline proportions of A) BND Anergic B cells, B) germinal 
center (GC) B cells, or C) class-switched IgM (IgM C-S) B cells, and D) post-stimulation 
AID mRNA expression and proportions of IgM C-S B cells. 
 
with only a slight, but significant increase in effector memory cells (Figure 4.10B).  All 
subsets, however, were more activated in the HIV-1-infected group (p<0.03), a reflection 
of constant antigen stimulation during chronic HIV-1 infection.  Similar to CD4
+
 T cells, 
the CD8
+
 effector memory population was also significantly higher in the HIV-1-infected 
patients compared with controls (Figure 4.10C).  The proportion of naïve cells was 
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decreased.  All CD8
+
 T cell subsets were significantly more activated in the HIV-1-
infected group as well (p<0.0001).  
T cell subsets and activation correlate with AID, VH3-IgD SHM frequency, and B 
cell subsets.   We have previously shown in the VH3-IgG cloned dataset that AID mRNA 




 T cell activation, though not B cell 
activation.  Thus, we tried to correlate AID expression with T cell subset proportions and 
activation levels in the 454-pyrosequenced dataset as well (Figure 4.11).  While baseline 
AID mRNA expression did positively correlate with activation in CD8
+
 T cells (Figure 
4.11A), as before, surprisingly, they did not correlate with CD4
+
 T cell activation 
(p=0.18).  Interestingly, baseline AID mRNA expression also correlated with activated 
proportions of TFH cells (Figure 4.11B), though not total proportions of TFH cells.  As 
these T cells are the predominant T cell subset in GCs this result is not surprising and 
potentially provides another mechanism of AID mRNA upregulation during HIV-1 
infection. 
 Baseline TFH proportions were also found to correlate with both VH3-IgA (Figure 
4.12A) and VH3-IgG (Figure 4.12B) SHM frequencies, despite the frequencies in VH3-
IgG sequences being lower.  No correlations were seen between TFH proportions and 
VH3-IgD or VH3-IgM sequence SHM frequencies.  It is interesting to note that TFH 
proportions only correlate with the isotypes commonly associated with T cell-dependent 
GCs and not with isotypes commonly believed to be of a more naïve phenotype or to 
class-switch outside of GCs.  Surprisingly, however, neither VH3-IgA (p=0.46) nor VH3-
IgG (p=1.00) SHM frequencies correlated with GC B cell proportions, nor to AID mRNA 
expression (Figures 4.7C and D). 
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Figure 4.10:  T Cell Subsets in 454-Pyrosequenced PBMCs.  CD3
+
 T cells were divided into subsets based on marker 








 T cells was calculated in control 
subjects (black circles, n=13) and HIV-1-infected patients (HIV-1
+
, white triangles, n=19).  Subset proportions were also 
measured in control subjects (gray bars) and HIV-1-infected patients (HIV-1
+
, white bars) in CD4
+
 T cells (B) and CD8
+
 T 




























) T cells.  Median, interquartile range, and minimum and 
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Figure 4.11:  CD8
+ 
T Cell Activation and TFH Activation Correlate with Baseline 
AID mRNA Expression.  Spearman correlations were calculated for baseline AID 
mRNA expression and A) baseline activated CD8
+
 T cells and B) baseline activated 
follicular helper (TFH) T cells. 
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Figure 4.12:  TFH Cell Proportions Correlate with VH3-IgA and VH3-IgG SHM 
Frequencies.  Spearman correlations were calculated for baseline proportions of 
follicular helper (TFH) T cells and A) VH3-IgA CDR amino acid SHM frequency and B) 




 Finally, we correlated activated T cells and T cell subsets with B cell subsets.  We 
found T cell activation, both CD4
+
 (Figure 4.13A) and CD8
+
 (Figure 4.13B) to be 
negatively correlated with baseline BND Anergic B cells, possibly suggesting a role in T 
cell-mediated maturation or deletion of this B cell subset.  Similarly, a significant 
negative correlation was also found between CD4
+
 (Figure 4.13C) and CD8
+
 (Figure 
4.13D) T cell activation and MZ B cell proportions.  Activated TFH T cells, which 
provide survival signals to GC B cells, were positively correlated with activated GC B 
cells (Figure 4.13E), suggesting that activated TFH cells may be providing sufficient 
stimulation to activate GC B cells.  Interestingly, however, activated TFH cells did not 
correlate with total GC B cell proportions, possibly hinting that while activated TFH cells 
can activate GC B cells, they may not be able to prevent their apoptosis.   
In summary, baseline AID mRNA expression was found to be higher in HIV-1-
infected patients in both theVH3-IgG cloned dataset, as well as the 454-pyrosequenced 
dataset.  AID mRNA expression correlated positively with the increased VH3-IgD SHM 
frequency we described in the last chapter, but not with SHM frequency in any other 
isotypes.  Though AID mRNA expression increased significantly with stimulation in both 
groups in both datasets, the magnitude of the change was significantly lower in the HIV-
1-infected group compared with control subjects in only the VH3-IgG cloned dataset, 
suggesting that AID mRNA induction may be impaired during HIV-1 infection and this 
impairment may affect multiple activation pathways.  The expression of the 5 different 
isoforms of AID, which could have functional implications on AID dimers formed in 
vivo, was not different between groups.  Baseline B cell activation levels were higher in 
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Figure 4.13:  Activated T Cell Subsets Correlate with Activated B Cell Subsets.  
Spearman correlations were calculated for baseline proportions of BND Anergic B cells 
and A) CD4
+
 T cell activation and B) CD8
+
 T cell activation; baseline proportions of 
marginal zone (MZ) B cells and C) CD4
+
 T cell activation and D) CD8
+
 T cell activation 
or; E) baseline proportions of activated TFH cells and activated germinal center (GC) B 
cells. 




HIV-1-infected patients in both datasets, and are reflective of the high baseline AID 
mRNA levels, though no significant correlations were found between them.  Unlike AID 
expression, however, we did not detect any significant difference in B cell activation 
post-stimulation, suggesting that B cells are capable of upregulating activation markers to 
levels matching controls upon stimulation.  Baseline AID mRNA levels did correlate 





 T cells in the VH3-IgG cloned dataset, and in CD8
+
 T cells and activated TFH T 
cells in the 454-pyrosequenced dataset.  Taken together, these data indicate that increased 
AID expression may be driven, in part, by high levels of T cell activation during HIV-1 
infection.  However, while increased AID expression may lead to increased SHM 
frequencies in B cell subsets which may not participate in T cell-dependent GC reactions 
(i.e. IgD
+
 B cells), increased AID expression may not translate to increased SHM activity 
within a GC environment (i.e. low VH3-IgG SHM frequency). 
 
Discussion 
High baseline AID mRNA expression is likely driven by T cell activation   
HIV-1 infection results in perturbations of B cell populations and function, 
particularly high levels of B cell activation and hypergammaglobulinemia [22, 163, 233].  
Despite this activity, humoral responses to both recall and neoantigens are diminished in 
HIV-1-infected patients [140, 142, 164, 198].  Effective antibody responses, including 
affinity maturation through SHM and isotype class switching are dependent on the 
activity of a B cell-specific enzyme, AID [80, 81].  In both the viremic and aviremic  
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HIV-1-infected cohorts from both the VH3-IgG cloned and 454-pyrosequenced datasets, 
we found high baseline AID mRNA expression. AID is upregulated in response to a 
variety of stimuli, such as T cell engagement (CD40 signaling) [82], TLR signaling (e.g., 
TLR-9, [87]), hormone signaling [88], and exposure to many viruses and bacteria [87, 
89-91], including HIV-1 [92].  During HIV-1 infection, activated CD4
+
 T-cells, as we 
also observed in our HIV-1-infected cohorts, and circulating levels of antigens and 
cytokines likely lead to the high levels of bystander B cell activation reported in multiple 
studies in HIV-1-infected patients [22, 64, 93, 139, 141, 231, 232).  The high baseline 
levels of AID expression seen in our datasets are consistent with these results, though 
none of the serum or plasma biomarkers that we measured, including EndoCab IgM, 
LPS, or sCD14 were elevated in the HIV-1-infected viremic group (VH3-IgG cloned 
dataset patients) nor correlated with either B cell activation or AID expression.  
Similarly, neither B cell activation nor AID expression were correlated with HIV-1 viral 
RNA levels in either dataset.  Thus, these markers of systemic antigen and cytokine 
exposure are not likely directly causing the high frequencies of B cell activation and high 
baseline AID expression we observed.  Indeed, unlike in mice, human B cells do not 
express receptors for LPS and are not readily activated by LPS.  Activated T cell 
frequencies, including the GC T cell subset TFH cells, were higher in our HIV-1-infected 
patients, however, and did correlate with AID expression, suggesting that T cell 
activation, and likely T cell signaling, contributed to the high B cell activation levels and 




Induction of AID mRNA expression and B cell differentiation may be impaired during 
HIV-1 infection   
Within the viremic HIV-1-infected patients in the VH3-IgG cloned dataset, we 
also found decreased AID mRNA expression post-stimulation in response to B cell-
specific stimuli compared with those in seronegative control subjects.  In contrast, B cell 
activation markers in the same dataset, also high at baseline, reached equivalent levels in 
HIV-1-infected patients compared with controls.  Differentiation into CD27-expressing 
memory B cells in response to stimulation, however, was diminished in this set of HIV-1-
infected patients.  Taken together, these data suggest that in these HIV-1-infected 
patients, B cells can be activated in response to appropriate stimulation compared with 
control patients, but may be limited in their ability to advance further in maturation and 
differentiation.   
The significant but decreased capacity to upregulate AID expression seems 
contrary to the increased levels of B cell activation marker expression with stimulation in 
cells from viremic HIV-1-infected patients in the VH3-IgG cloned dataset.  The 
stimulants used in our study were selected to mimic activation provided by antigen 
engagement of the BCR by anti-IgM and by cognate CD4
+
 T cell binding of CD40 on B 
cells with anti-CD40 and T cell-derived cytokine stimulation with IL-4.  Whereas B cells 
from control subjects up-regulated AID mRNA in response to either IL-4 or anti-IgM 
alone, response to these single stimuli were reduced in the HIV-1-infected groups, 
suggesting an intrinsic B cell defect in signaling capacity through these pathways.  
Analogous to this observation, changes in CD23 expression, an IL-4-responsive gene 
[234], were reduced, though not significantly, from those in controls.  Although AID 
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expression was only marginally upregulated in response to anti-CD40 in both HIV-1-
infected groups and controls, similarly, the B cell memory marker (CD27) expression 
was also lower in the HIV-1-infected groups compared with controls post-stimulation.  
Progression from activated mature B cells to memory B cells may require long-term 
signaling through the CD40 receptor [42, 235], expression of which may be 
downregulated during HIV-1 infection.  Consistent with our results, inefficient signaling 
in B cells from viremic HIV-1-infected patients, such as may have occurred during 
stimulation, could result in decreased levels of both AID mRNA expression and 
decreased frequencies of memory B cells.   
These results could not be confirmed in the 454-pyrosequenced dataset, however, 
where we found comparable levels of both AID mRNA expression and CD27
+
 B cell 
subsets post-stimulation between HIV-1-infected patients and control subjects, despite 
using identical reagents and protocols.  This discrepancy could be due to the differences 
between control subjects and HIV-1-infected patients in the VH3-IgG dataset, as 
described below, or could simply be a sampling error.  Despite significant differences in 
the levels of both AID mRNA expression and CD27
+
 B cell populations post-stimulation 
in the VH3-IgG dataset, there is overlap between the two groups, suggesting that at least 
some of the HIV-1-infected patients even in this dataset were capable of reaching similar 
levels of expression and differentiation as those in control subjects.  A larger number of 





Correlation of high VH3-IgD SHM frequency and high baseline AID implies normal AID 
function during HIV-1 infection   
Potential AID mRNA expression disparities in HIV-1-infected patients may lead 
to functional disparities as well.  As seen in the last chapter, levels of SHM in viremic 
HIV-1-infected patients in both the VH3-IgG cloned and 454-pyrosequenced datasets 
were lower in VH3-IgG sequences, either a direct result of AID activity or possibly fewer 
rounds of affinity maturation.  In contrast, SHM frequencies of VH3-IgD sequences were 
significantly higher in the HIV-1-infected patients.  That the IgD SHM frequency would 
correlate with baseline AID mRNA expression but not the IgG SHM frequency, suggests 
that the VH3-IgD SHM frequency may be a direct result of AID activity, while the VH3-
IgG SHM frequency may be the result of another mechanism.  This conclusion would 
imply, therefore, that AID may be functioning normally during HIV-1-infection. 
 
AID isoform expression does not likely affect AID function during HIV-1 infection   
If, in addition to dysregulation of AID mRNA, the activity of AID is abnormal 
during HIV-1 infection, such activity does not appear to be due to differential expression 
of different isoforms of the AID enzyme that may also affect function [116].  
Dimerization of different isoforms, which can lack functional domains of the enzyme, 
including the cytidine deaminase functional domain, could confer increased or decreased 
functional capacity on the operative AID molecule.  Our data show for the first time that 
while at baseline, multiple isoforms of AID are expressed in both control subjects and 
HIV-1-infected patients, and upon stimulation, the full length AID isoform is  
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predominantly expressed and expressed to a comparable degree in both groups.  Thus, 
isoform expression should not substantially alter the functional capacity of AID during 
HIV-1 infection. 
 
B cell subset proportions cannot account for discrepancies in SHM frequency   
Discrepancies in SHM frequency were not readily explainable by examining the 
proportions of B cell subsets in HIV-1-infected patients in the 454-pyrosequenced 
dataset.  Indeed, with higher SHM frequencies found in the VH3-IgD sequences, we 
might have expected to see a higher proportion of class-switched IgD B cells.  These B 
cells are known to harbor extremely high mutation levels in their VH genes [75].  An 
increase in this population, would, therefore, have accounted for the increased SHM 
frequency.  However, no differences were seen in this B cell subset either at baseline or 
post-stimulation.  Further experiments are needed to identify which IgD
+
 B cell subset(s) 
is (are) accumulating high SHM frequencies.  Similarly, lower SHM frequencies may 
have been explained by higher proportions of switch IgG
+
 memory cells, which may 
accumulate fewer mutations than similarly isotype-switched plasma cells [236].  The 
proportion of switched memory B cells was not significantly different in the HIV-1-
infected patients, although we did not specifically look at the IgG
+
 subset of switch 
memory B cells, only switch memory cells as a whole.  Therefore, inclusion of IgA
+
 
switch memory cells may be masking a potential increase in the proportion of IgG
+
 





Limitations of the study   
Potential limitations of the study include stimulation of the B cells in the mixed 
PBMC population rather than of purified B cells.  However, we chose to maintain the 
cells in a more physiologic context.  Moreover, the B cell-specific stimuli did not appear 
to significantly activate the T cells by expression of activation markers but cytokines 
from T cells or antigen-presenting cells may have contributed to the effects seen, as they 
may in vivo.  In addition, the seronegative control subjects in the VH3-IgG cloned dataset 
were more likely to be younger and female then either group of HIV-1-infected patients 
(Table 1) in the same dataset.  Studies in mice and humans have reported lower levels of 
AID expression in older populations post-stimulation [237].  However, the ages of our 
control and HIV-infected populations among whom AID expression was measured span 
the same range (23-54 for controls, 26-55 for viremics, and 33-62 for aviremics), though 
the group medians differed (30, 46, and 52, respectively).  Indeed, we found no 
correlation between age and AID expression in our group of seronegative controls or 
HIV-1-infected patients either at baseline or with stimulation (data not shown).  
Moreover, an age-related deficit in AID expression would not explain the high levels of 
AID expression at baseline among the HIV-1-infected adults.  Finally, in a model 
controlling for age, HIV-1 status, and gender, overall differences between all three 
groups were still significant at baseline (overall p=0.001, p<0.01 for both aviremic vs. 
controls and viremic vs. controls) and when measuring the change in AID expression 
post-stimulation (Ct overall p<0.0001, p<0.005 for both aviremic vs. controls and 
viremic vs. controls).  Therefore, discrepancies in gender or age do not appear to be 
significantly confounding our results.  That we could not confirm all results in the more 
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carefully age, gender, and ethnically-matched 454-pyrosequenced dataset, however, casts 
some doubt as to the reliability of the post-stimulation AID mRNA expression and B cell 











SUMMARY AND DISCUSSION 
 
Summary 
The goal of this thesis was to provide insights into the mechanism of B cell 
dysfunction which results in a decreased quantity and quality of antibody responses to 
infection among HIV-1-infected patients.  Several processes direct the development of an 
effective antibody response, including the diversification of the antibody repertoire 
through V(D)J recombination, additional nucleotide modifications to enhance antibody 
affinity (SHM), and improving the functionality of an antibody by altering its effector 
constant region (CSR).  More limited previous studies and those described herein using 
novel high-throughput molecular sequencing and analytic tools reveal that V(D)J 




) is comparable 
during HIV-1-infection to that of healthy control subjects [29].  In contrast, substantial 
data support the conclusion that CSR is affected by HIV-1-infection by both direct and 
indirect mechanisms.  CSR may be impaired by HIV-1 itself, perhaps by signal blockade 
by HIV-1 Nef protein [131, 133, 169] and the quantities of class-switched circulating 
antibodies in serum (IgG and IgA) are increased, likely by indirect non-specific bystander 
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B cell activation from activated T cells [29, 64, 135-137, 140, 202].  However, very little 
evidence is available in the literature that describes the effect of HIV-1 infection on the 
process of SHM.  Therefore, we focused our studies on characterizing the consequences 
of HIV-1 infection on SHM, the accumulation of nucleotide point mutations in the 
variable regions of expressed antibody genes that bind antigen and on the enzyme 
required for both CSR and SHM, activation-induced cytidine deaminase. 
 
Disparate frequencies of SHM by isotype during HIV-1 infection 
 SHM is an antigen-driven process designed to improve the affinity of an antibody 
for its specific antigen.  The introduction of point mutations by AID and the subsequent 
changes to the expressed protein can increase or decrease the antibody’s specificity and 
avidity for an antigen, making it more or less effective in binding and supporting 
antibody function to preventing and controlling infections.  Indeed, we identified 
decreased SHM frequency in nucleotides of expressed VH3-IgG transcripts both by direct 
cloning and sequencing and high-throughput sequencing (Figures 3.4 and 3.15) and in the 
predicted amino acid sequences.  These observations may underlie the poor vaccine 
responses and higher incidences of infections in HIV-1-infected patients which are 
normally controlled by VH3-IgG antibodies in healthy controls (e.g. Streptococcus 
pneumoniae, Haemophilus influenzae, Cryptococcus neoformans, and Salmonella spp.)  
[65, 144-149, 165-167].  Our data suggest also, that antiretroviral treatment may increase 
the effectiveness of antibody responses in HIV-1-infected patients, as patients 
successfully treated with Highly-Active Anti-Retroviral Therapy (HAART) with no 
detectable circulating HIV RNA had SHM frequencies closer to those in control subjects 
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that in untreated HIV-1-infected patients with advanced disease (Figure 3.4).  We 
confirmed that SHM is impaired during HIV-1 infection by revealing for the first time 
that mutation frequencies in Bcl6, the second most common gene target of AID in vivo, 
are also significantly reduced (Figure 3.21).  Therefore, we concluded that SHM, like 
CSR, can be impaired during HIV-1 infection.  Whether the decreased prevalence of 
these mutations in VH3-IgG and Bcl6 genes is due to decreased function of the AID 
protein or differential expression of B cell subsets is under investigation.  Preliminary 
data from our lab suggests that the decreased avidity of IgG reactive with pneumococcal 
polysaccharides after vaccination of HIV-1-infected adults in vivo is associated with a 
decreased function; the ability of these antibodies to support opsonophagocytic killing of 
S. pneumoniae in vitro. 
 Much to our surprise, however, results in antibodies of other were not consistent 
with these decrements in SHM and VH3-IgG.  Indeed, in another class-switched isotype, 
IgA, despite greater variance, SHM frequencies did not differ significantly between HIV-
1-infected patients and controls (Figure 3.15).  Similarly, in IgM transcripts, an isotype 
expressed in naïve and some memory B cell subsets, SHM frequencies also did not differ 
between groups.  In contrast to results from all other isotypes, however, IgD transcripts 
showed a significantly increased SHM frequency in half of our patients with HIV-1 
infection.  IgD, like IgM, is an isotype predominantly expressed in naïve and selective 
memory B cell subsets.  Therefore, HIV-1 infection is associated with discordant and 
differential effects in different B cell isotypes and, likely, subsets.  Because SHM is 
initiated by AID in vivo and the enzyme is required for this process, we sought to 
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determine a mechanism for the disparate SHM frequencies by characterizing expression 
of AID mRNA and its alternatively-spliced isoforms during HIV-1 infection. 
 
High baseline AID mRNA expression and decreased expression post-stimulation 
  AID mRNA expression was measured by real-time PCR in HIV-1-infected 
patients.  Baseline levels of AID mRNA were significantly higher in HIV-1-infected 
patients compared with controls.  We considered these results in the context of the lower 
frequencies of SHM in the VH3-IgG transcripts, for which the high AID would seem 
inconsistent, and for the higher frequency of SHM in half of the HIV-1-infected patients 
for VH3-IgD, for which the high AID would be consistent.  Regarding the VH3-IgG 
results, a murine study showed that increased AID mRNA expression can yield decreased 
SHM frequencies, likely through negative regulation [109], although the exact 
mechanism is unknown.  When we stimulated PBMCs the absolute level of AID mRNA 
expression and the change from baseline AID mRNA induced by stimulation were 
reduced in some patients compared with controls.  These data suggest that upon 
stimulation in vitro by mixed stimuli (engagement of the B cell receptor (BCR) with anti-
IgM and cognate and soluble T cell factors with anti-CD40 and IL-4, respectively) and 
perhaps by antigen in vivo, the ability to upregulate AID may be diminished with a 
consequent diminution of IgG SHM.  Regarding the IgD results, baseline AID activity 
correlated positively with the high SHM frequencies in VH3-IgD sequences.  IgD- 
expressing B cells comprise the majority of circulating B cells (>60-70%) so the 
correlation suggests that the primary effect of high AID may be related to the IgD results, 
whereas the lower change in AID with stimulation may be more closely related to the 
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lower SHM in class-switched IgG cells that have previously been exposed to antigen 
stimulation.  That neither result was targeted to any individual VH gene(s) or gene 
segment (V, D, or J) in either isotype indicates that the underlying mechanisms were 
generalized effects and not likely due to a common antigen, such as HIV-1 itself.  Future 
work will be directed to sorting out these differential effects in IgG versus IgD and in 
baseline versus stimulated AID, initially by sorting relevant B cell subsets and 
determining the AID expression and frequency of SHM.   
 
B and T cell subsets are more activated during HIV-1 infection 
 B and T cell subset proportions and activation levels were measured by flow 
cytometry in HIV-1-infected patients.  Consistent with previous reports [22, 64, 218], we 
found both higher overall B cell activation at baseline (Figure 4.4), as well as activation 
within specific B cell subsets examined, including Naïve mature, GC, IgM memory, and 
switch memory subsets (Figure 4.8).  Higher activation levels in these B cell subsets is 
reflective of the higher baseline AID mRNA discussed earlier, although interestingly, 
baseline AID mRNA has not been found to correlate either with overall B cell activation 
levels, nor activation levels in any specific subset.  Baseline AID mRNA expression, did, 
however correlate with both GC and IgM Memory cell proportions, both cell subsets  
where AID mRNA expression may be detected in vivo.  Of note, baseline AID mRNA 
levels were negatively correlated with BND anergic IgD
+
 B cells, such that higher AID 
mRNA levels were associated with lower BND anergic B cell proportions (Figure 4.9).  
As VH3-IgD SHM frequency had a positive association with AID mRNA expression 
(Figure 4.7), these two results taken together suggest that the high SHM frequency in 
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VH3-IgD sequences is not likely to be found in the BND anergic population.  Similarly, 
high VH3-IgD SHM frequency may also be explained by lower proportions of BND 
anergic B cells with low or unmutated Ig genes and higher proportions of IgD memory B 
cells known to harbor high levels of mutation in their Ig genes [73-75].  
Overrepresentation of IgD memory cells in the periphery would skew overall SHM 
frequencies in VH3-IgD sequences.  However, overrepresentation of IgD memory B cells 
was not seen in our HIV-1-infected patients, either in patients with high VH3-IgD SHM 
frequencies or low frequencies, and similarly, BND anergic B cell proportions were also 
lower in our HIV-1-infected patients.  It may be interesting in future studies, therefore, to 
more carefully characterize the IgD
+
 B cell subsets during HIV-1-infection, their 
activation states, as well as the degree of SHM. 
 Consistent with our B cell activation results and studies in the literature [7, 23, 




 subsets  were significantly more activated at 
baseline in HIV-1-infected patients compared with control subjects.  This result remained 




 T cell populations as well (Figures 
4.4 and 4.10), which included Naïve, Central Memory (CM), Effector Memory (EM), 
Terminally Differentiatied Effector cells (TD), and additionally for CD4
+
 T cells, 
Follicular Helper (TFH) cells.  That all T cell subsets identified were more highly 
activated in the HIV-1-infected patients is reflective of the high levels of circulating 
antigen and pro-inflammatory cytokines previously reported during HIV-1 infection [22, 
141].  Though baseline AID mRNA expression did not correlate with B cell activation 
levels, it did correlate with T cell activation, both overall CD8
+
 T cell activation, and 
more specifically activated TFH cell proportions (Figure 4.11).  That activated TFH cells 
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would associate with increased AID mRNA expression is contradictory to our results in 
VH3-IgG Gene SHM frequency.   TFH cells are the primary T cell population in GCs, 
where IgG memory cells are induced.  High activation of TFH cells and high AID mRNA 
expression within GCs would suggest that VH3-IgG SHM frequency would be increased 
not decreased.  Of note, however, VH3-IgG SHM frequency correlated only with TFH cell 
proportions, but not TFH cell activation (Figure 4.12), suggesting that perhaps a reduction 
in TFH number in the GC, though not activation levels, may result in a decreased level of 
SHM in the IgG B cell subset.  While we cannot rule out reduced numbers of TFH cells in 
GCs, we did not find a decrease in the number of TFH cells in the periphery in our HIV-1-
infected patients.  Finally, levels of TFH activation also correlated significantly with levels 
of GC B cell activation, although, similarly, not with the proportion of GC B cells (Figure 
4.13), suggesting that while TFH cells can become activated and may, in turn, provide 
sufficient stimulus for GC B cells, they may not be capable of preventing apoptosis of 
GC B cells.  Characterization of GC versus peripheral blood population subsets and 
activation levels, therefore, will be necessary to discern associations between GC cell 
populations (i.e. GC B cells and TFH cells, AID expression, and SHM frequency). 
 
Potential mechanisms 
AID may be less functional in germinal centers during HIV-1 infection 
 Despite high baseline levels of AID expression during HIV-1 infection, SHM 
frequency in VH3-IgG sequences and Bcl6 sequences was low, suggesting that AID may 
be impaired on a functional level.  In addition, as noted above, the ability to stimulate 
AID mRNA expression may also be impaired during HIV-1 infection.  AID mRNA 
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expression is induced by stimulation through either immune signaling (i.e. via cognate 
signaling by engagement of CD40 on B cells by CD40 ligand on CD4
+
 T cells or by 
soluble factors such as BAFF or APRIL through BAFF-R/TACI) (Figure 5.1) or by 
pathogen or their products stimulating B cells (i.e. signaling through TLRs, or in the case 
of HIV-1 CD40, CD21, and the BCR) [58, 59, 87, 90, 92, 93, 139, 141, 216].  This 
stimulation can also be impaired by HIV-1.  The HIV-1 viral protein Nef has been shown 
to be taken up by B cells in vivo and in vitro.  The presence of Nef can inhibit AID 
mRNA production by preventing the activation of NF-B by signaling through CD40 
[131].  Similarly, the presence of HIV-1 Vif can also impair induction of AID expression 
in vitro through an unknown mechanism [117]. 
 In addition, HIV-1 Vif can also impair AID function [117].  AID protein enters 
the nucleus through active import mediated, in part, by the nuclear localization signal 
(NLS) [101] (Figures 1.7 and 5.2).  In the nucleus, AID is phosphorylated by Protein 
Kinase A (PKA) and possibly PKC [99, 107, 124, 214] and is recruited to the VH region, 
likely by Spt5, which is itself recruited by stalled RNA Pol II at active transcription sites 
[212, 213].  At transcription sites phosphorylated AID associates with Replication Protein 
A (RPA), a single stranded DNA binding protein, and CTNNBL-1, another nuclear 
protein thought to be involved in RNA splicing [213, 238, 239].  Deamination of cytidine 
residues then follows, creating U:G lesions in the transcribed DNA [84, 103, 104].  U:G 
lesions are subsequently mutagenically repaired by several DNA repair pathways, 







Figure 5.1:  Induction of AID mRNA Expression.  Activation of signaling pathways 
(BAFF/BAFF-R, CD40/CD40L, TLR/TLR ligands, and APRIL/TACI) have all been 
shown to lead to activation of NF-B and when coupled with other transcription factors 
at the AID promoter (E47, STAT6, Pax5, E2A, and/or estrogen), to upregulate AID 
mRNA expression.  Blockade of NF-B activation has been shown by HIV-1 Nef.  
Inhibition of AID mRNA induction has been shown by HIV-1 Vif, and Ca
2+
/calmodulin 
or progesterone binding at the AID promoter.  After transcription AID mRNA can also be 
targeted for degradation by binding of microRNAs, miR-155 and miR-181B, to the 3’ 





Activity of AID within the nucleus is controlled by several mechanisms.  Most 
AID is found in the cytoplasm [99, 100].  AID is actively exported out of the nucleus by 
CRM-1 associating with the nuclear export signal (NES) signal at the 3’ end of AID [101, 
102, 213].  AID is also targeted for degradation in the nucleus by polyubiquitination 
[108].  Polyubiquitination targets AID for proteasomal degradation.  How HIV-1 Vif 
impairs AID in vitro is not known, however, it does require direct Vif-AID protein 
interaction [117]. 
Inhibition of AID function may explain decreased SHM frequency that we have 
found in VH3-IgG sequences as well as another AID target, Bcl6.  Impairment of function 
would lead to a decrease in the creation of U:G lesions in transcribed DNA without 
affecting the downstream low-fidelity repair mechanisms.  Thus, lower AID activity 
would lead to fewer mutation but not change the pattern of mutation, just as we see in our 
VH3-IgG sequences (Tables 3.3-3.6).  Since SHM of IgD- B cells and expression of both 
Bcl6 and AID are most often localized to the GC, the SHM decrement that we found in 
VH3-IgG genes is most likely an effect in GCs.   
An overall deficit in AID function cannot explain either the increased SHM 
frequency in VH3-IgD sequences which may not have undergone a GC reaction, or the 
normal SHM frequencies in VH3-IgA and VH3-IgM sequences.  Inhibition of AID, 
therefore, would have to occur only in B cells which class switch to IgG.  Such a process 
in which B cells with impaired AID that are prone to IgG switch may occur in GCs where 
HIV-1 preferentially replicates and accumulates high concentrations of HIV-1 viral 







Figure 5.2:  AID Protein Function.  Control of AID concentration within the nucleus 
and cytoplasm is controlled by active import and export of the AID protein through the 
nuclear pore.  Mediators of active import have not been identified, however, active export 
is believed to be mediated by CRM-1.  AID concentrations within the nucleus are also 
controlled by polyubiquitination and subsequent proteasomal degradation.  Inside the 
nucleus, AID is phosphorylated at multiple sites by PKA and PKC.  AID is believed to be 
targeted to actively transcribed target sequences (including VH and Bcl6 genes) by Spt5, 








antibodies induced in GCs is of the IgG isotype [240-242].  If affinity maturation to HIV-
1 viral products, particularly envelope peptides, drives B cell activation and class switch 
to IgG, the presence of viral products in the GC (such as Nef and Vif) may be able to 
specifically impair AID expression and function in cells likely to class switch to IgG.  
Determining AID expression and function in specific B cell subsets, both in the periphery 
and in GCs, therefore, would be instructive in determining whether or not as well as 
where AID expression and function may be impaired during HIV-1 infection. 
 
 
Early dissolution of the germinal center during HIV-1 
 An alternative hypothesis to the low SHM frequency in VH3-IgG genes is 
inadequate GC activity that typically includes multiple rounds of replication in the dark 
zone and selection by FDC in the light zones.  These processes may be compromised by 
the early dissolution of GC integrity as a result of loss of CD4
+
 T cells, attenuation of the 
FDC network and progressive fibrosis in these tissues [21, 223].  If B cells cannot 
complete enough rounds of proliferation, mutation, and selection to achieve a level of 
affinity maturation necessary to obtain high affinity effective antibodies, these B cells 
will potentially accumulate fewer mutations than the number found in B cells which have 
undergone a complete germinal center reaction.  Several factors are required for germinal 
center maintenance (Figure 5.3).  Integrin ligands (Vascular Cell Adhesion Molecule-1, 
VCAM-1, and Intercellular Adhesion Molecule-1, ICAM-1), BAFF, Notch ligands 
(Delta-like 1 and Jagged1), and PD-L1 are all produced by resident FDCs in the light 
zone where selection of high affinity BCR-expressing B cells is thought to occur [45, 
204].  CD40L, CD28, ICOS, PD-1, IL-4, and IL-21 are produced by TFH cells also in the 
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light zone [43, 45, 46, 204, 236].  Blockade of any of these factors results in a reduction 
of GC cell survival and dissolution of the [31, 43, 45, 46, 204, 205, 235, 243, 244].  B 
cell factors may also affect affinity maturation.  Overexpression of anti-apoptotic signals 
Bcl-xL, Bcl-2, and Bim can prevent apoptosis of low affinity B cells, resulting in their 
prolonged survival and accumulation in the germinal center [205, 245].  Only blockade of 
some of these factors, however, leads to a reduction in affinity maturation, as seen in the 
VH3-IgG sequences of our HIV-1-infected patients (Table 5.1).   
Several mutation and blocking studies have been done to illuminate the role of 
these factors in germinal center function in vitro and in vivo (Table 5.1).  Disruption of 
BAFF or Notch signaling affects B cell survival and GC size, but not affinity maturation 
[45].  Overexpression of Bcl-xL, similar to blocking PD-1/PD-L1 signaling, results in an 
increase in affinity maturation [45, 204, 236, 245].  Affinity maturation is reduced, 
however, when signaling through integrin ligands, CD40, CD28, ICOS, and IL-21 is 
interrupted, and when Bcl-2 and Bim are overexpressed in B cells [45, 204, 205, 236, 
245], similar to our results in the VH3-IgG sequences.  However, reduced levels of 
integrin ligands or blocking CD40L or CD28 signaling results in a reduction in serum 
IgG levels, a phenotype not found in our subjects nor reported in other HIV-1 studies [45, 
205].  Bcl-2 and Bim are also not likely candidates in this case, as overexpression of 
these proteins results in increased numbers of memory B cells, the opposite of what is 
seen during HIV-1 infection [205, 245].  Disruption of ICOS signaling leads to decreased 
affinity maturation, but has no effect on the numbers of memory B cells produced [205, 






Figure 5.3:  Germinal Center Signaling.  Germinal centers are composed of dark zones 
and light zones.  CXCR4
+
 centroblasts traffic to dark zones in response to an SDF-1 
(CXCL12) chemical gradient in the dark zone produced by stromal cells.  Centroblasts 
undergo SHM and several rounds of proliferation then downregulate CXCR4 expression 
and upregulate CXCR5 expression.  CXCR5 expression hones the non-proliferating 
centrocytes (formerly centroblasts) into the light zone through its attraction to CXCL13, 
produced in the light zone by FDCs.  Centrocytes express the newly mutated BCR and B 
cells expressing high affinity BCRs are positively selected.  High affinity B cells receive 
survival signals (ICOS, IL-4, IL-21, PD-1, CD28, CD40L, BAFF, IL-6) from FDCs and 
TFH cells.  Low affinity B cells do not receive survival signals and undergo apoptosis.  
High affinity B cells can return to the dark zone for further rounds of proliferation and 
SHM by upregulating CXCR4 expression, or they can undergo CSR and differentiate into 






149].  Blockade of IL-4 and IL-21 signaling resulted in lower affinity maturation and 
lower plasma and memory cell numbers [45, 204, 205, 236].  In addition, Bcl6 expression 
is maintained in GC B cells by IL-21 signaling, and impairment of Bcl6 led to a decrease 
in SHM in IgG expressing B cells [205, 244], matching our phenotype in VH3-IgG 
specific cells.  The significantly lower mutation frequency we found in Bcl6 may also be 
explained by a deficiency in IL-21 signaling, either levels of the cytokine or the receptor 
and its downstream signaling network, as a resulting decrease in Bcl6 transcription would 
allow for less AID-mediated SHM.   
 




Plasma Cell Number 
 
Other 
BAFF Unknown Decreased  
Notch Ligands Unknown Decreased  
Bcl-xL Increased Increased  
PD-1/L1 Increased Decreased  
Integrin Ligands Decreased Decreased Decreased IgG Titers 
CD40L Decreased Decreased Decreased IgG Titers 
CD28 Decreased Decreased Decreased IgG Titers 
Bcl-2 Decreased Increased  
Bim Decreased Increased  
ICOS Decreased No Change  
IL-4 Decreased Decreased Decreased CSR 
IL-21 Decreased Decreased Decreased Bcl6 
expression 
Blockade or knockout of the above factors can affect affinity maturation (increased or 
decreased levels) and the numbers of memory cells and plasma cells produced (increased 
or decreased numbers). 
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During HIV-1 infection, serum IL-21 levels have been reported to be decreased 
beginning early in infection and progressively decrease in association with decreasing  
CD4
+
 T cells numbers in later stages of the infection [206, 246].  IL-21 is produced by 
TFH cells [43, 45, 46, 246].  Although TFH cell numbers have not been shown to be 
decreased during HIV-1 infection in our ongoing studies in blood and in others [203] or 
in lymph nodes [247], levels of IL-21 produced by TFH cells infected with HIV-1 are 
significantly lower [206].  In addition, though CD4
+
 T cell counts increase with 
successful antiretroviral therapy (ART), IL-21 serum levels remain significantly lower 
than those measured in healthy controls.  This lack of effect of ART on IL-21 levels is 
similar to the persistently decreased frequencies of SHM in VH3-IgG genes in aviremic 
patients on therapy (Figure 3.4) and with reports showing limited reconstitution of B cell 
subsets during ART [206].  This inadequate recovery with ART could be due, in part, to 
persistent effects of HIV as low levels of viral replication continue in GCs during 
successful viral treatment [248].  Though levels of virus are undetectable in the serum, 
low copy numbers of viral RNA have been detected within germinal centers.  With 
ongoing viral replication occurring in germinal centers during treatment, infected TFH 
cells, thought to be a major viral reservoir in these tissues [203], may be producing lower 
amounts of IL-21 in response to activation compared with their uninfected counterparts 
[206].  Similarly, a recent report highlighted the importance of the interactions between 
all of these signals.  High PD-L1 expression on lymph node GC B cells in patients with 
HIV-1 infection bound to PD-1 on TFH cells was discovered to lead to a decrease in both 
ICOS and IL-21 production by TFH cells [247]. 
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A putative loss of IL-21 signaling in germinal centers provides an intriguing 
hypothesis to explain the decreased SHM in VH3-IgG sequences, but cannot explain the 
increased SHM observed in VH3-IgD sequences, nor the normal levels of SHM found in 
VH3-IgM and VH3-IgA sequences.  The effect of IL-21 signal disruption would have to 
either be focused in GCs responsive to antigens that lead to IgG class-switch exclusively, 
or only have a significant impact on Bcl6 expression without affecting B cell survival or 
affinity maturation in IgA class-switched B cells.  As discussed above, IgG-specific SHM 
decrements may occur in GCs where HIV-1 viral products are the target antigen.  The 
majority of anti-HIV-1 antibodies produced in germinal centers are of the IgG isotype 
[240-242].  If affinity maturation to HIV-1 viral products drives class switch to IgG, IL-
21 signaling may be most highly affected in germinal centers where TFH cells are virally 
infected and a) producing lower levels of IL-21 as a consequence of infection and b) 
productively replicating virus and therefore creating increased levels of antigen in the 
germinal center.  Therefore, investigation of IL-21 and its effects on Bcl6 expression and 
SHM in IgG
+
 B cells during HIV-1 infection may provide a mechanism for the reduced 
SHM we have described in this B cell compartment.  None of our studies to date have 
included stimulation of T cells in the context of B cell activation.  Such an approach will 
likely provide complementary information on the T-B interaction during HIV-1 infection. 
 
Abnormal trafficking within germinal centers during HIV-1 infection 
 Signaling deficiencies in GCs during HIV-1 infection also extend to GC B cell 
trafficking between the dark zone and light zone [22, 249, 250].  The dark zone has been 
proposed to be the site of SHM, whereas CSR is thought to occur in the light zone 
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(Figure 5.3) [42, 45].  Trafficking between dark and light zones is determined by 
chemical gradients produced by stromal cells in the dark zone (SDF-1/CXCL12) and 
FDCs in the light zone (CXCL13).  Centroblasts in the dark zone express CXCR4, which 
is attracted to its ligand CXCL12 and thus directs B cells within this GC area.  However, 
transformation into centrocytes in the light zone results in downregulation of CXCR4 and 
upregulation of CXCR5.  The activating ligand for CXCR5, CXCL13, is produced in 
high concentrations in the light zone and directs centrocytes to leave the dark zone and 
migrate to the light zone [42-44].  Interrupted trafficking could lead to accumulation of B 
cells in one zone or the other.  Accumulations could possibly lead to increased 
frequencies of SHM without additional CSR in the dark zone, consistent with the high 
SHM frequencies in our VH3-IgD sequences.  Alternatively, B cells accumulating in the 
light zone after fewer cycles through the dark zone could produce class-switched 
antibodies with low SHM frequencies, consistent with the low SHM frequencies in our 
VH3-IgG sequences.  Lower levels of both CXCR4 and CXCR5 on B cells with an 
exhausted phenotype and decreased CXCR5 levels in peripheral B cells have been 
reported during HIV-1 infection [22, 250].  However, despite lower CXCR5 levels, in 
vitro chemotactic ability towards CXCL13 and in CXCR4
+
 B cells towards CXCL12 was 
actually increased in HIV-1-infected patients with low CD4
+
 T cell counts compared with 
healthy controls [250].  Therefore, altered GC trafficking patterns during HIV-1 infection 







Non-specific, T cell-independent B cell activation during HIV-1 infection  
 Excessive B cell activation during HIV-1 infection is manifested in several ways 
[19, 22, 24, 64, 65, 218].  Hypergammaglobulinemia, high serum levels of 
autoantibodies, lymphadenopathy, and high incidence of B cell lymphomas are all 
characteristics of chronic HIV-1 infection [19, 29, 64, 135, 136].  Several mechanisms 
have been proposed to explain high B cell activation both directly and indirectly by HIV-
1.  Directly, HIV-1 Env glycoproteins can directly bind B cells on C-type lectin receptors 
[141] and on specific VH3 genes in the BCR [175, 176].  HIV-1 gp160 binding to B cells 
can also lead to activation of the B cell in the presence of T cells [216].  HIV-1 Tat 
stimulates B cell activation, although its mechanism is unknown [19].  Indirectly, B cells 
have been shown to bind complement proteins associated with HIV-1 virions via the 
CD21 complement receptor [93].  Similarly, HIV-1 virions can also incorporate host 
CD40L into their envelopes during viral budding which can bind CD40 on B cells [92, 
139].  HIV-1 Nef has been shown to induce ferritin protein production in macrophages 
which can also stimulate B cells [22, 249].  Finally, high levels of circulating cytokines 
and chemokines such as IFN, TNF, IL-6, IL-10, CD40L, and BAFF produced by 
monocytes, macrophages, DCs, activated CD4
+
 T cells, or activated epithelial and 
endothelial cells have been reported during HIV-1 infection and can lead to increased B 
cell activation [20, 22, 55, 58, 59, 141, 145, 251, 252].  In addition to increased levels of 
B cell activation, several of these mechanisms have been shown to induce AID 




 SHM may occur outside of the traditional T cell-dependent (TD) GC environment 
[42, 45].  GCs may be generated in response to high doses of T cell-independent (TI) 
antigens.  High concentrations of antigen in addition to stimulatory cytokines from 
nearby antigen presenting cells can support the formation of a GC without the need for T 
cell help.  These TI-generated GCs are short-lived, however, and collapse within days 
[43, 45].  SHM has been shown to occur in the absence of CSR, which is reminiscent of 
the high SHM found in VH3-IgD sequences, although early collapse of these TI GCs 
would likely prevent the accumulation of high frequencies of somatic mutations [236].  
Of note, the introduction of CD40L signaling within TI GCs may rescue early dissolution 
of these GCs [45].  CD4
+
 T cells are also highly activated during HIV-1 infection [7, 19, 
23] (see Chapter IV).  It is possible that high circulating levels of T cell-derived cytokines 
or immune complexes on FDCs which can signal through CD40 could potentially extend 
these short-lived GC reactions in the absence of TFH cells within the GCs [45].  Similarly, 
HIV-1 virions themselves may provide T cell signals in the form of host CD40L within 
its viral envelope budded off from activated and HIV-1-infected CD4
+
 T cells [92, 139].  
Binding of virion-bound CD40L to CD40 on activated B cells could prolong TI GC B 
cell survival and allow accumulation of high levels of point mutations.  Indeed, addition 
of non-T cell-derived CD40L to TI GCs has been shown to rescue B cell centrocyte 
apoptosis and induce transformation back into centroblasts, in which SHM predominantly 
occurs [45].  SHM frequency can also increase when antigen is presented as immune 
complexes [45].  Class switch in a TI GC environment appears to be rare, however [236].  
Additionally, CSR outside of GC (whether TD or TI) predominantly leads to switch to  
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IgM and IgA isotypes [58, 59].  Therefore, non-specific B cell activation and subsequent 
development of TI GCs may underlie the high SHM frequency seen in our VH3-IgD 
sequences. 
In summary, several mechanisms may be affecting SHM during HIV-1 infection 
(Figure 5.4).  Within the GC B cell, impairment of AID expression and function by the 
HIV-1 viral proteins Nef and Vif may directly decrease AID activity.  Concurrently, 
outside the GC B cell, GC signaling may be interrupted during HIV-1 infection, 
preventing the survival and differentiation of high affinity isotype-switched B cells.  
Blocking of IL-21 expression by TFH cells through either active HIV-1 replication or by 
signaling through PD-1 can prevent necessary levels of survival signals from 
accumulating in the GC and lead to apoptosis of B cells potentially expressing high 
affinity antibodies.  Simultaneously, lack of IL-21 signaling in both B and T cells 
prevents upregulation of Bcl6 expression, which, in addition to other transcription 
factors, controls CXCR4, CXCR5, CD40L, ICOS, CXCL13, and PD-1 expression [246], 
further exacerbating aberrant GC signaling.  Outside the TD GC, non-specifically 
activated B cells with increased AID expression in the presence of large amounts of 
antigen may be forming TI GCs and accumulating high numbers of mutations without 
undergoing class switch.  Correction of these deficiencies through therapeutic 
interventions (such as supplemental IL-21) may allow HIV-1-infected patients to develop 








Figure 5.4:  Impairment of AID, IL-21 Signaling Deficiencies, and T Cell-
Independent Germinal Center Formation during HIV-1 Infection.  In TD GCs, 
impairment of AID expression can be mediated by both HIV-1 viral proteins Nef and Vif.  
Impairment of AID function can be mediated by Vif.  HIV-1 replication within TFH cells 
as well as PD-L1 signaling from B cells can downregulate IL-21 expression in TFH cells.  
Impairment of IL-21 production and signaling results in decreased induction of Bcl6 
expression in both B and T cells which can lead to decreased levels of CXCR4, CXCR5, 
CD40L, ICOS, CXCL13, and PD-1 expression, and can also result in decreased B cell 
survival and differentiation.  X indicates blockade or impairment.  In TI GCs, B cells can 
be stimulated through surface receptor signaling by HIV-1 viral proteins and virion-
associated CD40L and complement.  Activation and survival signals can be released from 








Which B cell subsets have disparate SHM frequencies during HIV-1 infection? 
 The discovery of high SHM frequencies in VH3-IgD genes was surprising and 
intriguing.  IgD
+
 B cells represent the majority of circulating B cells, but the proportions 
of this subset were not significantly different in patients with and without HIV-1 
infection.  As a result, it is difficult to explain the phenotype of the cells harboring the 
significantly increased SHM frequencies beyond their isotype.  Since similarly increased 
rates of SHM frequency were not seen in VH3-IgM sequences, it seems unlikely that 




 B cells.  Sorting IgD
+
 B cells into different subsets may 
determine which subset is harboring the increased SHM frequency.   
Freshly isolated PBMC from HIV-1-infected and control subjects would be sorted 
into IgD
+
 B cell subsets by flow cytometry based on B cell marker expression.  Cells 
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which have been shown to have 2-3-fold higher SHM frequencies compared with other 
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), which are the largest subset (40-50% of control B cells) and typically show few 
to no mutations.  mRNA would be extracted from each of the subsets and VH3 genes 





subset may have increased SHM frequencies.  If this is the case, additional B cell markers 
(i.e. activation markers such as CD40, CD80, and CD86 or plasma cell markers such as 
CD38 and CD138) could be used to further differentiate the IgD
+
 B cell subset 
populations, as would staining for AID protein and measuring AID mRNA in each 
population. 
 Similarly, further characterization of IgG
+
 B cells with low SHM frequency may 
direct additional experiments to determine the mechanism of decreased SHM in VH genes 
from these cells.  IgG
+
 B cells could be sorted based on B cell marker expression such as 








) with relevant receptors (IL-21R, PD-






).  mRNA from sorted cells would be tested for AID and Bcl6 expression and 
sequenced for SHM frequency in VH3 and Bcl6.  This experiment would clarify in which 
class-switched subsets low SHM is occurring and its relationship to AID expression.  
Additionally, expansion of VH-IgG sequencing could be done in other VH families, 
especially VH4, the second most commonly expressed family, and VH1, the third most 
common, which is frequently utilized by broadly neutralizing antibodies against HIV-1 
[253].  Indeed, the development of broadly neutralizing antibodies requires high levels of 
mutation accumulation [249].  This assay could be used to determine whether broadly 
neutralizing antibodies are only rarely developed in HIV-1-infected patients because of 






Which B cell subsets have high AID expression? 
 We have found high baseline AID expression in circulating B cells during HIV-1 
infection.  However, we have not determined which B cell subset is expressing the 
increased levels of AID mRNA.  If these are naïve activated B cells, which are increased 
during HIV-1 infection [22, 249], these cells may or may not accumulate increased levels 
of mutations.  Indeed, high levels of AID have been shown to be negatively regulated in 
vitro in a murine model [109].  Perhaps AID expression in naïve B cells would not 
support SHM or CSR if cofactors of AID are not also upregulated simultaneously.  In 
contrast, if high AID expression is found in GC B cells, concurrent with low SHM 
frequencies, this may implicate an HIV-1-specific mechanism of inhibition of AID 
function or impaired selection of attenuated GCs in vivo.  Therefore, characterization of 
AID expression in different circulating and GC-derived B cell subsets should be 
performed. 
 Freshly isolated PBMC from blood and lymphoid tissue from HIV-1-infected and 


























) B cell subsets by marker expression by FACS.  AID 
mRNA expression could then be measured from isolated mRNA by real-time PCR.  
Similarly, AID mRNA expression could be measured in PBMC from different lymphoid 
follicles, such as spleen, lamina propria, and tonsils to determine if AID expression varies 




Studies in blood are facilitated by accessibility but often limited by the number of 
B cells available (3-6% of PBMC).  Studies from lymphoid tissues are limited by the 
availability of these tissues but facilitated by the substantial numbers of cells available in 
these tissues.  For blood cells, for each of the experiments described above, the most 
straight forward and feasible approach would be to perform a separation of B cell subsets 
by sorting CD19
+
 B cells by flow cytometry into 4 subsets and test for a) mRNA levels of 
AID and b) Bcl6 and mutation frequencies in IgD (groups 1-3) and IgG (memory cells; 









































 (includes IgM, IgG and IgA memory cells; second largest 
subset; ≈15-30%). 
 
Does increased AID expression translate to increased SHM frequencies during HIV-1 
infection? 
 This question could be addressed by two methods.  First, freshly isolated PBMC 




populations by FACS.  This experiment would require a well-tested and very specific 
anti-AID antibody, a commodity that we have not yet identified despite considerable 
testing of commercially available antibodies (see Appendix B).  Should such an antibody 
become available, mRNA could be extracted from the sorted populations and sequenced 
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to measure SHM frequency in the expressed VH genes.  One could then correlate AID 
protein expression with SHM frequency. 
 Conversely, AID function could be directly measured by monitoring a specific 
mutation to a transfected substrate molecule.  Such functional assays have been designed 
and used in B cell lines to determine relative AID function [254-256].  We have also 
designed a functional assay using a mutated GFP plasmid designed to be transfected into 
primary human B cells (see Appendix B).  This plasmid would be transfected into fresh 
PBMC isolated from HIV-1-infected patients and control subjects and cultured for 24 
hours, then assayed for GFP expression by flow cytometry.  While the plasmid 
containing the mutated GFP sequence has been created, transfection of the primary 
human B cells and measurement of GFP expression need to be optimized for this assay to 
be informative.  This assay could also be used more generally with primary B cells to 
determine the requirements for SHM in vitro. 
  
Are GC signaling molecule levels normal in HIV-1-infected patients? 
 Low levels of IL-21 in serum from HIV-1-infected patients have been reported in 
other studies [206, 246].  However, IL-21 expression within GCs has yet to be 
characterized, and may be different than serum levels.  IL-21 can be rapidly depleted 
from the circulation by GC cells [247], thus IL-21 levels in serum may not be reflective 
of IL-21 expression in GCs.  IL-21 production in GC cells could be measured by RT-
PCR in cells extracted from GCs from HIV-1-infected patients and controls.  Additional 
GC signaling protein expression, such as PD-1/L1, ICOS, and IL-4 could also be 
measured in the same tissues.  Furthermore, correlation of these results with both VH-Ig 
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SHM frequency and Bcl6 mutation frequency from GC B cells would provide compelling 
evidence that impairment of these signaling pathways has a detrimental effect on SHM. 
 
Impact of the work in this thesis 
The work described herein will advance the field of HIV-1 research for several 
reasons.  First, this work may, in part, explain why vaccine responses are low in HIV-1-
infected individuals.  One explanation for the high rates of secondary infections to 
pathogens normally controlled by antibody responses that have been reported in HIV-1-
infected patients is reduced SHM frequencies in VH3-IgG genes that we report here.  The 
inability to develop high affinity antibodies may impair an antibody’s ability to neutralize 
and clear infections.  The next steps for this work would be to clarify the defects 
associated with high IgD mutation and low IgG mutation and to correlate these results 
with actual vaccine responses in vivo.  We could then attempt to replace (e.g. IL-21) or 
block (e.g. PD-1 or PD-L1) the relevant molecules during vaccine administration.  
Similarly, the low frequency of development of broadly neutralizing antibodies to HIV-1 
in chronically infected patients may result from similar mechanisms.  Neutralization 
breadth is positively correlated with the level of affinity maturation for anti-HIV-1 
antibodies, the most effective of which are of the IgG isotype [249].  Potentially reversing 
the cause of low VH-IgG SHM may, therefore, not only improve antibody responses to 
secondary infections, but improve antibody responses to HIV-1 also.  Thus, this work has 
implications for understanding the basic consequences of chronic immune activation 
during HIV-1 infection, and potentially other such chronic infections such as Hepatitis C 
and malaria, and the resultant B cell dysfunction, and may provide direction to reverse 
204 
 
these defects and enhance the efficacy of humoral defenses against these infections and 
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Residue characteristics were calculated with the number of each type of residue divided 
by the total number of residues in the CDR3 region of each sequence.  Values are listed 















Table A2:  RGYW/WRCY Motifs and Targeted Mutation Frequencies in CDR and 
FR Regions in VH3 454-Pyrosequenced Samples. 
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Table A3:  Nucleotide Mutation Patterns and Proportions in VH3 454-
Pyrosequenced Samples. 
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 Day 0 p value 
CDR Median Percent (Subject Range) 
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“% C nucleotides mutated” indicates the proportion of nucleotides in either the CDR1/2 or 
FR1/2/3 regions that were mutated relative to the total number of C nucleotides present in the 
unmutated reference sequence, expressed as a percent.  “% of mutations that were C nucleotides” 
indicates the proportion of mutations in either the CDR1/2 or FR1/2/3 regions that were C 
nucleotides in the unmutated reference sequence relative to the total number of mutations in the 
region, expressed as a percent.  The medians of each group are listed with individual patient mean 
ranges in parentheses. 
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Table A4:  Nucleotide Mutations and Adjacent Nucleotide Patterns in VH3 454-
Pyrosequenced Samples. 
  IgD   
Mutation R:Y Ratio 
5’               3’ 
 Mutation R:Y Ratio 
5’                 3’ 
C → G (Tr)    G → C (Tr)   
Control 2.5 : 1 1.1 : 1  Control 3.4 : 1 1 : 3.1 
Viremic 2.0 : 1 1 : 1.2  Viremic 4.6 : 1 1 : 3.0 
p value 1.00 0.28  p value 0.96 0.88 
C → A (Tr)    G → A (Ts)   
Control 1.1 : 1 1.4 : 1  Control 2.1 : 1 1.3 : 1 
Viremic 1.2 : 1 1.0 : 1  Viremic 2.2 : 1 1 : 1.1 
p value 0.57 0.96  p value 0.72 0.64 
C → T (Ts)    G → T (Tr)   
Control 1.4 : 1 1 : 1.7  Control 1 : 1.8 1 : 4.2 
Viremic 3.6 : 1 1 : 2.4  Viremic 1 : 1.4 1 : 5.9 
p value 0.08 0.19  p value 0.60 0.51 
       
A → C (Tr)    T → C (Ts)   
Control 1 : 2.6 1 : 1.6  Control 1 : 1.4 1.3 : 1 
Viremic 1 : 1.7 1 : 1.9  Viremic 1.3 : 1 1.9 : 1 
p value 0.19 0.96  p value 0.28 0.44 
A → G (Ts)    T → G (Tr)   
Control 1.6 : 1 3.1 : 1  Control 1.3 : 1 1 : 1.2 
Viremic 1.4 : 1 2.6 : 1  Viremic 1.0 : 1 2.1 : 1 
p value 0.38 0.13  p value 0.75 0.13 
A → T (Tr)    T → A (Tr)   
Control 1 : 1.7 1 : 3.3  Control 1.6 : 1 5.1 : 1 
Viremic 1 : 1.9 1 : 3.8  Viremic 1.3 : 1 4.5 : 1 










  IgM   
Mutation R:Y Ratio 
5’               3’ 
 Mutation R:Y Ratio 
5’                 3’ 
C → G (Tr)    G → C (Tr)   
Control 3.0 : 1 1 : 2.3  Control 3.9 : 1 1 : 3.0 
Viremic 3.2 : 1 1 : 1.2  Viremic 3.4 : 1 1 : 3.4 
p value 0.33 0.88  p value 0.43 0.72 
C → A (Tr)    G → A (Ts)   
Control 1.4 : 1 1 : 1.1  Control 2.7 : 1 1 : 1.1 
Viremic 1.1 : 1 1.2 : 1  Viremic 2.0 : 1 1 : 1.9 
p value 0.57 0.83  p value 0.57 0.16 
C → T (Ts)    G → T (Tr)   
Control 2.4 : 1 1 : 1.6  Control 1 : 1.3 1 : 3.0 
Viremic 2.6 : 1 1 : 2.0  Viremic 1 : 1.5 1 : 3.3 
p value 0.43 0.23  p value 0.23 0.96 
       
A → C (Tr)    T → C (Ts)   
Control 1 : 1.8 1 : 1.4  Control 1 : 1.1 1.8 : 1 
Viremic 1 : 1.4 1 : 1.3  Viremic 1.2 : 1 2.3 : 1 
p value 0.09 0.33  p value 0.10 0.23 
A → G (Ts)    T → G (Tr)   
Control 1.2 : 1 2.2 : 1  Control 1.5 : 1 1 : 1.4 
Viremic 1 : 1.1 2.2 : 1  Viremic 1.1 : 1 1.1 : 1 
p value 0.60 0.60  p value 0.02 0.04 
A → T (Tr)    T → A (Tr)   
Control 1 : 2.6 1 : 2.5  Control 1.6 : 1 3.0 : 1 
Viremic 1 : 2.0 1 : 2.3  Viremic 1.8 : 1 4.4 : 1 












  IgA   
Mutation R:Y Ratio 
5’               3’ 
 Mutation R:Y Ratio 
5’                 3’ 
C → G (Tr)    G → C (Tr)   
Control 4.3 : 1 1 : 2.3  Control 3.4 : 1 1 : 3.0 
Viremic 4.5 : 1 1 : 2.3  Viremic 3.3 : 1 1 : 3.0 
p value 0.54 0.68  p value 1.00 0.92 
C → A (Tr)    G → A (Ts)   
Control 2.2 : 1 1 : 1.3  Control 2.4 : 1 1 : 3.3 
Viremic 3.0 : 1 1 : 1.3  Viremic 2.2 : 1 1 : 3.3 
p value 0.06 0.84  p value 0.35 0.79 
C → T (Ts)    G → T (Tr)   
Control 3.9 : 1 1 : 1.9  Control 1.1 : 1 1 : 4.1 
Viremic 4.1 : 1 1 : 2.1  Viremic 1 : 1.0 1 : 3.8 
p value 1.00 1.00  p value 0.47 0.79 
       
A → C (Tr)    T → C (Ts)   
Control 1 : 1.3 1 : 1.0  Control 1.4 : 1 2.6 : 1 
Viremic 1 : 1.1 1 : 1.0  Viremic 1.4 : 1 2.6 : 1 
p value 0.35 0.96  p value 0.20 0.84 
A → G (Ts)    T → G (Tr)   
Control 1 : 1.3 1.9 : 1  Control 1.4 : 1 1.3 : 1 
Viremic 1 : 1.2 2.0 : 1  Viremic 1.1 : 1 1.5 : 1 
p value 0.84 0.47  p value 0.03 0.35 
A → T (Tr)    T → A (Tr)   
Control 1 : 3.5 1 : 1.8  Control 1.9 : 1 3.6 : 1 
Viremic 1 : 4.8 1 : 1.8  Viremic 2.1 : 1 4.1 : 1 












  IgG   
Mutation R:Y Ratio 
5’               3’ 
 Mutation R:Y Ratio 
5’                 3’ 
C → G (Tr)    G → C (Tr)   
Control 4.5 : 1 1 : 3.0  Control 3.0 : 1 1 : 2.8 
Viremic 4.2 : 1 1 : 2.1  Viremic 3.0 : 1 1 : 2.9 
p value 0.24 0.04  p value 1.00 0.74 
C → A (Tr)    G → A (Ts)   
Control 3.2 : 1 1 : 1.7  Control 2.4 : 1 1 : 3.1 
Viremic 1.9 : 1 1 : 1.1  Viremic 2.2 : 1 1 : 2.9 
p value 0.009 0.24  p value 0.74 0.32 
C → T (Ts)    G → T (Tr)   
Control 4.3 : 1 1 : 1.9  Control 1.2 : 1 1 : 3.5 
Viremic 4.2 : 1 1 : 2.0  Viremic 1 : 1.1 1 : 3.0 
p value 0.89 0.56  p value 0.17 0.23 
       
A → C (Tr)    T → C (Ts)   
Control 1 : 1.3 1.1 : 1  Control 1.6 : 1 2.5 : 1 
Viremic 1 : 1.5 1 : 1.2  Viremic 1.6 : 1 2.6 : 1 
p value 0.89 0.24  p value 0.61 0.81 
A → G (Ts)    T → G (Tr)   
Control 1 : 1.0 1.9 : 1  Control 1.3 : 1 1.2 : 1 
Viremic 1 : 1.1 2.2 : 1  Viremic 1 : 1.0 2.0 : 1 
p value 0.96 0.54  p value 0.14 0.32 
A → T (Tr)    T → A (Tr)   
Control 1 : 2.7 1 : 1.8  Control 1.7 : 1 3.9 : 1 
Viremic 1 : 2.8 1 : 2.3  Viremic 1.0 : 1 3.9 : 1 
p value 0.89 0.09  p value 0.31 0.77 
R = A or G nucleotides, Y = C or T nucleotides.  Mutations:  Ts = transition (purine ↔ 
purine or pyrimidine ↔ pyrimidine); Tr = transversion (purine ↔ pyrimidine).  The 
group median ratio of R:Y nucleotides in the adjacent -1 (5’) or +1 (3’) positions is listed 












AID Functional Assay 
Introduction 
 Directly measuring human AID protein function has proven difficult.  Several in 
vitro assays have been developed in numerous cell lines to measure both endogenous and 
transgenic AID protein function [A1-A5].  In the past, studies have either looked 
indirectly at AID function by looking at mutation frequencies in sequences from the V 
genes of stimulated human B cell lines [A1, A2], or more directly, by looking for mutator 
activity in a receptor gene assay [A3-A5].  As seen in Chapter III, we have already 
looked indirectly at AID function through sequencing of IgG-VH3 mRNA in fresh 
primary human B cells.  Our results indicated that AID function may be impaired.  We 
attempted to confirm these results by developing a reporter gene assay to measure AID 
function in primary human B cells.  We intended to correlate the results of the reporter 
gene assay with the sequencing results to further validate our hypothesis. 
 The AID functional reporter gene assay is modeled after the in vitro assay 
designed by Ruckerl et al [A4].  This group measured AID activity in a cell line known to 
express AID (BL70, a human germinal center-derived Burkitt’s lymphoma cell line) and 
in a cell line with no AID expression (Nalm-6, a human pre-B cell line).  AID activity  
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was measured by the frequency at which a GFP gene with a premature stop codon present 
on a transfected plasmid was reverted back into a full-length functional protein through 
AID-mediated mutation.  Reversion of the stop codon present in the GFP sequence would 
indicate hypermutation.  Indeed, in the AID-expressing cell line, all 8 samples tested 
were positive for GFP expression when measured by flow cytometry.  Consistent with the 
hypothesis that AID activity mutated and caused the reversion of the stop codon, in the 
cell lines that did not express AID, none of the 8 samples tested had any GFP 
fluorescence. 
 We attempted to optimize this assay for use in primary human B cells (derived 
from PBMCs) in order to test AID functional capacity in PBMCs isolated from healthy 
control subjects and HIV-1-infected patients.  The plasmid to be transfected was 
constructed using a pmaxFP-Green-C plasmid backbone (Lonza, Gaithersburg, MD).  
This plasmid contains a GFP gene controlled by the constitutively active cytomegalovirus 
(CMV) promoter and a Kanamycin resistance gene for propagation in E. coli cells.  The 
complete mechanism of targeting AID to Ig V genes in vivo is unknown, however a few 
elements have been identified that enhance SHM at specific regions [A6-A10].  
Immunoglobulin heavy chain large intron enhancer sequences (ELi) have been identified 
in both mice and humans and are thought to encourage SHM by regulating VH gene 
transcription [A11-A13].  The presence of an enhancer sequence near the reporter gene 
on a transfected plasmid has also been shown to increase mutation frequencies in a 
reporter gene [A9, A10].  Therefore, the human HS1,2 ELi sequence was also cloned into 
the pmaxFP-Green-C plasmid backbone at the 3’ end of the GFP gene (Figure B1).  AID  
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also preferentially deaminates cytidine residues in the hotspot sequence motif “RGYW” 
[A14-A16].  Such motifs are prevalent in the V genes [A17-A19] and also found in other 
genes known to be mutated by AID in vivo, including Bcl6 [A10, A19, A20].  The GFP 
gene sequence in the pmaxFP-Green-C plasmid has several RGYW sequence motifs.  In 
one of these motifs, a stop codon has been introduced, preventing translation of the full-
length GFP protein (Figure B1).  The final element added to the plasmid backbone is a 
triple-encoded FLAG-tag sequence (5’-ATGGACTACAAAGACCATGACGGTGATTA 
TAAAGATCATGACATCGATTACAAGGATGACGATGACAAG-3’) at the 5’ end of 
the GFP gene to measure transfection efficiency (Figure B1). 
 Fresh and stimulated PBMC were transfected with the plasmid using a Human B 
Cell Nucleofector kit from Lonza, shown to have up to a 36% transfection efficiency with 
a control plasmid.  We hypothesized that in our stimulated control PBMCs, in B cells that 
were transfected, AID activity would mutate the stop codon in the GFP gene, reverting 
the stop codon back into an amino acid.  Should this occur, GFP fluorescence would be 
measured by flow cytometry.  However, in stimulated PBMCs isolated from HIV-1-
infected patients, who may have diminished AID activity, fewer mutations would revert 
the stop codon in GFP to an amino acid, and therefore, fewer CD19
+
 B cells would 
express GFP.  We developed the functional assay and tested the ability of PBMC to be 
nucleofected using this plasmid.  While our nucleofection efficiencies are currently quite 








Amplification of ELi enhancer sequence.  Primers used for amplification were 
previously published [A11] commercially synthesized primers designed to amplify the 
HS1,2A enhancer region at the 3’of the constant alpha genes of the human 
immunoglobulin gene locus (Table B1).  PCR (25 l) consisted of:  100 ng DNA, 2.5 l 
10x KOD Hot Start buffer, 2.5 l 2 mM dNTPs, 1.5 l 25 mM MgSO4, 0.6 l Eli FWD 
primer (10 M), 0.3 l Eli REV primer (10 M), 0.75 l STC1 Eli REV primer (10 M), 
and 0.5 l KOD Hot Start DNA Polymerase (1 U/l; Novagen, Gibbstown, NJ).  Samples 
were heated to 95
o
C for 2 minutes in an Applied Biosystems 9700 thermocycler (“hot 
start”; Applied Biosystems, Foster City, CA), followed by 45 cycles consisting of a 20 
second 95
o
C denaturation, a 10 second 60
o
C annealing, and a 10 second 70
o
C extension.  
PCR product was run out on a 1.5% 1x TAE agarose (Sigma, St. Louis, MI) gel and 
stained with ethidium bromide.  PCR product was excised from the agarose gel and 
purified using a MinElute Gel Extraction Kit (Qiagen).  PCR product (10 l) was cloned 
into a pSTC1.3 vector (Eurogentec, San Diego, CA), according to the manufacturer’s 
protocol. 
 
Mutagenic PCR.  Primers used for mutagenesis were commercially synthesized 
primers designed to introduce point mutations into the p3xFLAG plasmid (p3xFLAG 
AgeI FWD1/REV1 and p3xFLAG AgeI FWD3/REV3) and the pMAX plasmid 
(5’GFPstop3, 3’GFPstop3) (Table B1).  PCR (50 l) consisted of:  50 ng plasmid, 5 l 
10x Pfu Ultra High Fidelity buffer, 1 l 10 mM dNTPs, 125 ng of each primer, and 2.5 
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Table B1:  Primer Sequences 
Primer Name Primer Sequence 
Eli FWD 5’- GACTCATTCTGGGCAGACTTG-3’ 
Eli REV 5’- GTCCTGGTCCCAAAGATGG-3’ 
STC1 Eli REV 5’- CCTTCGCCGACTGAGTCCTGGTCCCAAAGATGG-3’ 
p3xFLAG AgeI FWD1 5’- GAGCTCGTTTAGTGAACCGGTCAGAATTAACCATGGAC-3’ 
p3xFLAG AgeI REV1 5’- GTCCATGGTTAATTCTGACCGGTTCACTAAACGAGCTC-3’ 
p3xFLAG AgeI FWD3 5’- CGATGACAAGCTACCGGTCGCGAATTCATCGATAG-3’ 
p3xFLAG AgeI REV3 5’- CTATCGATGAATTCGCGACCGGTAGCTTGTCATCG-3’ 
5’GFPstop3 5’- GACCTTCAGCCCCTAGCTGCTGAGCCACGTG-3’ 
3’GFPstop3 5’- CACGTGGCTCAGCAGCTAGGGGCTGAAGGTC-3’ 
pMAX fwd2 5’-AGGAGGATCACAGCAACACC-3’ 
5’GFPseq 5’-CACCAAAATCAACGGGACTT-3’ 
 
units of Pfu Ultra High Fidelity DNA polymerase (Stratagene, La Jolla, CA).  Samples 
were amplified and mutated using an Applied Biosystems 9700 thermocycler using a 
program consisting of 20 cycles (p3xFLAG) or 22 cycles (pMAX) of a 30 second 95
o
C 
denaturation, a 1 min 55
o
C annealing, and a 4.75 minute (p3xFLAG) or a 5 minute 
(pMAX) 68
o
C extension.  Mutagenized plasmids were digested with 1 l of DpnI 





Plasmids were digested using BamHI (Invitrogen, Carlsbad, CA; ELi sequence 
insert, pMAX vector) or AgeI (New England Biolabs, Ipswitch, MA; p3xFLAG insert, 
pMAX + ELi vector) according to the manufacturers’ protocols.  Restriction digests (50 
l) consisted of:  2000 ng plasmid substrate, 30 units of enzyme, and 5 l 10x enzyme 
buffer.  Restriction digests were incubated at 37
o
C for 2 hours (BamHI) or overnight 
(AgeI), then purified using a PCR Purification kit (Qiagen).  Purified digested vectors 
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(pMAX or pMAX + ELi) were further digested with Calf-Intestinal Alkaline Phosphatase 
(CIAP; New England Biolabs) for ligation reactions.  One unit of enzyme was added to 
49 l of purified digested vector plasmid and incubated at 37
o
C for 1 hour.  All digested 
inserts and vectors were run on a 1.0% 1xTAE agarose (Sigma) gel and stained with 
ethidium bromide.  Products were excised and purified using a MinElute Gel Extraction 
kit (Qiagen).  Purified inserts and vectors were quantified using a NanoDrop 
spectrophotometer (NanoDrop Technologies Inc., Wilmington, DE). 
 
Ligation Reactions 
Digested insert sequences and vector plasmids were ligated using T4 DNA ligase 
(Invitrogen).  Ligation reactions (20 l) consisted of:  1 unit of T4 DNA ligase, 4 l 5x 
ligase buffer, and digested and purified vector plasmid and insert DNA at a 3:1 ratio.  
Ligation reactions were incubated at room temperature for 1 hour (ELi insert + pMAX 
vector) or 3 hours (p3xFLAG insert + pMAX + ELi vector). 
 
Transformation of E. coli 
Chemically competent E. coli (XL1-Blue cells for PCR-mutated plasmids, 
Stratagene; CYS21 cells for cloned PCR product plasmids, Eurogentec; or 5 cells for 
ligated plasmids, New England Biolabs) were transformed with 10 l of plasmid 
according to the manufacturer’s protocols.  Cells were plated on LB agar + Kanamycin 
(50 g/ml) plates (pMAX plasmids) or LB agar + Ampicillin (100 g/ml) plates 
(pSTC1.3 and p3xFLAG plasmids) and grown overnight at 37
o
C.  Individual bacterial 
colonies were selected from the plates and used to inoculate 3 ml LB broth + antibiotic 
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cultures.  Cultures were grown overnight with shaking at 37
o
C.  Plasmid DNA was 
isolated from the cultures using a QIAprep Spin Miniprep kit (Qiagen).  Purified plasmid 




Mutagenic PCRs and ligation reactions were verified by sequencing.  Sequencing 
reactions (17 l) consisted of:  1000 ng of template plasmid + 1.25 l 10 M sequencing 
primers (Table B1).  Sequencing was performed by the Colorado Cancer Center Core 
Sequencing Facility using an ABI 3730 Sequencer (Applied Biosystems). 
 
Endotoxin-Free Plasmid Isolation 
AID functional assay plasmids (Figure A1) were amplified and purified using an 




See Chapter II, PBMC Isolation. 
 
Nucleofection 
Ficoll-isolated fresh human PBMC (1x10
6
 cells/100 l Human B Cell 
Nucleofector solution/condition) were nucleofected with either 5 g of the unmutated 
FEpM1-3 functional assay plasmid, 2 g of the control plasmid pmaxGFP (Lonza), or 
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mock-nucleofected with Endotoxin-free EB buffer (Qiagen; no plasmid) using the U-015 
program on a Nucleofector device (Lonza) according to the manufacturer’s protocol.  
Immediately after nucleofection, 500 l of fresh RPMI media (Invitrogen) + 10% heat-
inactivated fetal bovine serum (HyClone Laboratories, Logan, UT) + 10 g/ml 
gentamicin (Invitrogen) were added to the cells.  Cells were incubated in 6 well plates for 
24 hours at 37
o
C in 5% CO2. 
 
Flow cytometry 
Nucleofected PBMCs were washed in cold FACS buffer (Dulbecco’s PBS 
(Invitrogen) + 1% heat-inactivated BSA (Fisher Scientific)) and stained with 20 l 
CD19-APC-AF750 monoclonal antibody (Invitrogen) for 30 minutes at room 
temperature, then washed again.  Stained PBMCs were permeabilized and fixed using a 
Caltag Permeabilization/Fixation kit (Caltag, Grand Island, NY) according to the 
manufacturer’s protocol, then stained with 2 l anti-FLAG-M2-Cy3 antibody (Sigma) for 
30 minutes at room temperature.  PBMCs were washed again and fixed in 1% 
paraformaldehyde (Sigma) then run immediately on an LSRII Flow Cytometer (BD 
Biosciences, San Jose, CA). 
 
Results 
Building the plasmid 
 The human HS1,2A ELi sequence was PCR-amplified from DNA isolated from 
frozen human PBMCs.  The amplified HS1,2 ELi sequence was then cloned into the 
pSTC1.3 vector backbone and sequenced.  The cloned sequence was cleaved out of the 
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pSTC1.3 vector using BamHI and ligated into the pmaxFP-Green-C vector backbone 
behind the end of the GFP gene.  Ligation was verified by sequencing.  Next, the 
3xFLAG sequence present in the expression vector p3xFLAG-CMV-7.1 (Sigma) was 
mutated to introduce two AgeI sites at the 5’ and 3’ ends of the 3xFLAG sequence.  
Mutations were verified by sequencing.  The 3xFLAG sequence was cleaved out of the 
mutated p3xFLAG-CMV-7.1 plasmid using AgeI and ligated into the pmaxFP-Green-C + 
ELi vector between the CMV promoter and the start of GFP.  Ligation was verified by 
sequencing.  Finally, the pmaxFP-Green-C + ELi + 3xFLAG plasmid was mutated to 
introduce a premature stop codon into the GFP sequence.  This stop codon is present at 
amino acid 57 (GFP is 257 amino acids total) and its inclusion introduces a new 
RGYW/WRCY AID hotspot motif, AGCT.  In this motif, AID targets the G residue for 
mutation, and the AG nucleotides in this sequence make up the final two nucleotides in 
the stop codon TAG.  The mutation was verified by sequencing.  Both the unmutated 
(FEpM1-3) and mutated (M5-7) pmaxFP-Green-C + ELi + 3xFLAG assay plasmids 
(Figure A1) were amplified in large cultures of E. coli and isolated using an EndoFree 




Figure B1:  AID Functional Assay Plasmids.  Both the unmutated FEpM1-3  assay 
plasmid (A) and the mutated M5-7  assay plasmid (B) were constructed using the 
pmaxFP-Green-C vector as a backbone.  The human HS1,2 ELi enhancer sequence was 
cloned into the backbone vector to attract AID to nearby sequences.  The 3xFLAG 
sequence was cloned to be expressed along with GFP as a positive indicator of 
nucleofection.  The M5-7 (B) assay plasmid contains a single point mutation in the GFP 





Testing the plasmid 
Freshly isolated human PBMCs were nucleofected with either buffer alone 
(mock-nucleofected; negative control), a control GFP plasmid (pmaxGFP), or the 
unmutated pmaxFP-Green-C + ELi + 3xFLAG plasmid FEpM1-3.  Cells were then 
cultured for 24 hours to allow GFP expression, then stained with a monoclonal antibody 
to detect CD19 expression, a pan B cell marker, then permeabilized and fixed and stained 
for intracellular 3xFLAG expression.  





 (Figure A2D), indicating only low levels of background fluorescence 
in these two channels.  As expected, 18.4% of gated lymphocytes were CD19
+
 B cells 
(Figure A2C). 
 In cells nucleofected with the positive control GFP plasmid, only 13.5% of gated 
lymphocytes were GFP
+
 (Figure A3B).  Only 10% of CD19
+
 B cells were also GFP
+
, 
indicating that the nucleofection protocol will need to be optimized further.  Background 




 In cells nucleofected with the FEpM1-3 assay plasmid, both GFP (Figure A4B) 
and 3xFLAG (Figure A4D) expression were extremely low, with levels of 3xFLAG not 
above background levels seen in the negative controls.  Only 0.5% of CD19
+
 B cells were 
GFP
+
, and only 0.25% of CD19
+
 B cells were 3xFLAG
+
, suggesting that nucleofection 
with the assay plasmid is much less efficient than with the positive control GFP plasmid.  
Only 27.8% of GFP
+
 cells were also 3xFLAG
+
, indicating that the 3xFLAG peptide is not 




Figure B2:  Mock-nucleofection of primary human B cells.  A)  Cells were gated on 
lymphocytes based on size (forward scatter, X axis) and granularity (side scatter, Y axis).  
150,673 events were collected.  62.8% of cells were lymphocytes.  B)  Negative control 
for GFP expression.  C)  18.4% of gated lymphocytes were CD19
+
 B cells.  D)  Negative 




Figure B3:  Nucleofection of primary human B cells with control GFP plasmid.  A)  
Cells were gated on lymphocytes based on size (forward scatter, X axis) and granularity 
(side scatter, Y axis).  58,555 events were collected.  40.2% of cells were lymphocytes.  
B)  GFP fluorescence was detected in 13.5% of lymphocytes.  C)  22.5% of gates 
lymphocytes were CD19
+




Figure B4:  Nucleofection of primary human B cells with the FEpM1-3 assay 
plasmid.  A)  Cells were gated on lymphocytes based on size (forward scatter, X axis) 
and granularity (side scatter, Y axis).  88,966 events were collected.  51.1% of cells were 
lymphocytes.  B)  GFP fluorescence was detected in 1.9% of lymphocytes.  C)  26.8% of 
gated lymphocytes were CD19
+
 B cells.  D)  The 3xFLAG peptide was detected in 0.9% 
of lymphocytes.  
 
Discussion/Future Directions.   
The ability to detect AID function in primary human B cells would greatly 
enhance our understanding of the protein not only during HIV-1 infection, but also in a 
more biologically relevant setting.  Thus, using assays designed for B cell lines as a 
model, we sought to create an assay for use in primary human B cells.   
 Highly efficient nucleofection of primary human B cells has been reported by 
Lonza using their control plasmid, pmaxGFP, however, we were not able to replicate 
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such high efficiencies in our experiments using either the control plasmid or our assay 
plasmid FEpM1-3.  This inability may be corrected by further optimization of the 
nucleofection protocol.  Several parameters may be adjusted which may improve 
nucleofection efficiency, including the number of cells used in each experiment, the ratio 
of cells to plasmid, the voltage used for nucleofection, and perhaps the nucleofection 
buffer, which can vary from cell type to cell type.   
 Flow cytometric analysis will also need to be optimized in order to detect both 
levels of nucleofection and GFP expression.  The magnitude of GFP fluorescence 
detected using either the control plasmid or our assay plasmid was much lower than 
expected based on results presented by Lonza.  GFP fluorescence should peak at a much 
higher level.  It is possible that our fixative reagent, paraformaldehyde, may be quenching 
the GFP signal prior to signal detection on the Flow cytometer (Matt Downey, personal 
communication).  Thus, one way to correct this problem would be to test other fixative 
agents which may have a less detrimental effect on GFP fluorescence.  Detection of the 
p3xFLAG signal in nucleofected cells was also lower than expected given the number of 
GFP-fluorescent cells detected using the assay plasmid.  We were expecting to see 




 cells in our experiment.  The quantity of antibody 
used and the intracellular staining protocol, therefore, may also need to be optimized to 
more accurately measure 3xFLAG expression.   
Another area of optimization is the time point at which GFP expression is 
measured.  According to the protocol provided by Lonza, GFP expression should be 
measured 24 hours after nucleofection.  Indeed, we were able to detect GFP expression at 
this time point in our experiment.  However, this may not be the ideal time point at which 
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to detect GFP reversion.  Upregulation of AID expression, translation of the protein, 
traffic to the nucleus, and deamination at the stop codon may take much more than 24 
hours to complete.  Therefore, once the nucleofection and flow cytometry protocols are 
optimized, the proper time point at which to measure GFP expression will need to be 
determined. 
Finally, the stimulants used to upregulate AID expression and function may need 
to be optimized as well.  While the anti-CD40 + anti-IgM + IL-4 cocktail is known to 
both increase AID expression and enhance CSR, it is known whether these stimuli induce 
SHM.  Other stimuli, including antigens, cytokines, and antibodies may need to be tested 
to determine which combination lead to increased SHM frequencies in primary human B 
cells.  Though much work is left to be done, successful optimization of the nucleofection, 
flow cytometry, and stimulation protocols may eventually allow us to detect AID 
functional levels in PBMC in both HIV-1-infected patients and controls. 
 
Measuring AID Protein Expression by Flow Cytometry 
Introduction 
 Expression of AID mRNA may not translate directly to AID protein expression.  
Multiple microRNAs have been characterized which inhibit AID translation post-
transcriptionally [A21-A23].  Therefore, the increased levels of AID mRNA expression 
may not mean that increased levels of AID protein are produced during HIV-1 infection.  
Decreased levels of AID protein may result in decreased CSR and SHM.  In order to 
determine AID protein levels in PBMCs from both HIV-1-infected patients and control 
subjects, we tested multiple monoclonal anti-human AID antibodies commercially 
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produced by several companies (see Methods below).  Despite their recommended use in 
flow cytometry by the companies that produce them, we could not identify an antibody 
that was specific enough for use by this method. 
 
Methods 
PBMC Isolation and Stimulation 
See Chapter II, PBMC Isolation and Stimulation section for the Ficoll-isolation 
protocol of PBMCs from fresh blood and stimulation reagents and protocols. 
 
Flow Cytometry 
See Chapter II, Flow Cytometry for staining protocol.  PBMC were stained with 3 
color panels with monoclonal antibodies to AID, B cell, and T cell markers.  Several 
labeled and unlabeled anti-human AID antibodies were tested from Cell Signaling 
Technologies (mouse and rat antibodies; Danvers, MA), RnD Systems (mouse and rat; 
Minneapolis, MN), Invitrogen (mouse), Abcam (rat; Cambridge, MA), Novus Biologicals 
(mouse; Littleton, CO), Abnova (mouse; Walnut, CA), and Santa Cruz Biotechnologies 
(mouse; Dallas, TX).  Secondary antibodies used were purchased from eBiosciences 
(Sann Diego, CA).  Prior to antibody staining, PBMC were incubated in 50 l of Human 
AB serum for 5 minutes at room temperature to block any non-specific binding.  Data 
were analyzed within 24 hours of staining using Flow Jo Software (Tree Star, Inc.).  Cells 
were gated on singlets, followed by lymphocytes and divided into two populations, 
CD19
+








Results.   
Many anti-human AID monoclonal antibodies were tested on Ficoll-isolated 
human PBMCs using flow cytometry with varying degrees of success.  In general, the 
antibodies tested either did not stain cells at all (Invitrogen), or displayed high amounts of 
background and/or non-specific staining.  In one representative experiment, we stained 
unpermeabilized cells (AID is an intracellular protein) using one of our antibodies from 
RnD Sytems as a control (Figure B5).  The RnD Systems antibody was the primary 
antibody, followed by secondary staining using an anti-mouse PE-conjugated antibody 
(eBiosciences).  AID signal was detected in both CD19
+
 B cells (Figure B5-A) and in 
CD4
+
 T cells (Figure B5-B), despite AID being an intracellular protein expressed mainly 
in B cells [A24, A25].  AID was detected in over 5% of B cells and, surprisingly, in over 
9% of T cells (Figure B5-C).  The results of the RnD antibody tested in this experiment 
are representative of the other antibodies where staining was detected. 
 While all AID antibodies tested showed high background staining in 
unpermeabilized PBMC, we decided to try testing the antibodies on both fresh and 
stimulated PBMC to determine if we could see an increase in AID expression with B cell 
stimulation.  For this experiment we tested two antibodies, the RnD antibody as above, 
and an antibody from Cell Signaling Technologies which had been used in previously 
published AID protein studies in humans [A26].  In fresh PBMC, the Cell Signaling (CS) 
Technology antibody showed a low degree of background in the CD4
+
 T cells (Figures 
B6-B and –C), however, staining in CD19
+
 B cells was not much higher (6.0% in B cells 
vs. 4.0% in T cells (Figures B6-A and –C).  AID protein has never been reported in T 





Figure B5:  Staining of Non-Fixed/Permeabilized PBMC.  Freshly isolated PBMC 
were stained without fixation/permeabilization to measure background levels of binding 
for each antibody.  For the RnD antibody, staining was detected in CD19
+





 T cells (B).  The percentage of positively-stained cells was determined in 
each subset (C). 
 
development and in very small numbers [A27].  In addition, staining with only the 
secondary antibody did not result in significantly high levels of background in either 
CD19
+
 B or CD4
+
 T cells (0.7% staining in both, data not shown).  Therefore, we must 
conclude that the AID expression detected in T cells is non-specific staining.   
In stimulated cells, we found the same results.  AID protein expression in B cells 
did increase significantly with stimulation (6% in fresh cells vs. 52.5% in stimulated 
cells; Figure B-6A vs. B-7A), however, staining in T cells also increased (4% in fresh 
cells vs. 26.8%; Figure B6-B vs. B-7B).  Though the increase in AID protein levels was 




Figure B6:  Staining of Fresh PBMC using the Cell Signaling Technologies anti-
Human AID Rat Monoclonal Antibody.  Freshly isolated PBMC were stained after 
fixation/permeabilization using the antibody purchased from Cell Signaling (CS) 
Technologies.  Staining was detected in CD19
+




 T cells (B).  
The percentage of positively-stained cells was determined in each subset (C). 
 
Taken together, the degree of non-specific staining measured in T cells both at baseline 
and post-stimulation do not make this antibody suitable for measuring AID protein 
expression in primary human B cells. 
 We next tried staining fresh and stimulated PBMC using the RnD antibody that 
had showed promising staining results in experiments using human tonsil B cells (data 
not shown).  Using fresh PBMC, we found staining in 29.2% of CD19
+
 B cells (Figures 
B8-A and –C), but also in 33.2% of CD4
+
 T cells (Figures B8-B and –C), suggesting that 




Figure B7:  Staining of Stimulated PBMC using the Cell Signaling Technologies 
anti-Human AID Rat Monoclonal Antibody.  Stimulated PBMC were stained after 
fixation/permeabilization using the antibody purchased from Cell Signaling (CS) 
Technologies.  Staining was detected in CD19
+




 T cells (B).  
The percentage of positively-stained cells was determined in each subset (C). 
 
specific staining.  Staining with only the secondary antibody resulted in only 2.7% PE-
stained B cells and 2.1% PE-stained T cells (data not shown).  Therefore, high levels of 
non-specific staining are due to aberrant binding of the primary antibody. 
 This result was even more evident in the stimulated PBMC.  Only a slight 
increase was seen in AID protein expression from baseline to post-stimulation (29.2% vs. 
31.2%; Figures B8-A vs. B9-A), however, a huge increase was seen in CD4
+
 T cells, 





Figure B8:  Staining of Fresh PBMC using the RnD anti-Human AID Mouse 
Monoclonal Antibody.  Freshly isolated PBMC were stained after 
fixation/permeabilization using the antibody purchased from RnD Systems.  Staining was 
detected in CD19
+




 T cells (B).  The percentage of positively-
stained cells was determined in each subset (C). 
 
B vs. B9-B).  Consistent with the Cell Signaling Technologies antibody, the extensive 
degree of non-specific binding associated with the RnD antibody does not make it a 
suitable candidate for flow cytometry. 
 
Discussion/Future Directions.   
Our attempts at identifying an antibody specific for human AID were 
unsuccessful.  All antibodies tested failed to either stain CD19
+
 B cells and CD4
+
 T cells, 
or have high non-specific staining in the T cells, where AID protein is not produced.  




Figure B9:  Staining of Stimulated PBMC using the RnD anti-Human AID Mouse 
Monoclonal Antibody.  Stimulated PBMC were stained after fixation/permeabilization 
using the antibody purchased from RnD Systems.  Staining was detected in CD19
+
 B 




 T cells (B).  The percentage of positively-stained cells was 
determined in each subset (C). 
 
though AID is an intracellular protein.  The antibodies that we tested constitute the entire 
repertoire of anti-human AID antibodies commercially available.  Testing antibodies 
reactive to mice, however, may allow us to find an antibody specific enough for human 
use in CD19
+
 B cells (mouse and human AID protein sequences are >90% identical).  
 Few studies in the literature report AID protein expression using flow cytometry, 
and our results may explain why this is the case.  Indeed, one study used the same 
primary antibody from Cell Signaling Technologies that we tested and reported increased 
AID protein expression, concurrent with increased AID mRNA expression, after 
stimulation with HIV-1 virions [A26].  However, in this study, CD19
+
 B cells were first 
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sorted from the total PBMC (including CD4
+
 T cells) and staining in CD4
+
 T cells was 
either not performed or not reported.  Our results showing high non-specific staining, 
therefore, call into question the validity of the data reported by Epeldegui et al, as high 
levels of non-specific staining undermine any conclusions that can be drawn from the 
CD19
+
 B cell subset, despite finding expected patterns of expression (i.e. staining levels 
are lower at baseline and increase with stimulation, similar induction of AID mRNA 
expression) [A26].  Careful consideration of controls, therefore, is required for accurate 
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